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ABSTRACT
This study set out to examine the practicalities of producing silica-based (PS and CPG) 
affinity solid phases for purifying materials of biological origin. The silica based solid-phases 
produced in this study were used in order to assess the rapid affinity clean-up of materials in 
a manner applicable to HPLAC and FPLC systems. In addition, the feasibility of using silica 
based solid phases in process-scale affinity purification processes was explored. This has required 
the development of techniques for activating silica-based matrices, immobilizing ligands to 
activated matrices, and evaluating the performance of the affinity solid phases.
In order to compare matrices commonly used as stationary phase supports for affinity 
purifying proteins, a specific non-competitive enzyme-linked immunosorbent assay (ELISA) was 
developed to detect and quantify protein A (SpA) levels, present as a trace contaminant in 
therapeutic murine monoclonal antibodies (MAb), purified on immobilized SpA solid phases. 
This assay was used to compare eight commercially available SpA solid phases, demonstrating 
a number of matrix materials, and ligand immobilization chemistries; to establish their 
potential for the large-scale purification of a murine monoclonal antibody (MAb, m lgG j. Solid 
phases were tested for the effects of ionic strength, pH, the presence of MAb, flow rate and 
mode of operation (stirred-tank or flow-through) on the level of ligand leakage. Solid phases 
have also been evaluated to determine the effect of buffer composition on their non-specific 
protein adsorption (NSA), and plasma protein (albumin and transferrin) contamination of 
purified antibodies.
The porous silica Matrex™ Si (particle size, 90 - 130 fxm; pore size 1000 Â  Amicon 
Ltd.), was used as the starting material for the development of a number of silica-based solid 
phases. In particular, the grade of Matrex chosen had a pore accessibility suited to the model 
affinity chromatographic applications in this study; involving the purification of biological 
macromolecules from biological matrices (filtered tissue homogenates, serum, whole blood, and 
bile) on immobilized bio ligands (SpA and Ab’s).
The introduction of functional groups onto the surface of silica-based matrices by the 
process of silanization was assessed. This technique was used for preparing epoxide and 
aminopropyl derivatives of PS as the initial stages in matrix activation. The bis-oxirane
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1,4-butane diol diglycidyl ether was also evaluated, to determine its merit as a bifunctional 
agent for immobilizing ligands. The most appropriate technique for coupling ligands to silica 
based matrices (PS or CPG) appeared to be by: firstly aldehyde activating the matrix surface, 
followed by Schiff’s base bond formation with the free amine groups of the ligand, and finally 
reduction of the Schiff’s base bonds. This proved the quickest of the techniques investigated 
and resulted in the greatest degree of ligand substitution.
Activated Matrex based matrices were used to immobilise a number of proteins (BSA, 
MAb, PAb, SpA), charged molecules (DEAE, QAM), a hapten (Tb-CMO), and a dye (Rivanol). 
These solid phases were used in order to judge the success of immobilization procedures, 
determine the best operating conditions for silica-based matrices and to purify biological 
samples. The solid phases produced in this study were able to operate at high flow rates, 
allowing the rapid of purification biological samples. This was demonstrated by the HPLAC  
resolution of Ig’s from plasma, and the development of a rapid automated lAC-ELISA system 
for the anabolic agent clenbuterol in bovine bile samples.
Strategies to limit the level of bioligand leakage from silica-based solid phases during 
normal purification and hydroxide sanitising operations were investigated using BSA and SpA 
as model bioligands (proteins). One approach to limiting the level of ligand leakage from 
affinity solid phases investigated was to empirically optimise their production an operating 
conditions. Another approach explored was to incorporate metal ions into chromatographic 
buffers or onto the surface of affinity solid phases. Sanitising conditions which may be used to 
clean up SpA-(PS or CPG) solid phases without any ill effects were also investigated as 
alternatives to molar NaOH.
The chromatographic performance of solid phases produced using PS and CPG matrices 
in this study have performed in a manner comparable to many commercially available solid 
phases. Furthermore, silica based matrices have allowed the development of rapid AC processes 
without loss of purification efficiency. In the light of the findings presented within this study, 
many of the more common objections aimed at the use of silica-based matrices for AG 
applications would appear to no longer be a problem or easily overcome.
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CHAPTER ONE  
IN TR O D U C TIO N
1.1 GENERAL INTRODUCTION
It is essential, in order to understand the nature and/or function of any naturally 
occurring substance, to firstly devise a method for its resolution and isolation from the 
complex mixture of its source. The increasing demand for large quantities of purified reagents 
of biological origin (or biologicals) for use in biomedical research as therapeutics and 
diagnostics, suggests the need to develop highly specific, cost effective separation techniques. 
Whether an isolated biological is destined for analytical investigation, or use as a therapeutic, 
possibly the most important aspect of its preparation is the removal of trace contaminants.
A general approach to the separation of substances of biologicals follows a strategy 
consisting of three elements. Firstly, available information on the particular biological is 
collated (e.g., pi, molecular weight, glycosylation, number of subunits), and an assay developed 
to determine the best source of the biological. Secondly, extraction processes are evaluated (e.g., 
cell/tissue disruption, enzymic break-down of conjugates) and a preferred technique developed. 
Thirdly, the separation and purification stages are refined and standardized, and a standard 
operating procedure (SOP) is proposed for the isolation of the biological (e.g., expertise, 
equipment, reagents). When a purification protocol is to be used for the isolation of trace 
biologicals, such as when screening for drug residues in edible tissues, the separation method 
should also be sensitive enough to isolate residue levels as low as the maximum residue limits 
(MRL) (Heitzman., 1986; and Jones., 1991).
A number of separation techniques have been developed, allowing the sorting of 
complex mixtures into smaller populations according to different principles. Consequently, 
published procedures for the isolation of components of, or residues in, biological samples 
usually incorporate a combination of techniques, each increasing the specific biological 
component of the recovered fraction. The United States Federal Drug Administration (FDA) 
acknowledged this widely accepted principle in stipulating that in order to license products of 
plasma origin for therapeutic use an applicant must present a purification process containing 
at least three distinct isolation principles (FDA, 1985).
Techniques such as electrophoresis, ion exchange chromatography, and isoelectric 
precipitation exploit the overall charge of molecules, whereas preparative ultracentrifugation, 
SDS-PAGE, gel filtration, and dialysis fractionate molecules according to their size or diffusion 
coefficient.
Chromatography literally means colour drawing and involves the separation of 
components of a mixture using an immobile matrix, or an immobilized layer on an insoluble 
matrix (the stationary phase), through which a flow of solvent, the mobile phase, is passed to 
achieve differential migration of solutes. This separation is commonly performed in a hollow  
tube filled with solid phase (matrix, or matrix bound stationary phase), to form a column or 
packed bed through which dissolved sample (solute) and solvent may flow. The stationary phase 
retards the percolation of substances through the column, different substances being retarded 
to differing degrees, thus migrating through the bed with different velocities. This type of 
chromatography is generally referred to diS partition chromatography. Here interactions between 
the chromatographic matrix, solutes and solvents are minimal.
Adsorption chromatography utilises more or less specific interactions between 
components of the mixture to be resolved and the stationary phase, the solvent being chosen 
to mediate these interactions. As the solvent moves through the column, solutes present in the 
sample (often referred to as the feed) may do one of three things, being:
i completely partitioned into the solvent, they will run with the solvent front 
(Retardation constant, R f =  1).
ii totally adsorbed, they will remain in their starting position (Rf = 0).
or iii partially adsorbed they are retarded and are eventually eluted (0 <  R f <  1).
Hence, solutes with similar retardation constants (Rf) may be separated on columns of sufficient 
length, conditions being such as to limit longitudinal diffusion (Scopes, 1982).
1.2 CHROMATOGRAPHIC MATRICES
1.2.1 General properties (Absolom, 1981 and Lynn, 1973)
An ideal support matrix should have many properties. Among these it should be:
i easily derivatized, allowing the covalent attachment of ligand;
ii porous, increasing the effective surface area whilst allowing ligand accessibility;
iii mechanically and chemically stable, providing resistance to chemical, microbial, 
enzymic and mechanical degradation during derivatization, storage, and use;
iv uniformly spherical and rigid, facilitating good flow characteristics allowing the 
passage of large volumes of feed;
V chemically inert, its surface charge approaching zero, no hydrophobic binding
sites and a hydrophilic nature; 
and vi cheap, being commercially available to a standard quality for cost effective
reproducible manufacture.
A summary of those matric materials commonly used in the preparation of affinity 
chromatography solid phases is give in table I.
TABLE I. AFFINITY CHROMATOGRAPHIC MATRICES
Matrix Source Comments Examples.
Advantages Disadvantage
Dextran
(a -l,6 -Iinke<j
glucose).
Leuconostoc
mesenteroides
cultures.
High ligand capacity on 
CNBr activation (Axen 
et al, 1967), chemically 
stable; 250 mM N aO H  
or 20 mM H Cl, heat 
resistant; to 110°C 
(Lowe, 1979).
Gels are soft, 
biodegradable, vol. 
proportional to ionic 
strength.
Sephadex. 
(Pharmacia Ltd.).
Agarose
(poly 1,3-linked fi- 
D-galactose and 3- 
anhydro- galactose).
Marine algae. Easy CNBr activation, 
cheap.
biodegradable, 
chemically degradable 
(Strosberg, 1986), non­
specific binding of 
proteins.
Sepharose. 
(Pharmacia Ltd.).
Bio-gel A. 
(Bio-Rad Labs.).
Cellulose 
(1,6 linked, fi-1,4- 
glucose chains).
Fibrous plants. Solvent resistant, cheap. High non-specific 
adsorptions, low  
permeability; thermal 
and mechanical 
stabilities.
Excellulose. 
(Pierce Europe).
MemSep. 
(Mdipore Ltd.).
Polyacrylamide 
(acrylamide 
copolymerised by 
N ,N ’-methylene- 
acrylamide.
Synthetic. pH  stable (1 - 10) low  
biodégradation, good 
mechanical stability.
Gels adhere to glass 
(Inman & Dintzis, 
1969), low  porosity.
Bio-Gel P. 
(Bio-Rad Labs.)
Sephacryl. 
(Pharmacia Ltd.).
Alumina
(particulate AI2 O 3).
Synthetic. Alkaline resistant, 
defined pore sizes, rigid, 
high flow rates.
Expensive, difficult to 
derivatise.
Kimal.
(Anatrace).
Macrosorb. 
(Sterling Organics).
Silica
(SiOz-xH^O).
Mineral extracts. Rigid, good mechanical 
and pore stability, high 
flow rates.
Irregular bead shape, 
hydrolysis at pH  >  9, 
weak cationic 
exchanger, and difficult 
chemistries.
Matrex.
(Amicon).
Glass
(borosilicates).
Synthetic. Rigid, good mechanical 
and pore stability, 
specific pore size and 
shape, very high flow  
rates.
Hydrolysis at pH  >  9, 
difficult chemistries, and 
weak cationic 
exchanger.
Controlled pore glass, 
CPG.
(CPG Inc.)
1.2.2 Non-synthetic matrices
These are generally polysaccharides (dextran, agarose, and cellulose), and due to their 
lack of mechanical stability, their application is usually limited to conditions of low flow rate 
and operating pressures. High non-specific adsorptions and low permeability to macromolecules 
present their major drawbacks. The mechanical and thermal stability related problems of these 
matrices may largely be overcome by chemical modification (cross-linking of molecules). A 
number of highly cross-linked (improved) matrices are now commercially available, these 
include:
i Superose (Pharmacia Limited), a dextrose derivative, 
and ii Excellulose (Pierce Limited Europe), a thermal solgel transtituted cellulose.
These matrices have been developed with a view to their use in the relatively low pressure Fast 
Protein Liquid Chromatography system (FPLC, Pharmacia Biosystems Ltd.).
1.2.3 Synthetic matrices
1.2.3.1 Polyacrylamides
Polyacrylamide is a synthetic hydrocarbon polymer, produced by the co-polymerisation 
of acrylamide, with the bifunctional cross-linking agent N,N^-methylenebisacrylamide (Hjertén 
and Mosback, 1962). The properties of this material are summarized in table 1. Beaded 
polyacrylamide gel matrices are readily available in a number of mesh sizes, from Bio-Rad 
Laboratories under the trade names Bio-gel P (with molecular weight exclusion limits from 
1,800 to 400,000); they have also been used as the matrix in the production of a number of 
solid phases (Sephacryl, Pharmacia). Though an improvement on the earlier polysaccharide 
matrices, there remained the drawback of these matrices having an apparent lack of mechanical 
stability, and low degree of porosity. More recent developments have lead to the synthesis of 
polyacrylamide gels with improved properties in terms of being more hydrophilic, 
mechanically stable, and porous, resulting in better all round flow properties. Among these are 
the matrices:
i Sephron (Laboratory Instruments Works), a co-polymer of 2 -hydroxyethyl- 
methacrylate and ethylene-dimethylacrylate.
ii Trisacryl GF 2000 (IBF Réactifs, Paris), obtained by the polymerisation of 
N-acrylol-2-amino-2-hydroxymethyl-l,3-propanediol.
iii Eupergit C (Roehm-Pharma), a co-polymer of methacrylamide, N-methylene- 
bisacrylamide and a monomer containing oxirane groups.
iv Ultrogel (LKB), a co-polymer of agarose and acrylamide.
and V Dynospheres, obtained by the co-polymerisation of methylmethacrylate,
hydroxyethyl methacrylate, and ethylene glycoldimethylacrylate.
Polyacrylamide matrices achieve all those characteristics desirable of a good 
polysaccharide matrix, with the added advantages of greater biological and mechanical stability. 
Activation in order to couple ligands may be achieved in much the same way as performed for 
polysaccharides (cyanogen bromide, chloroformâtes, 1,1 '-carbonyldiimidazole and 
sulfony 1-chlorides), producing supports with a greater degree of ligand immobilisation; and also 
by further co-polymerizing with N,N^methylenebisacrylamide.
1.2.3.2 Silica
Silica is the term given to the oxide of silicon (stoichiometric composition, Si0 2  to 
Si0 2 .xFÎ2 0 ); its degree of hydration will depend generally upon its production technique, and 
will be reflected in the dispersity of its oxide atoms. With respect to dispersity, silica has a 
number of forms which include:
i soluble silica, an amorphous or crystalline monosilicic acid;
ii silica sols, non-porous colloidal spherical and amorphous particles (1 - 1 0 0  nm);
iii silica hydrogels, aggregated particles;
iv silica xerogels, hard porous grains;
V silica aerogels, silica particles 1 ytm in diameter non-porous;
and vi polymeric silica solutions, siloxane chains linked to form a gel.
Particles of silica for use as chromatographic matrices can be produced by grinding large 
particles of xerogels, followed by selective sieving to the desired size fraction. This process 
produces a heterogeneous silica matrix, with irregular shape and pore size. A regular matrix 
with better flow characteristics may be produced by modifying the sol-gel production 
procedure, to produce spherical particles, of controlled particle size and distribution. Silica sols 
are generally prepared by the addition of a sodium silicate solution to an acid. Refinement to 
regular porous silica particles involves dialysis and ion exchange of the sol, peptidisation of the 
hydrogel, hydrolysis of silicon tetrachloride and tetra-alkoxysilanes, dissolution of elemental 
silicon, and finally dispersion of non-porous finely divided silica (lier and Matijevic, 1973).
1.2.3.3 Controlled porosity silica matrices (CPS)
In creating silica matrices of controlled porosity (CPS), a number of techniques are 
available; these include the following:
i modified sol-gel preparations, followed be sintering (Le Page et al, 1967): the sol 
passing through a non-aqueous solvent is solidified, dried, and calcined (at 400 
- 800°C) forming hydrogel beads, with a homogeneous but fairly wide pore size 
distribution.
ii polyethoxysiloxane procedure (Unger and Schich-Kalb, 1971): this is a two stage 
process in which liquid polyethoxysiloxane is prepared by partial hydrolysis of 
tetraethoxysilane, followed by émulsification in ethanol-water (50% v/v). This 
hydrolytic polycondensation results in the production of spheres, spongy rather 
than globular in nature.
iii agglutination of finely dispersed non-porous silica particles: two procedures are 
commonly employed. In the first, silica sol with a narrow particle size 
distribution is mixed with melamine and formaldehyde; co-condensation of the
organic components yields microbeads with colloidal silica distributed about the 
polymer beads. Heat treating these (calcination at 500°C) removes the organic 
components, and a further increase in temperature to 1000°C produces a slight 
sintering, resulting in colloidal strengthened and mechanically stable beads (Her 
and McQeston, 1974; and Kirkland, 1974).
In the second process aerogels (e.g. Aerosil or Cabosil) are suspended in 
water and the suspension sprayed into an oven at 400°C. On further 
hydrothermal treatment in an autoclave, mesoporous and macroporous beads 
can be prepared with a high specific pore volume and thermal stability (Kiselev 
et al, 1972).
and iv controlled sintering (Krebs and Heinz, 1970): this technique employs the use of 
a high-melting point salt such as sodium chloride, to fill the pores of silica in 
order to maintain i its porosity during sintering. As a result, macroporous 
silica can be created from mesoporous samples, the pore size enlargement being 
controlled by temperature, or the type and amount of salt employed.
Silica provides a rigid matrix able to operate at the high pressures required by HPLC, 
FPLC, and demanded of industrial scale chromatography. In buffered aqueous solutions with 
a pH of about 2 the surface area of porous silica remains unaffected; any deviation from this 
pH decreases the surface area. This effect presents possibly the major disadvantage to the use 
of silica as an affinity chromatography support matrix. At pHs above 9, silica matrices may 
hydrolyse, dissolving to form silicates (Ernst-Cabrera and Wilchek, 1988). Another problem  
associated with the use of silica in the production of matrices for separating biologicals is its 
ability to non-specifically bind proteins by either hydrophobic interactions, or weak ionic 
exchange (Equation 1). These may be reduced by suitable derivatisation.
‘ SiOH + H p  -  =Si~ + H,0*  (1)
In order to reduce dissolution at high pH ’s, metal oxides such as those of zirconium and 
titanium have been used as silica surface coatings; a number of these matrices are commercially 
available under the trade name Zorbax (Du Pont). Non-specific ionic interactions may be 
reduced by the process of silanisation, with a reagent such as 3-glycidoxypropyl- 
trimethoxysilane. This produces a polymeric monolayer surface coating, resistant to hydrolytic 
cleavage. This technique also allows functional groups to be introduced on the surface of silica 
matrices.
1.2.3.4 Glass
Glass is an inorganic substance in a condition which is continuous with, and analogous to, 
the liquid state of that substance, but which, as a result of a reversible change in viscosity during 
cooling, has attained so high a degree of viscosity as to be for all practical purposes rigid (Morey, 
1954). The term glass usually refers to the silicate glasses which are transparent and chemically 
inert, whilst maintaining an ability to be shaped in the hot plastic state. Glass is resistant to 
water and acids of all strengths.
Borosilicate glass (Fig. 1) when heated at 700 - 800°C forms two intermingled 
continuous phases, one rich in boric oxide (acid soluble), and another rich in silica (acid stable). 
On cooling, and subsequent acid leaching, a porous structure is produced made up of 96% silica 
glass, 3-5% B2O 3, and trace amounts of metal oxides (<  0 .2 %). These matrices have pore 
diameters between 30 - 60 Â (Nordberg, 1944; Weetall and Filbert, 1974). Larger pore glasses 
may be prepared by mild caustic soda treatment of the glass; this removes siliceous residues 
from the pores and etches the surface further. Fine control of these processes allows the 
synthesis of a whole range of controlled pore glasses (CPG).
10
No 0
.90
Nq O^
20/ .00
30/
40/
96 V. SILICA GLASS
50/ .50,
60/ .40
70/ 30  E30R0SILICATE 
\ / ------- CLASS
7^2080,A
90/
20 80  9 0
Figure 1. Phase diagram of sodium borosilicate system (Weetall and 
Filbert, 1974).
CPG is a free flowing white powder consisting of rigid granules of quartz glass 
permeated by an interconnecting network of pores with a very narrow size distribution (CV 
<  10%). When used as the matrix in the production of affinity solid phases, these result in 
rigid columns which do not deform, and are unaffected by ionic strength, flow  rate, or 
solvents. As a result back pressures are directly proportional to flow rates, which at a given 
pressure are directly proportional to column diameter and inversely proportional to column 
length (Clonis, 1987). Chromatographic CPG particles are generally prepared by selective 
sieving of crushed bulk glass preparations. Regular spherical beads are produced (more 
expensively) by forming droplets of molten borosilicate glass prior to the leaching/etching 
process. Both techniques result in particles of CPG with the majority of its surface area 
contained within its pores; for example, CPG particles with a pore size 75 Â, have a surface 
area of 248 mVg, with a column void volume (KJ greater than 50 %.
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1.2,3.5 Alumina as a matrix
Porous particulate alumina (aluminium oxide, AI2O 3) was first studied as a possible 
support for the immobilisation of enzymes by Barabino and Keyes (1974). It was intended that 
alumina should become the support material in instruments where flow rates limit the use of 
more conventional (soft) matrices. In addition, alumina is resistant to alkaline treatment (for 
sanitizing), so may be NaOH cleaned.
Porous alumina is commercially available under the trade names Kimal (Anatrace) and 
Macrosorb (Sterling Organics), sold as stable beads of well defined pore and particle sizes. They 
are able to bind proteins to levels approaching those for organic matrices with the advantages 
of being difficult to deform or fracture, and being able to withstand high flow rates without 
physical change. Immobilisation of proteins was achieved by first adsorbing them to the 
alumina surface, followed by subsequent cross-linking with a bifunctional agent such as 
N-Succinimidyl-(2 -pyridyldithio)-propionate (SPDP), a three stage heterobifunctional 
cross-linker; or Bis-(sulfosuccinimidyl) suberate (BS3, Pierce Europe), a one stage 
homobifunctional cross-linker.
The major disadvantage of using alumina in the purification of biologicals is its ability 
to bind organophosphates (R-H^POJ. Organophosphates are selectively and strongly bound 
to alumina, desorbing undenatured only in the presence of excess inorganic phosphate ions. 
Consequently, an alumina column may resolve proteins displaying external phosphate groups. 
Equally, on employing a bifunctional compound containing a phosphate group, proteins may 
be resolved (Coletti-Previero and Previero, 1989).
1.3 CHROMATOGRAPHIC TECHNIQUES
1.3.1 Partition chromatography (PC)
In analysing this technique, the behaviour of all components is assumed to be 
thermodynamically ideal. However, interactions in biological materials are rarely so, 
particularly when dealing with proteins which are by nature polyionic. To some extent most
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natural products interact, usually resulting in chromatographic band broadening, and poor 
resolution of peaks (Lowe. C. R., 1979). PC separates molecules on the basis of their relative 
physicochemical characteristics (Stokes’ radius, polarity, and hydrophobicity). When the 
stationary phase concerned is hydrophobic (octadecane, C^ g; or benzene), and the mobile phase 
hydrophilic (methanol, formaldehyde, or water) the chromatographic bed may resolve 
non-polar solutes in reverse phase’, solutes emerging in order of decreasing polarity. When the 
stationary phase is hydrophilic (n-butanol) and the solvent non-polar, polar solutes may be 
resolved in normal phase. A  solute dissolved in two immiscible liquids ideally has a constant 
distribution at equilibrium (Equation 2):
(2)
^2
where and A 2  represent the concentration of solute in two solutions respectively, and k  the 
partition coefficient. The matrices of choice for the production of a hydrophilic or 
hydrophobic stationary phases are often silica, alumina, and cellulose.
Gel filtration (Porath and Flodin, 1959), is a PC technique in which molecules are 
separated on the basis their molecular sizes, due to molecular sieving (eg Sephadex; Pharmacia 
Ltd.).
Ion Exchange is a technique carried out on matrices coated with a dense cluster of 
charged groups (eg. diethylaminoethyl, DEAE cellulose; and carboxymethyl, CM cellulose), 
these may be substituted as much as 0.5 mMol cm' ,^ equivalent to 0.5 M of charged groups 
(Scopes,1982). Ion exchange partition chromatography (lEPC) occurs primarily as a result of 
electrostatic forces (Wolf, 1969), separating solutes due to differences in their affinities for the 
exchanger, as a result of differences in their net surface charge. Desorption of adsorbed proteins 
is achieved by altering the buffering pH, such that the net surface charge of the proteins is 
altered, or by the addition of competing ions. lEPC solid phases are typically based on the 
matrices of cross-linked polystyrene, cellulose, polysaccharides, or resins; all of which require
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careful system design for process scale applications, exemplified by the use of radial flow  
systems to prevent compaction. In this study, the production of silica based IE matrices was 
investigated as an alternative to the more conventional matrices for use at process scale. These 
have been compared to commercially available matrices in order to evaluate their relative 
merits and potentially greater versatility.
1.3.2 Adsorption chromatography
Separation is achieved here by more or less specific interactions with some or all the 
components of a mixture, retention being an expression of the intermolecular forces between 
surface atoms of the matrix and those of the solute(s). The forces responsible for the adsorption 
of a solute include: Van der Waal’s, electrostatic, hydrogen bonding, and hydrophobic bonding. 
Adsorption of a given solute to a matrix occurs as a result of a combination of these forces, 
to a number of binding sites. This heterogeneity of adsorptive forces results in a decreasing 
level of solute immobilisation, per unit increase in mobile phase solute concentration (Lowe, 
1978).
This observation may be expressed mathematically in terms of a Langmuir adsorption 
isotherm (Equation 3):
where q  represents the solute adsorbed per unit mass of adsorbent; C, the equilibrium constant, 
and and ^2 constants, q  has the finite limit k f k 2 , or Q, equal to the maximum amount of 
adsorbate, adsorbable per unit mass of adsorbent, otherwise known as its capacity. 
Consequently, a highly curved isotherm for a solid-phase may be considered indicative of 
strong adsorption, as a result of a high ratio of available binding sights to the concentration of 
solute molecules present. Adsorption is a reversible binding process, adsorption 
chromatographic techniques being classified in terms of the binding force(s) employed.
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1.3.3 Affinity chromatography
Affinity chromatography (Cuatrecasas et al., 1968; AC), is an adsorption 
chromatographic separation technique in which a solute molecule(s) is selectively adsorbed to 
an immobilized secondary molecule, such that if components A and B form the complex 
[Ah[B]i,, then A (the ligate or adsorbate) may be separated from substances of identical size and 
charge by attaching itself to B (the binder or ligand), covalently attached to an insoluble matrix 
(termed the solid phase). Isolation then occurs on a relatively specific functional, rather than 
physicochemical basis.
The use of specific interactions as a means of isolating and purifying a protein was first 
demonstrated by Hedin (1907), desorbing trypsin from charcoal. Starkenstein (1910) expanded 
on this principle by employing a biological interaction in order to resolve amylase from a 
crude extract. The use of a ligand covalently attached to an insoluble (cellulose) matrix was first 
reported by Campbell et al (1951) in which immobilized bovine serum albumin (BSA) was used 
to purify rabbit anti-BSA antibodies. This was an example of biospecific adsorption (Porath, 
1973), as may occur between bio-ligands and their ligates, in a bioselective, rather than specific 
manner (Scouten, 1974). These interactions include those between enzymes and substrates, 
inhibitors, coenzymes, and allosteric modulators; antibodies and antigens; plant lectins with cell 
surface antigens, carbohydrates, and polysaccharides.
In theory it is possible to purify any substance by an AC technique provided that:
i a specific complementary ligand is available, that may be attached to a matrix 
forming a chromatographic bed;
ii on immobilizing a ligand it must maintains its specific binding quality for the 
ligate;
and iii a selective non-denaturing method for desorbing immobilized ligate exists
(Absolom, 1981).
AC as a technique in the purification of biologicals has a number of advantages over 
classical methods, achieved largely due to the AC solid phase (often referred to as the adsorbent)
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having been designed and constructed specifically for the biological to be purified. Among these 
advantages are one step separation and isolation; high yields of non-denatured compounds; 
enrichment of solutes (removing contaminating proteases and endotoxins); bioselectivity 
(tailored systems producing specific products); and the purification of solute from low  
concentration samples.
«
WASH
Figure 2 . Affinity chromatography (Lowe, 1991; T = target molecule).
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1.3.3 1 Batch binding performance
In order to optimise the operation of an AC separation, the nature of the adsorption 
stage, when crude feed and solid phase first come into contact needs to be understood. 
Theoretical models of the ideal conditions for an adsorption process are initially evaluated by 
pilot scale batch adsorptions of purified adsorbate in a clean system (Jankowski et al., 1976). 
The biospecific interactions of affinity adsorption are considered to be largely analogous to 
those of biological recognition occurring in free solution, which may be described by a 
reversible equilibrium (Chase, 1984; Lowe, 1979; Philips, 1989). Thus:
K (4)
K ^A  + B ^ A:B
K
where v4 is a molecule of adsorbate and B is the biospecific binding site on the solid phase or 
adsorbent (more specifically an adsorbate binding site on the ligand), andy4;R is a non-covalent 
complex formed between the two. k^ , and ^2» are rate constants governing the net direction 
of the reactions respectively. The ratio of the constants is equal to the effective
dissociation constant (Kj), and {k^/k^ the association constant (/Q, of the immobilized system. 
The rate of adsorption of an adsorbate onto an adsorbent is described by (Chase, 1984):
-  q) -  k^q
where C  is the concentration of adsorbate in solution, q  is the adsorbent concentration of the 
adsorbed material per unit volume of settled solid phase, and q^ is the maximum adsorption 
capacity of the adsorbent. This approach assumes biospecific interaction to be the rate limiting 
step of the adsorption process. The equilibrium position of adsorption processes is therefore:
0^ 7* (6) 
where C" and q  are the concentrations of adsorbate in solution, and adsorbed per unit volume
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of settled adsorbent at equilibrium respectively. From equation (6), it can be shown that at 
equilibrium, the solid phase concentration of the adsorbed material will vary with the 
concentration of the adsorbate in a manner described by:
.  (7)q = -------------
Equation (7) predicts that adsorption should be non-linear, and of the type first described by 
Langmuir (1916), characterized as being a favourable binding isotherm. Rearrangement of this 
equation gives:
Ç 2  _ C  + (8)
q ’
When values of C  /q  are plotted against C  the result is a straight line plot which has the slope 
1 /q  and intercept -K  ^ on the ( f  axis. Consequently, values of effective dissociation constant 
(Æj) and maximum binding capacity of an adsorbent {q^ or Q) may be calculated by small-scale 
batch adsorption experiments by a modified method of Chase (1984b).
1.3.3.2  Packed bed performance
The thermodynamically ideal scenario of affinity chromatographic interactions 
presented above for batch binding processes has been considered as too simplistic by many 
researchers to explain the performance of a packed bed system. More recently, theoretical 
models have been constructed by a number of workers in the area of process design (Liapis, 
1988, 1989, 1990; Arve and Liapis, 1987; and Petropoulos et al, 1990) to describe packed bed 
adsorption and elution stages and account for the following solid phase mass transfer 
interactions:
i the transport of adsorbate from the bulk liquid to the stationary phases (film 
mass transfer);
ii the transport of adsorbate with in the solid phase pores (intraparticle diffusion);
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and iii the adsorbate ligand interaction (binding mass transfer).
Hence, the overall mass flow during adsorbate and ligand interactions as a solution flows 
through a may be expressed as follows (equation 9):
\
/
Kl {C ,-C ,)  (9)
where Q  is the bulk solute concentration (g cm' )^, f is  time (s), u is the superficial velocity (cm 
s'^ ), e is the column void fraction, is the axial dispersion coefficient (cm s^'% z  is distance 
along the column (cm), a  is the shape factor (2 = sphere), is the solid phase particle radius 
(cm), Kj^  is the fluid film mass transfer coefficient (cm s'^ ), and is the pore solute 
concentration (g cm' )^.
The majority of large-scale AC separations are carried out in packed beds, with efficient 
adsorption and desorption processes, and with minimal solid phase handling. These systems are 
invariably quick, and lend themselves to relatively easy automation (Clonis, 1987). The 
performance of the adsorption stage of a packed bed affinity process can best be determined 
by frontal analysis, in which a fixed concentration of adsorbate (Q) is continuously applied to 
the adsorbent bed inlet, whilst the variation of outlet adsorbate concentration {bC} is 
monitored (Lowe and Dean, 1984). The variation with time of adsorbate concentration of the 
bed outlet is referred to as the adsorbate breakthrough, and may be plotted as a breakthrough 
curve, (C/Cj,; Chase, 1984). The shape of an adsorptive breakthrough curve reflects the degree 
to which a packed bed operation has been optimized. This is of value when assessing process 
scale operations where maximized utilisation of available adsorbent capacity, with minimal of 
adsorbate is essential. Important factors here include flow rate, the solid phase mass transfer 
properties (particle, pore, ligand, and adsorbate sizes), and the values of K^, Q , and Q (Dean 
et al., 1985; Sofer, 1986).
For preparative purposes, adsorbate (in the form of crude feed with particulates 
removed) is usually applied to a column under maintained conditions of flow and 
concentration, to a bed initially devoid of any bound material. The bed output initially
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contains no adsorbate, but as adsorption continues, adsorbate concentrations in the 
breakthrough will rise to equal the input concentration as the affinity adsorbent approaches 
equilibrium with the feedstream. However, due to the dynamic nature of affinity adsorption, 
under these conditions q  will only be equal to Q, when the input concentration of adsorbate 
is much greater than the effective dissociation constant. The equilibrium capacity of the bed 
can be assumed from batch binding, and is given by:
9* -  -  9„ when C„ >
In practice, as Q is approached adsorption is usually stopped (at about q / Q  = 0 .8) so as to 
avoid losing too much adsorbate to the breakthrough. However, this process does have the 
disadvantage of leaving a number of free ligand sites available for non-specific adsorptions, and 
as a result the co-purification of contaminants may occur.
By evaluating those factors which affect the shape and position of the breakthrough 
curve of an adsorption process, the most appropriate process conditions for a feedstock may 
be ascertained.
1.3.3.3 Sources of non-specific adsorption
Batch and packed-bed analysis of affinity chromatographic solid phases are useful tools 
for characterizing the performance of adsorbents in the presence of homogeneous adsorbate and 
take no account of the influence of resistance to diffusion in particular solid phases, nor the 
possibility of heterogeneous interaction with other adsorbates. These evaluations are based on 
the assumption that adsorptions are thermodynamically ideal, biospecific interactions. 
However, non-specific adsorptions may occur due to the overall physicochemical properties 
of the ligand, adsorbate, and components of the feed stock to be purified. Most commonly, 
non-specific adsorptions occur as a result of hydrophobic and ionic forces, which must be 
minimized in order to optimise an affinity separation process (O’Carra, et al., 1974).
The non-polar side chains of proteins, matrices, ligands or spacer arms (molecules with
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functional groups attached to ligands), may result in non-specific hydrophobic adsorptions. 
Spacer arms anchor the ligand to the matrix while keeping it clear of the matrix surface. Spacer 
arms usually consist of hydrophilic hydrocarbon chains (generally 10 to 2 0  Â) so as to limit 
non-specific adsorptions. These effects may be reduced by using spacer arms of no more than 
6 carbon atoms (Steers, et al., 1971; Hofsee, 1974), blocking uncoupled spacers after ligand 
immobilisation, and avoiding excessively hydrophobic ligands. Proteins being polyionic may 
non-specifically interact with ionic moieties on a solid phase. These interactions may be kept 
to a minimum by selective buffering of feed solutions and washing buffers (pH and ionic 
strength).
1.3.3.4 Desorption of adsorbates
Desorption (or elution) should ideally result in the rapid recovery of concentrated 
adsorbate (within 3 column volumes); however, this is frequently unachievable with AC  
systems due to the high binding affinities involved. Eluents must reverse recognition such that 
the combined efforts of electrostatic, hydrophobic, van der Waal’s and hydrogen bonding 
which bind the adsorbate to the adsorbent are overcome. Promoted complex dissociations 
(increasing are therefore the most effective means by which to recover adsorbates, rather 
than the mere inhibition of the forward binding reaction k^ . Elution processes may therefore 
be classified into the categories biospecific and non-specific methods.
1.3.3.5 Biospecific elution
In the process of biospecific elution, ligand-adsorbate complexes are exposed to a high 
concentration of free competing ligand, the adsorbate being released under the pressure of 
competition (Walters, 1985b). When the competing ligand is present in sufficient excess, 
adsorbate is totally partitioned into the mobile phase. The soluble ligand may then be separated 
from the adsorbate by gel filtration, or ion-exchange, but this clearly requires major differences 
of character (molecular size, charge density) between an adsorbate (product) and an affinity 
ligand. Biospecific desorption is normally used for low affinity systems in which the affinity
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ligand is a compound with a low molecular weight and low cost. Biospecific desorption is not 
suitable for affinity systems utilizing immobilized antibodies, since elution would necessitate 
addition of large quantities of high-cost free antibody, which would create further recovery 
problems following dissociation of adsorbate soluble antibody complexes.
1.3.3.6  Non-specific elution
The methods most frequently used to desorb adsorbed products from affinity solid 
phases are non-specific, and involve alterations in physical and chemical properties of the 
mobile phase such that the affinity of binding is reduced (Arve, 1988; Lowe and Dean, 1984; 
and Scouten, 1981). Non-specific desorption may involve the following:
i altering the pH in the range 2-4, using solutions containing propionic acid or 
glycine/HCl buffer (Secher and Burke, 1980) has been widely used. Alkaline 
pH has also been used with some success (Paus, 1976) and such methods may 
involve only slight modification of ionic strength which is advantageous in 
avoiding the dénaturation of biologicals as may occur in other applications.
ii protein dénaturants, such as urea (<  8 M) or guanidine hydrochloride (6 M) can 
reversibly perturb protein conformation, and have been used as eluents at 
neutral pH in AC protocols. This technique is particularly advantageous when 
the adsorbate involved is unstable at acid pH (Melchers and Messer, 1970).
iii chaotropic ions, which reduce the binding strength of hydrophobic interactions 
important to protein conformation. Strong solutions (up to 3 M) of thiocyanate 
ions have been used extensively (Eveleigh and Levy, 1977), although use of these 
agents with materials destined for pharmaceutical purposes may prove 
unacceptable. Other useful chaotropic salts include iodide ions (Ternyck, 1967), 
divalent ions (eg. M gC y and halo acetates (Kristiansen, 1974).
iv polarity reducing agents when in the mobile phase may facilitate desorption 
since hydrophilic interactions make an important contribution to the net 
stability of adsorbate binding. Non-specific desorption with dioxan (up to 10%)
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or ethylene glycol (up to 50%) has been reported (Anderson, et al., 1979).
V temperature manipulation, has excited some interest; Frankel (1980) reported
values of for antigen-antibody complexes could be increased by two orders 
of magnitude as the operational temperature was raised from 4 to 43°C. 
Efficient adsorption will be advanced at low temperatures (low values of K^, 
whereas desorption is facilitated by increased temperatures (high values of K^. 
Such a system requires careful development to ensure the adsorbate and ligand 
(eg. antigen and antibody) remain stable and active at the higher operating 
temperatures.
vi electrophoretic desorption, for enhanced dissociation of ligand-ligate complexes.
The concentration achieved by this desorption involves migration of associated 
adsorbate carrying a net charge (dependent upon pH) toward an electrode of 
opposite pole. Affinity purified protein(s) may then emerge from an AC column 
in an electrically focused, concentrated band, separate from any trace 
contaminants (Sherrington, 1982; Morgan and Dean, 1978; Morgan etal., 1978). 
In applications involving unstable adsorbates or ligands, it is possible that particular 
combinations of certain agents perform as mild, non-specific eluents. The nature of a 
satisfactory desorption technique will vary from application to application and can only be 
determined by experiment.
1.4 DOWNSTREAM PROCESSING
The processing of biologicals (all the operations required to recover a biological from 
a feed: its extract or broth) has developed "hand in hand" with improvements in culture 
techniques. As the market for products of mammalian cell culture grows, and the range of 
available products increases, so too does the need for efficient recovery and isolation processes 
which may be operated on a process scale. Many of these products are destined for therapeutic 
applications, and as such must meet stringent regulatory standards. Downstream processing 
costs therefore may prove the most costly aspect of the manufacture of a bio-pharmaceutical.
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This is particularly true of the new, high purity products of mammalian cell culture (e.g. MAh, 
Factor Vlll, Tissue Plasminogen Activator etc.), where downstream costs may represent a 
significant proportion of total operating costs, often greater than 67% (Rossen and Datar, 1983).
N ovel applications of monoclonal antibodies in therapy, tumour imaging, and product 
processing, indicate an exponential increase in their demand to a market in excess of $6  billion 
per annum by the year 2 0 0 0  (Savin, 1990). Downstream operations in biochemical manufacture 
are required to fractionate products from contaminants which might otherwise impair their 
function or therapeutic acceptability. Furthermore, these processes increase the specific activity 
(activity/ unit mass) of a bio-pharmaceutical, such that effective doses may be 
delivered/administered in convenient quantities.
By tailoring downstream processes to the end use, the extent to which biological 
product is purified may justify the expense of its production. Diagnostic and analytical 
biologicals may require no more than preserving (removal or inhibition of proteases and 
freezing) where absolute purity is not required. However, therapeutics are required to be free 
of antigenic contaminants, genetic material and pyrogens if they are to receive commercial and 
regulatory acceptance.
The Commission of the European Community (CEC," 1986) pointed out the need to 
avoid unnecessary contaminants upstream by using pyrogen free water, and omitting the 
antibiotic penicillin from culture media, avoiding problems of allergy to the final product. In 
addition, it should be proven that all retrovirus, unwanted immunoglobulins, D N A , and 
irritants (e.g. adjuvants used to generate ascites) have been inactivated or removed. The FDA  
(1985) in a draft report further recommended that animal cell products destined for in vivo  use 
should contain less than 35 ng of endotoxin, and no more than 10 pg of D N A  in each patient 
dose. These targets stretch the practical capabilities of process scale purifications, but must be 
fulfilled if the new products are to have an impact on the expanding markets based upon 
diagnostic and therapeutic applications.
Contaminating components present in processed biologicals may include metabolites 
released by cells, microbial infections (viral, mycoplasma, fungal), process aids such as antifoams
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or antibiotics, ligand or contaminants leached from adsorbent resins, membranes or equipment 
surface residues. Furthermore, biologicals may themselves degrade to give inactive derivatives, 
physically and biochemically similar to the original adsorbate, and as a result these will be co­
purified, tainting an otherwise homogeneous purification. This situation was exemplified by 
the observation that insulin from pancreatic sources when processed to a therapeutic grade of 
purity contained several degraded forms, which emphasized the need for high resolution 
fractionations (Manil et a l, 1986).
1.4.1 Process scale AC
The development of an AC protocol for use at process scale should ideally begin with 
the design of a solid phase, with the desired end use in mind. The most appropriate form a 
solid phase should take is usually discovered in small scale laboratory trials (1 to 5 ml of solid 
phase), prior to a pilot study with the feed stock(s) in question at preparative scale (10  to 100 
ml of solid phase), and finally scale-up to process scale (1 - 10 litres of solid phase).
Flow rates may have a considerable effect on the performance of column AC due to 
the time required for the dynamic establishment of ligand-ligate complexes. Excessive flow rates 
lead to only partial adsorption of an adsorbate, as a result of a low contact times. When dealing 
with high value adsorbates an economic balance must therefore be drawn between the cost of 
the solid phase in question, and the rate at which product is produced. Furthermore, lower 
flow rates with greater contact times will produce high yields, but require larger columns, 
increasing the capacity for non-specific adsorptions, and time for biological/chemical 
degradation. As a result, for process scale purification of a known quantity of a biological, flow  
rates are usually calculated for minimal column size, taking into account parameters such as 
Q  and (Hubble, 1987).
Experimentally determined flow rates will however become lower on prolonged use (or 
reuse) of columns, due to solid phase fouling and/or compaction, which will alter the pressure 
drop over the bed. Mass transfer theory would suggest that the most efficient adsorbents will 
be those with particle sizes as small as possible. In practice, the choice of particle size is largely
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governed by the necessity to maintain high and steady flow rates through often soft and 
deformable bed materials at low hydrodynamic pressures.
Hydrostatic pressure above a column does not increase proportionally with flow rate 
for compressible solid phase particles, such as those based on agarose, dextran, and acrylamide. 
For rigid solid phases such as those based on silica/glass and alumina, a linear relationship has 
been established by combining Darcy’s Law (1859) and the Kozeny-Carman (1937) relationship. 
This allows a mathematical prediction of adsorbent flow rates, when other parameters such as 
particle size, porosity, and column length are varied. A good estimation of the flow rate is 
given by the following:
v - k E èI
r\L
where V  is the linear flow rate (or superficial flow rate), K  is the permeability, d  the mean 
particle diameter, ôP the pressure drop across the bed, n the eluent viscosity, and L  the b ed , 
height. Estimations of flow rate using this calculation proved consistent with experimental 
results found for rigid particles, giving a linear relationship between pressure drop and flow  
rate. For deformable particles, the relationship may be logarithmic and then may be expressed 
in an empirical relationship of the form (Joustra, 1967):
^  (12)
K  = K e  ^
-a -
where represents the permeability at bP = 0, and  ^is a function of the packed bed height, 
diameter and void volume. In general, for rigid particles, the smallest particle size possible 
should be used, within the pressure constraints of the system; when using deformable particles, 
a particle size should be chosen which gives an inlet pressure that will not exceed the 
maximum obtainable flow rate.
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Figure 3. Pressure drop as a function of particle diameter calculated for 
Sephacryl S-200 Superfine.
Industrial scale purification processes must be: cheap, easy, quick, specific, accurate and 
precise. At present, process scale AC tends to be used as a downstream final clean up step, 
selectively removing trace contaminants from commercially prepared biologicals. Ideally, 
bioselective techniques should be placed further upstream, allowing the selective isolation of 
large quantities of the desired biological, and effectively removing the bulk of trace 
contaminants in a single step. This has not been considered a viable proposition in the past, 
due to the high cost, short life, and very slow flow rates achievable using traditional affinity 
solid phases. By developing more robust silica/glass based solid phases with longer lives, higher 
flow rates, and lower cost than those previously available it was hoped that this study would 
demonstrate the ability to purify biologicals on these solid phases, and illustrate the potential 
use of these at process scale in rapid upstream processes to a high (sometimes even therapeutic) 
grade of purity.
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1.5 LIGANDS
Depending on the nature of the ligand involved AC techniques may be sub-divided into 
categories as shown in table II. A number of reviews have been written listing many of the 
ligands to be found in the literature and those biologicals to be purified on them. 
Comprehensive reviews of note include those of Wilchek et al (1974 and 1984), Lowe (1979), 
and Absolom (1981). The most important characteristic of a ligand is its ability to demonstrate 
specific, reversible binding to the substance to be purified. This binding should be such that 
the normal high tendency towards association of ligand and ligate may be shifted in favour of 
dissociation by altering the environmental conditions. It is usually recommended that a ligand 
should have a binding affinity for its ligate the order of lO"'^  moles/litre > >  10'*
moles/litre, or lO'^  litres/mole < K ^ <  10  ^litres/mole in free solution; this value being reduced 
for immobilized ligands (Absolom, 1981). The higher the association constant the harsher the 
conditions required to elute the ligate from the stationary phase, increasing the likelihood of 
denaturing biologicals.
TABLE II. AFFINITY CHROM ATOGRAPHY
- Biospecific Group Specific
- Immunoaffinity (antibodies).
- Enzymes (substrates, inhibitors, coenzymes, and allosteric
modulators).
- Lectins (cell surface antigens, carbohydrates, glycoproteins, and
polysaccharides).
- Protein A /G  (Fc, immunoglobulins).
- Metal Chelates (Haem, Histidine).
Ligate Specific
- Steroids (receptors).
- fatty acids (FA binding proteins, albumins).
- Gelatin (fibronectin).
- Dye-ligands - Reactive dyes (triazines, and remazols).
- Mimetic™ ligands (ACL).
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Ideally, in addition to having a specific binding site(s) for their ligate, ligands should also 
possess functional groups facilitating immobilisation to a matrix. Furthermore, immobilisation 
should have little or no effect on ligate binding, which is a major consideration in the use of 
bioselective ligands, which rely on their unique conformation and configuration for their 
interaction with complementarily positioned groups or sites on their ligates. Immobilisation 
conditions must therefore be gentle enough to prevent dénaturation, and not result in steric 
hindrance of binding sites. The former can generally be overcome by careful choice of 
immobilisation buffers, the latter may be avoided by the incorporation of a spacer arm.
A fully optimized AC protein separation will create a balance between resolution and 
strength of binding required. The quality of an isolate will reflect the quality of a ligand, its 
purity and condition, not its concentration; homogeneousness of ligand requires a uniform 
non-denaturing immobilisation. High concentrations of immobilized ligand will result in 
increase binding affinities, at the cost of increased steric hindrance, and non-specific adsorptions 
(Absolom, 1981).
1.5.1 Immunoaffinity
The technique of immunoaffinity chromatography (lAC) relies entirely on the strength, 
and selectivity of binding between an antibody (Ab) and its corresponding antigen (Ag). In lAC  
processes, immobilized antibodies provide the ligand covalently bound to the immobile matrix 
(to form a solid phase) and the antigenic determinants or epitopes on the target antigen the 
ligate. When antibody and antigen are in close proximity the antibody binding sites and 
antigen’s epitopic foci are attracted, and orientated, primarily by electrostatic attraction. This 
then elicits the formation of secondary hydrogen bonds, pulling the molecules closer together, 
and excluding water. Finally, van der Waal’s forces are initiated to form a stable non-covalent 
bond (target antigens therefore being adsorbed (fig 4).
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A N T I B O D Y A N T I G E N
NH- C O G
H --  H
V A T E R  E X C L U D E D
Figure 4. Diagrammatic representation of the forces involved in the 
formation of antibody-antigen complexes: A, ion attractive 
forces; B, the formation of H-H bonds; C, the exclusion of water 
and the formation of hydrophobic bonds; and D, the formation 
of the oscillating dipoles of van der Waal’s forces (Philips, 1989).
Elution of an Ag is achieved by adjusting the conditions of the buffer stream flowing 
through the column such that there is a reversible conformational shift in the tertiary structure 
of either the Ab or Ag, resulting in a lack of fit  ^the desorbed Ag then emerging from a column 
closely following the solvent front (about 0.5 col vols).
lAC separations require antibodies that have values which are neither too high, 
resulting in inferior fractionation; nor too low, leading to diminished recovery of active 
product and in reduced ligand longevity (fanson, 1984). Antisera Ab:Ag interactions have 
dissociation constants, on the whole, in the region of 10’^  M to 10'^ '^  M at 25°C (Capra and 
Edmundson, 1977). Those in the range 10'^  to 10'^ ° moles/litre (M) are particularly suited to 
immunoaffinity adsorption, whilst those with lower values (<  10'^ )^ are more suited to 
immuno-diagnostic applications where near-irreversible binding is of greatest advantage.
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The use of an immobilized antibody as a bioselective adsorbent was first reported by 
Campbell and co-workers over forty years ago (Campbell et al.^  1951). Techniques employing 
immobilized antibodies to purify many biologicals (enzymes, hormones, vaccines, interferons, 
antibodies) on laboratory scales have since been developed, and widely reported (Campbell and 
Weliky, 1967; Hill etal.^ 1986; and Silman and Katchalski, 1966). Immobilized antibodies have 
found particular application in the recovery of biological compounds where simpler methods 
have failed. Such is the case where molecules in nature with suitable specific affinities for the 
ligate in question are not practically known (e.g. as in the case of interferon purification), or 
are difficult to obtain in sufficient quantities (e.g. hormone receptors for hormone purification). 
The increased availability of monoclonal antibodies, by the development of tools such as the 
hollow fibre bioreactor, has made immunoaffinity purification a method worthy of 
consideration for purifying high value products, such as interferon (Mutami and Dyer, 1986), 
Factor VIII (Zimmermann and Fulcher, 1986) and Lymphokines (Ambrus, et al., 1985).
lAC separations may result in a high degree of purification in a single step clean up of 
biological samples for quantitative evaluations. This process is of particular value when the 
analytes in question are small molecules (eg, steroid hormones, antibiotics, and anabolic agents). 
When incorporated into a routine analytical regime for these residues, lAC systems are 
relatively simple to operate, and automate.
The use of lAC however, as with all antibody based processes, does have its drawbacks. 
Antibodies have a high molecular weight, which may limit adsorbate accessibility, while 
rendering the solid phase susceptible to dénaturation and/or fouling. In addition, spatial 
constraints on matrix surfaces may lead to Fab regions being sterically hindered (IgG has M.wt. 
150 K Daltons and a stokes radius of 40 Â; Stryer, 1981). Also, the ligand (e.g. antibody specific 
to the required antigen) is often not readily available and may need to be produced specifically 
for a particular application. Furthermore, if an lAC process is to be incorporated into the 
standard operating procedure for the production a vital isolate, then an immortalized cell line 
producing fully characterised monoclonal antibodies may be required.
The use of silica/glass derivatives as supports for bio affinity ligands in the resolution
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of biological macromolecules allows the principles of high performance liquid chromatography 
(HPLC) to be applied to affinity chromatography. Ohlson (1978) and his colleagues termed this 
technique high performance liquid affinity chromatography(HPLAC). A further modification 
of this technique utilizing antibodies as the ligand has been termed high performance 
immunoaffinity chromatography (HPIAC; Philips, 1985).
In this study the rapid flow rates achievable and robust nature of lAC solid phases 
based on silica/glass matrices were exploited in the rapid processing of biological samples for 
residue analysis. An automated lAC sample preparation and ELISA based quantitative system 
(lAC-ELISA), was developed for detecting the growth promoting agent clenbuterol in 
biological samples (mostly bile and urine).
1.5.2 Protein A and protein G
Protein A (SpA) is a cell wall protein found in the bacterium Staphylococcus aureus. SpA 
binds specifically to the Fc of immunoglobulins of various species. Protein G (StpG) and the 
receptor FcRc are immunoglobulin (Ig) binding proteins isolated from group C Streptococci 
(Reis et al, 1984; Fahnestock, 1987); unlike SpA, these proteins will bind to the human 
immunoglobulin IgG  ^ subclass. Stp G has been suggested as an alternative ligand to SpA, for 
the isolation and purification of Ig s, as it is reputed to have a wider range of IgG subclasses 
to which it will bind than protein A (including mouse IgG ,^ rat IgG2a,IgG2b and sheep IgG ;^ 
Ohlson et al, 1988). The adsorption of Igs to Stp G is of a greater avidity than that associated 
with the use of SpA, elution typically requiring exposure to harsher conditions, reflected in a 
loss of activity on recovery of product. Table III summarises a number of the reported degrees 
of SpA and StpG binding to Igs from different species found in the literature.
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TABLE III. THE B IN D IN G  OF SpA A N D  StpG TO IM M UNOGLOBULINS  
FROM DIFFERENT SPECIES
Species Subclass SpA StpG
Human IgGi Strong Strong
IgG^ Strong Strong
% None Strong
IgG^ Strong Strong
IgAz Weak N one
IgM None N one
Mouse IgGi Weak Weak
IgGza Strong Strong
IgGzb Strong Strong
% Strong Strong
IgM None N one
Rat IgGi Weak Weak
IgG:, None Strong
IgG:b None Weak
IgGzc Strong Strong
IgM None N one
Rabbit IgG Strong Strong
IgM N one N one
Ovine IgGi None Strong
IgG: Strong Strong
IgM None N one
Caprine IgGi Weak Strong
IgG: Weak Strong
IgM None N one
Bovine IgGi None
IgG: Strong Strong
Guinea Pig IgGi Strong Strong
IgG: Strong Strong
Chicken IgG None N one
Differences in binding are shown in italic. Data collected from Hjelm et al, 1972; Zindmark et al, 
1983; Ohlson and Niss, 1988; and Phillips, 1989).
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In this study SpA has been used as a model ligand for the evaluation and comparison 
of the performance of silica/glass affinity matrices, against those more traditionally used. Solid 
phases have been compared in order to assess their ligand stability and MAb AC performance. 
In order to evaluate levels of ligand leakage an ELISA was developed, capable of detecting SpA 
in the presence of stoichiometric excesses of murine IgG .^
1.5.3 D y e-ligand affinity chromatography
Reactive dyes were developed by the clothing industry to overcome the problem of the 
lack of fastness (a tendency to wash out) of the dye in coloured textiles. In order to overcome 
this problem, reactive groups were introduced to well known easily synthesized chromophores, 
enabling their covalent attachment to the primary hydroxyl groups of textiles. The discovery 
that certain kinases show abnormal behaviour on gel filtration columns in the presence of blue 
dextran (a conjugate of the triazine dye Cibacron Blue F3G-A with dextran) led to the 
observation that a large number of textile dyes show a strong interaction with proteins (Clonis 
et al., 1981). Since this discovery the use of immobilized triazine dyes in Pseudo-affinity 
chromatography has become increasingly popular (Clonis et al., 1987).
The most widely used reactive dyes in protein purification are the triazine dyes from 
Ciba-Geigy (Cibacron), from ICI (Procion) and the vinyl sulfone Remazol dyes from Hoechst. 
Textile dyes are useful tools in the separation of proteins because their structures usually 
include fused aromatic rings with charged groups (often sulphonyl groups) to obtain aqueous 
solubility and a variety of side groups which can make electrostatic, hydrogen-bond, or 
hydrophobic interactions with proteins (Lowe et al., 1986).
Due to the differential nonspecific interactions of proteins with an immobilized dye 
their resolution may require mild eluting conditions, varying pH or ionic strength of the buffer 
used. For example, fibroblast interferon binds avidly to blue dextran and is not displaced by 
changes in ionic strength; it can be, however, recovered with ethylene glycol, indicating the 
hydrophobic nature of the interaction (Jankowski et al., 1976).
In general, proteins which show biospecific interactions with dyes are usually enzymes
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which have negatively charged substrates, in particular those with phosphorylated substrates. 
These interactions are probably due to negatively charged sulphonate groups on the dye 
mimicking phosphates on the substrate (Scopes, 1987). In some cases, dye molecules even 
resemble natural ligands of proteins such as NAD+, NADP'*', ATP, coenzyme A and various 
nucleotides. Protein binding may then be biospecific and the protein eluted by competition of 
the free natural ligand (Dean and Watson, 1979; and Scopes, 1987).
However, some proteins interact with cationic substrates and a number of nonreactive 
cationic dyes are known to interact with biological macromolecules: for example acridine dyes 
such as acridine orange and proflavin interact with DNA, trypsin and chymotrypsin, whereas 
ethidium bromide, thionine and auramine O interact with double-stranded D N A , trypsin and 
horse liver alcohol dehydrogenase, respectively (Clonis et al., 1986).
In particular, the intensively studied anthraquinone dye Cibacron Blue F3G-A interacts 
strongly with several enzymes that possess the structural domain known as the "dinucleotide 
fold", such as certain kinases, dehydrogenases (including lactate and glyceraldehyde-3-phosphate 
dihydrogenase) and other nucleotide binding enzymes (Clonis et al., 1987a). However, it has 
been shown that Cibacron Blue F3G-A binds also to certain proteins that do not possess a 
dinucleotide fold, eg.., human serum albumin (Leatherbarrow and Dean, 1980), whereas some 
that do possess a dinucleotide fold do not bind to the dye (Scopes, 1987).
Many reactive textile dyes are now known for binding a large number of unrelated 
proteins like albumins, antibodies, blood clotting factors, growth factors, interferons, 
glycoproteins, proteases, lipases, restriction endonucleases, kinases, dehydrogenases, synthetases, 
collagenases, oxido-reductases, transferases, esterases, decarboxylases, etc. and in some cases with 
a remarkable degree of specificity (many reviewed by Dean and Watson, 1979; and Clonis et 
al., 1987a).
The use of immobilized textile dyes as chromatographic media offers many significant 
advantages over the more conventional immobilized biological ligands; theses dyes are produced 
on a very large scale and are therefore readily available at very low costs. Furthermore, they 
are easily coupled directly to various matrices via their reactive functions resulting in a fairly
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stable bond and thereby avoid the hazardous CNBr-activation of the support and/or complex 
organic synthesis.
In general, dye-ligand matrices are both chemically and biologically stable and are not 
hydrolysed easily to give the free dye (unlike CNBr-immobilized ligands which are susceptible 
to nucleophilic attack by amines). In addition, the protein binding capacity of immobilized dye 
solid phases is much higher than that of natural biological media (10-100 fold; Lowe et al., 
1986).
Dye columns are readily reusable, can be operated at high flow rates, will tolerate the 
presence of detergents, proteins and depyrogenating agents and may operate under mild 
conditions producing a good yield. All these properties show great potential for large-scale 
applications (Lowe et al., 1981).
In view of the different chemical structures of the various dyes available and their 
diverse interactions with proteins it has been suggested that their sequential use for the 
purification of a variety of plasma proteins may prove the best approach to their exploitation 
(Arnaud et al., 1983). A major disadvantage to the use of dye-ligand affinity solid phases for 
separating a particular protein, is the necessity to screen a number of different immobilized 
dyes, to find the one most suited to the particular protein in question (Lowe et al., 1986; 
Scopes, 1987). Another problem reported to be associated with the use of dy e-ligands was one 
of excessive levels of ligand leakage (Clonis, 1987a).
In this investigation, the non-reactive cationic acridine dye Rivanol which is known to 
interact with plasma proteins was immobilized and evaluated as a potential dye-ligand solid 
phase for the process-scale isolation of proteins (particularly immunoglobulins) from plasma. 
In doing so, it was hoped to further exploit the advantages offered by rigid silica based matrices 
and provide a universal tool for the isolation of plasma proteins.
1.6 IMMUNOASSAYS
Immunoassays (lA’s) take full advantage of (and best exemplify) the highly specific 
interactions between antibodies and antigens. Initial studies into the development of
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immunoassay technologies were carried out less than 40 years ago by Yalow'' and Berson 
(1959). Presently hundreds of lA ’s have been reported for a number of analytes. lA ’s operate 
within the Law of Mass Action (Equation 13):
Ab + Ag ** Ab’Ag
This reaction may be expressed in terms of an equilibrium constant (Equation 14):
k _ (14)
' (Ab) (Ag)
Traditionally, immunoassays develop this antibody (Ab) antigenic analyte (Ag or An) 
interaction further by the introduction of a label. Depending on the nature of the labelling 
used lA ’s may be divided into three categories; those with labelled Ab (Immunometric assays), 
those with labelled analyte (Immunoassays) and those where neither Ab or An are labelled 
(unlabelled lA ’s). The earliest immunoassays used a labelled analyte (An*), which was allowed 
to compete with free analyte for a limited number of Ab binding sites (Equation 15).
Ab + An + An* ** AbiAn + Ab:An*
When the Ab and An* concentrations are constant, the level of unbound An"' (the free fraction) 
at equilibrium and the level bound are inversely and directly proportional to the level of free 
analyte respectively. By comparing known standard amounts of the free analyte (characterized 
and pure) against levels of an unknown, a quantitative evaluation of analyte content of the 
unknown may be gained.
In this study the technique of affinity chromatography on rigid silica-based matrices is 
proposed and evaluated as a means of rapid sample clean up, applicable to process scale 
applications. Analyte specific ELISA techniques have also been developed andusedas the major 
tool in quantitative evaluations of the performance of solid phases. The prospect of combining 
the techniques of lAC and ELISA to develop lAC-ELISA technologies for detecting the 
presence of residues in biological samples has also been investigated.
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CHAPTER TWO 
MATERIALS AND REAGENTS
2.1  REAGENTS
2 .1.1 General reagents
Rivanol (6,9-diamino-2-ethoxy-acridine lactate) was purchased from the Sigma Chemical 
company (No. D-9001). The N aO H  solution (IM; Analar N o. 1824) used to evaluate the 
dissolution of silica matrices was supplied by BDH. The Amerlite chemiluminescent signal 
reagent was purchased from Kodak Clinical Diagnostics Ltd., Amersham (UK). 3,3’,5,5’-Tetra- 
methylbenzidine was purchased from Boehringer Mannheim GmbH, Bell Lane, Lewes, East 
Sussex BN7 ILG. Human serum albumin (HSA, 30 % solution) was purchased from Armour 
Pharmaceuticals Co Ltd., St. Leonards House, St. Leonards Rd, Eastbourne, East Sussex BN21 
3YG. Activated charcoal (No. 33032) was supplied by BDH, Poole (UK). OptiPhase "Safe" was 
supplied by Pharmacia Wallac O y (Milton Keynes, UK). Matrex™' Silica Si Chromatography 
medium (PS), particle size, 90 - 130 jxm; pore size 1000 Â, was purchased from Amicon Ltd., 
Upper Mill, Stonehouse, Gloucestershire CLIO 2BJ (UK). Amino activated CPC (No. 
C 100 /N H 2/130-250; 130-250 jum, 101.1 nm pore size) was purchased from Schott Cerate 
(USA). All other general reagents (unless otherwise stated) were of an analytical grade and were 
obtained from BDH Ltd (U.K.) or from Sigma Chemical Co. (UK).
2.1.2 Water
i General purpose water, the water used for cleaning vessels and making up 
buffers was of a reverse osmosis purified grade, produced and supplied by an in- 
house facility.
ii Cell culture water, this was produced by a process scale Millipore RO Water 
System fitted with a Super Q™- polisher. Freshly prepared batches of water 
were used to dissolve lyophilized media (RPMI), and the solution sterile filtered 
prior to use.
2.1.3 Unlabelled analytes
Native protein A was purchased from Fermentech Ltd, Research Avenue Two, Heriot-
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Watt University Campus, Riccarton, Edinburgh (UK), and supplied as a kind gift from Dr 
Kami Beyzavi of Bioprocessing Ltd., Consett, Co. Durham, D H 8 6TJ (UK). Recombinant 
protein A (rPro A) was purchased from the RepliCen Corporation, Cambridge, MA, USA. 
The A-agonists cimaterol, clenbuterol, terbutaline and salbutamol were purchased from the 
Sigma Chem. Co. The three "new" clenbuterol related compounds cimbuterol, mabuterol, and 
mapenterol were a kind gift from Dr R W Stephany (Head of laboratory for Residue analysis), 
Rijksintiuut voor Volksgezondheid en Milieuhygiene (RIVM), Antonie van Leeuwenhoeklaan 
9, P.O. Box 1 , 3720 BA Bilthoven, The Netherlands. Zeranol (Zl; a-zeralanol), and its related 
acid lactones (zeralenone, ce-zeralenol, B-zeralenol, zeralanone, and B-zeralanol) were obtained 
from the International Minerals and Chemical Corporation, Terre Haute, Indiana, (USA). 
Trenbolone (Tb) was obtained from Rousel-Uclaf, Paris, France.
All other analytes were purchased off-the-shelf from the Sigma Chem. Co. (address as
above).
2.1.4 Radio-labelled analytes
lodinated proteins were produced in-house by Dr Piotr Kwasowski (Kwasowski, 1986). 
The tritiated anabolic agents, trenbolone and zeranol, were kind gifts from Dr Steven N  Dixon, 
formally of The Food and Veterinary Laboratory Ltd (FAVL), 25 Frederick Sanger Road, The 
Surrey Research Park, Cuildford, Surrey (UK). Clenbuterol-H^ was purchased from Amersham 
International pic., Amersham Laboratories, White Lion Road, Amersham Buckinghamshire, 
England HP7 9LL.
2.1.5 Silanising agents
Aluminium triethoxide (No. 23,585-7), aminopropyltriethoxysilane (APTS; N o. 11,339- 
5), 1,4 butanediol diglycidoxy ether (bis-oxirane; N o. 22,089-2) 95 % v/v , 3-glycidoxypropyl- 
trimethoxy silane (CPTS; No.23,578-4) 96 % v/v , glutaraldehyde (No. C400-4), 25 % w /v , 3- 
(triethoxysilyl)propyl-trimethylammonium chloride (QAMTS; N o. 37,629-9) 65 % w /v  solution 
and triethylamine (no. 23,962-3) 99 % v /v  were purchased from the Aldrich Chem. Co. Ltd., 
The Old brickyard. N ew  Road, Cillingham, Dorset SP8 4JL (UK).
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2.1.6 Enzymes
Horseradish peroxidase (HRP, N o. HRP4B) was obtained from Biozyme Laboratories 
Ltd., Blaenavon, Gwent.
2.1.7 Antibodies and antisera
The murine IgGj (serum free hollow fibre bioreactor supernatant, AFP27 J.24), was a 
kind gift from Dr Handa-Corrigan of the Wolfson Cytotechnology Laboratory (WCL), 
University of Surrey, Guildford, England. Additional murine IgG  ^ monoclonal (AFP27, SZ; 
air lift fermenter supernatant, containing 5% NBCS) was a kind gift from Mr Shuyuan Zang, 
also of WCL. DEAE ion exchange purified murine IgC  ^monoclonal was a kind gift from Dr 
Kami Beyzavi of Bioprocessing Ltd (address as above). Cammabulin (hIgC) was purchased from 
Immuno Ltd., Arctic House, Rye Lane, Dunton Green, Nr Sevenoaks, Kent TN14 5HB. 
Rabbit anti-protein A (No. P-3775) was purchased from the Sigma Chemical Co (UK). Rabbit 
anti-clenbuterol PAbs were raised in four rabbits at the Institute for Animal Disease Research 
(IADR), Compton, Nr. Newbury, Berks, RC16 OPP (UK). Other immunological reagents 
were taken from existing stocks produced in-house.
Antisera collections from various sample bleeds were given the notation uppercase 
letter(s).number.lower case letter. Where the upper case letter (sometimes accompanied by a 
number) denotes the hapten and or animal, the number the boost (P for prime), and the lower 
case letters denoting bleeds post boosting.
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2.1.8 Buffer Solutions
i Borate adsorption buffer; disodium tetraborate (0.1  M), sodium chloride (0.15 
M), pH 8.5.
ii Citrate adsorption buffer; trisodium citrate (0.1 M), citric acid (0 .1  M), pH  6 .
iii Cit/Phos pH buffer; citric acid (0.1  M) and disodium phosphate (0 .2  M); these 
solutions were mixed (v/v), to give solutions with pH ’s between 1.7 and 8.6  
(Dawson et al, 1969).
iv Dextran/charcoal; activated charcoal (5 g), dextran T70 (0.5 g) and water (800 
ml).
V  Eluting buffer, citric acid (0.1 M).
vi Enzyme label preserving buffer; sodium acetate (8 mM), ammonium acetate (15 
mM), NaCl (100 mM), lactose (14 mM), Thimerosal (0 .0 1 %, w/v).
vii Clycine elution buffer; glycine (0.1 M), pH 2 .
viii HCl elution buffer; hydrochloric acid (30 mM), pH 1.5.
ix High salt adsorption buffer; glycine (1.5 M), sodium chloride (3 M), sodium 
hydroxide to pH 8.9 (Pharmacia, 1992).
X Low salt adsorption buffer; glycine (1 M), sodium chloride (0.15 M), sodium
hydroxide to pH 8 .6  (Bioprocessing Ltd., 1991).
xi Phosphate buffered saline (PBS); disodium phosphate (20 mM), sodium chloride 
(137 mM), potassium chloride (2.7 mM), potassium phosphate (1.5 mM), pH  7.2.
xii PBST; PBS containing Tween 2 0  (polyoxyethylene sorbitan monolaurate; 0.05
%).
xiii PBSCT; PBST containing gelatin (0.1 % w/v).
xiv PBSThio; PBS containing Thimerosal (mercury-[(0 -carboxyphenyl)-thio]ethyl 
sodium salt; 0 .0 2  % w/v).
XV Preserving solution; Lactose (5 % w/v), Thimerosal (0.02 %  w/v).
xvi SpA assay buffer; sodium acetate (1 M), glacial acetic acid to pH 5.6.
and xvii Carb/bicarb; sodium carbonate (15 mM), sodium bicarbonate (35 mM), pH  9.8.
All buffers when used for HPLC or for assessing the performance of affinity columns were
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filtered through a plug of glass wool and then degassed for an hour prior to their use.
2.1.9 Biological samples
Lyophilized oxen gall bladder bile was purchased from the Sigma Chemical Co. in 500 
g batches (B-3883). The four lyophilized quality control bovine urine samples were a kind gift 
from Dr R W Stephany (Head of laboratory for Residue analysis), Rijksintiuut voor 
Volksgezondheid en Milieuhygiene (RIVM), Antonie van Leeuwenho eklaan 9, P.O. Box 1, 3720 
BA Bilthoven, The Netherlands. Human blood serum samples were separated from fresh blood 
samples, obtained by veinipuncture of the veins of the antecubital fossa of volunteers in-house.
2.1.10 Solid phases
Prosep A "high capacity" was a kind gift from Dr Kami Beyzavi of Bioprocessing Ltd 
(address as above). As the use and production of other solid phases will form an integral part 
of this study, these areas will be elaborated upon in later chapters where appropriate.
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2.2 EQUIPMENT
2.2.1 General equipment
Small quantities of reagents (1 - 200 mg) were weighed out into vessels on a Mettler H I 8 
balance, accurate to plus or minus 0.1 mg. Larger quantities of reagent were weighed out on 
a Mettler P1200N top-pan balance, accurate to plus or minus 10 mg. Both these instruments 
were supplied by Gallenkamp (P.O. Box 290, Technico House, Christopher Street, London 
EC2P 2ER (UK)), and were serviced and calibrated regularly.
The Enfer 1000 chemiluminescent plate reader and the Enfer 1000 four place 
microtitration plate shaking incubator were supplied (on loan) by Mr Ken Ashwell of Enfer 
Scientific (UK) Limited, 5a Vernon Street, Derby, DEI IPS England. Measurements of buffer 
pH were made using a Kent pH Meter model 7020, fitted with a BIL 9142 sealed (dry) 
electrode. The pH meter was calibrated before each evaluation by using pH  buffer solutions 
made up on a Weekly basis using pH buffer capsules (pH’s 4, 7 and 9) manufactured by Russel 
and supplied by The Sigma Chem Co. General assessments of pH were performed using 
narrow range (0 .0  - 6 .0 , 4.5 - 10.0 and 7.0 - 14) pH test strips from the Sigma Chem. Co.
2.2.2 Disposable plastics
Columns were purchased from Lab m (No. D823, Bury Lancs, UK). The colorimetric 
96 well microtitration plates used in the developmentof ELISA’s were Nunc-Immuno Plate 
Maxisorp F96 (certified grade 1), supplied by Cibco Europe (Uxbridge, UK) and Falcon 
polyvinyl chloride flexible plates from Becton & Dickinson; others plates evaluated were 
dismissed for further use. The chemiluminescent microtitration plates used were solid flat 
bottomed white Microlite™’ 2 , purchased from Dynatech Lab. Ltd., Daux Road, Billingshurst, 
W. Sussex, RH14 9SJ (UK). Other formats assessed and dismissed for further evaluation 
included strips and alternative solid plates from Dynatec, Cibco and Amersham. Scintillation 
vials (CK16B Scint minivial tubes & caps; N o. 10200) were purchased from Rocket of London 
Ltd. (Tyne & Wear, UK). Conical skirted sterile plastic universals were supplied by L.I.P. 
Equipment & Services Ltd. (W. Yorks., UK). LP3 and LP4 tubes were purchased from
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Luckhams Ltd. (Sussex, UK). All pipette tips were purchased from Alpha Laboratories 
(Eastleigh, Hampshire, UK).
2.2.3 Manual liquid handling
i Single dispensing, all single pipetting was performed using positive displacement pipettes
manufactured by Gilson (pipetman’s; supplied by Anachem Ltd. 20 Charles Street, 
Luton, Beds, LU2 OEB) and by Labsystems (Finnpipette’s; Labsystems UK Ltd. unit 
5, The Ringway Centre, Edison Road, Basingstoke Hants RC21 2YH).
ii Repeat dispensing, repetitive pipetting’s were performed using a BCL 500 dispenser
(BCL Ltd, Lewes, UK), or an Eppendorf Multipette 4780. A Zippette 10 (Jencons Sci. 
Ltd., Leighton Buzzard, UK) was used for repeat dispensing of scintillation fluid.
2.2.4 Automated liquid handling
The Tecan 5051 and Tecan 5032 robotic sample processors connected to Compusys 286 
computers (Appendix I) were supplied and initially set up by Mr Ian Norington of Tecan UK  
Limited, 18 The High Street, Coring-on-Thames, Reading R C 8 9AR. The Wellwash 4 and 
Wellfill 3 instruments were supplied by Denley Instruments Limited, Natts Lane, Billingshurst, 
Sussex RH14 9EY, England. A Denley Wellprep II instrument, was also kindly supplied, on 
loan, from Mr Steve Weston of Denley Instruments Limited. HPLAC was performed by 
packing solid phases into glass (Omnifit) columns and connected to a Varian 5000 HPLC (high 
performance liquid chromatography) instrument. This was coupled to a Varian UV-50 variable 
wavelength detector with a Varian 9175 chart recorder. HPLC equipment was purchased from 
Varian., 28 Manor Road, Walton-on-Thames, Surrey KT12 2QF. Class HPLC columns were 
purchased from Omni (UK). For the slow application of solutions to columns a Syringe Pump 
model 341, supplied by Sage Instruments (UK) was used. The Gradient mixer C M l, Frac 100 
fraction collector and LKB Bromma 2120 Varioplex II peristaltic pump were purchased from  
Pharmacia Biosystems Ltd. The Acusyst-Jr hollow fibre bioreactor (Appendix II) and the HL-1
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serum-free medium liquid, were purchased from New  Brunswick Scientific, Edison House, 163 
Dixons Hill, North Mymms, Herts (UK).
2.2.5 Centrifugation
i Small (<  1 ml) volumes; these were aliquotted into capped conical
polypropylene vials and separated in an Eppendorf model 5412 microfuge.
ii Medium ( < 3 0  ml) volumes, samples were dispensed into, or larger volumes 
aliquotted into 30 ml batches and centrifuged in an MSE Super Minor bench 
top centrifuge (MSE Ltd., Crawley, UK).
iii Large (>  1 L) volumes, large volumes (>  100 x 2 ml vessels, or >  1 L) were 
centrifuged in a Beckman Model J6B refrigerated centrifuge.
2.2.6 Photometry
i Optical density (OD); the C D  of solutions was determined in an LKB 
Ultrospec 4050 instrument fitted with an auto-sampler device (flow cell had 10 
mm path length, 70 fA capacity) and connected to a controller model 4070. 
Absorbance readings taken for solutions in the visible range (<  350 nm) were 
measured using disposable polystyrene cuvettes; measurements of absorbance in 
the ultra-violet were made using quartz cuvettes. A Titertek Multiskan Plus 
microtitration plate reader connected to an Amstrad PC1640 computer using 
the Titersoft software was used to measure optical density of microtitration 
plates and to analyze sample results (Flow Laboratories. U.K.). This instrument 
was replaced in later experiments with a Labsystems Multiskan Bio chromatic 
Instrument supplied by Labsystems (UK) Ltd., Unit 5 The Ringway Centre, 
Edison Road, Basingstoke, Hants RC21 2YH.
ii Absorbance spectra; the absorbance spectra of compounds was assessed by 
diluting in solvent (buffer or alcoholic solution) and scanning them against a 
solvent blank (in matched quartz cuvettes) using a computerized Kontron 
Uvikon 860 instrument.
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2.2.7 Freeze drying (lyophilization)
Samples were dialysed against water (immunogens) or diluted with preserving solution 
and aliquotted into clean new glass vessels. Samples were then shell-frozen, or frozen in trays 
of freeze-drying vials in a compressible Edwards "stoppering-Shelf" ( N o. F05923000) at -40°C 
for 16 hours. Frozen samples were freeze dried for 16 to 30 hour in an Edwards Freeze-drier 
model "Modulyo", fitted with a Pirani 501 vacuum gauge and connected to an Edwards vacuum 
pump, model E2M5. Where possible vessels were sealed prior to removing from the vacuum.
2.2.8 Sample mixing
Samples were vortex mixed where appropriate either singly or in batches on a 
Rotamixer (Hook and Tucker Instruments Ltd, UK) or in an SMI multitube vortex (Model 
2601; Scientific Manufacturing Industries, USA) respectively. Samples were agitated gently by 
roller-mixing on a Spiramix 5 roller-mixer (supplied by Denley Instruments Limited).
2.2.9 Dialysis
i Small ( < 1 0  ml) volumes; these were performed using dialysis tubing cellulose 
membrane (Sigma, D-9277) 10 mm wide with a capacity of 10 m l/foot. Prior 
to use the appropriate length of tubing was boiled for an hour in water. 
Samples were decanted and sealed into inflated doubly knotted tubing and 
incubated in 3 changes of a bath of a minimum of 500 vols of buffer for 16 
hours at 4°C (cold room) stirring constantly.
ii Medium (10 - 1,000 ml) volumes; samples were dialysed as for smaller volumes 
using wider visking tubing (22 mm wide 30 ml/foot) supplied by Medicell Int. 
Ltd., 239 Liverpool Road, London N1 ILX (UK), or by using a Sartorius 
stirred-cell vacuum concentrator (200  ml).
iii Large (>  1 L) volumes; protein solutions were concentrated to 500 ml using an 
Amicon CH2A concentrator fitted with a 30,000 (Y30) molecular weight cut off 
filter and an RA2000 reservoir. Keeping the volume constant and the liquid 
expulsion rate at 5 ml/min, concentrated proteins were then dialysed by
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continued liquid removal, replacing the extracted liquid with PBS containing 
0.01% sodium azide (5L, added in 100 ml aliquotes).
2 .2 .1 0  Glassware
Where possible (usually for small volumes) all glassware was new and was only used 
once. When small volumes of buffered solutions were required, disposable plastic universals 
were used. Larger items (50 ml and above) were sent on a daily basis to an in-house washing 
facility and rinsed with water prior to use. For the production of standard stock solutions, 
vessels were either new or rinsed with 0.1  vols of alcohol followed by an equal volume of 
acetone and dried overnight prior to their use. A stock of Schott Duran vessels was also kept 
separate from the general laboratory glassware and used solely for the production of affinity 
solid phases.
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2.3 METHODS
2.3.1 Determination of liquid viscosity
The viscosity of solutions was determined using a Oswald viscometer. This was done 
by measuring the average time taken (n = 5) for a liquid to fall from the upper reference mark 
of the viscometer to its lower reference mark, and comparing this time to that of a reference 
(distilled water). The viscosity was then given by:
r\{Nsm-'^) -  % 0.00101 (16)
btfwater)
2.3.2 Determination of liquid density
The density of liquids was determined by 1 ml of volumes of the liquid pipetted into 
a new dry scintillation vial. From the average of 5 weighings the weight per ml was determined. 
This technique gave estimated densities of the low salt, citric acid affinity chromatography 
buffers and water of 1.01 x 10'^ , 9.80 x 10“^ and 9.98 x 10"^  Kgm"^  respectively.
2.3.3 Preparation of the monoclonal antibody (AFP27 J.28)
1 ml of the mlgGi secreting cell line was defrosted and aseptically resuspended in 15 ml 
of HL -1 containing glutamine (5 mM) and grown in a 50 ml static culture flask (37°C, 5% 
CO2) for 24 hours. This solution was then diluted (2 X  10  ^ <  viable cells/ml <  1 X  1 0 )^ and 
250 ml used to inoculate the external circuit (EC) of the hollow fibre bioreactor. The 
bioreactor was monitored daily (except weekends) and the following control parameters 
maintained; lactate <  150 mg/dL, glucose >  150 mg/dL, glutamine >  2.5 mM, ammonia <
2.5 mM, dissolved oxygen >  80 mmHg, pH 7.1 and temperature 37°C. These evaluations were 
carried out at WCL and performed in accordance with its ' in-house laboratory standard 
operating procedures.
2.3.4 Antibody purification and assessment
i Ammonium sulphate precipitation ((NHJ2SOJ; this technique was based on
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that described by Garvey et al (1977). Antibody solution (MAb or PAb, 2 vols) 
was equilibrated at 4°C and added to a glass conical flask. Saturated 
solution (1 vol) was added dropwise, with continuous magnetic flea mixing. The 
vessel was then left to stand without stirring for 30 minutes at 4°C. The 
precipitated immunoglobulin fraction was then isolated by centrifuging the 
solution at 1,600 X g for 5 minutes. The pellet was then resuspended (by 
vortexing) in PBS and made up to its original volume. The (NHjzSO^ 
precipitation process was again carried out twice and the resulting pellet 
resuspended in PBS and frozen (adding 0.01 % sodium azide), or freeze-dried.
ii SpA affinity purification; a Prosep A "high capacity" column (Bioprocessing 
Ltd.) was conditioned by applying 5 col vols of acetone, followed by eluting 
buffer, then low salt adsorption buffer. These were all allowed to percolate 
through under gravity flow. Antibody sample was then applied (PAb diluted 1 
in 10 in low salt adsorption buffer or neat cell culture supernatant) to the 
column and allowed to percolate through. The column was then washed with 
5 vols of low salt adsorption buffer and adsorbed antibodies eluted in 5 vols of 
elution buffer. Eluted antibodies were then dialysed against 3 changes of 500 
vols of PBS (azide, 0 .01  %).
iii Assessment of antibody (MAb or PAb) titre; this was carried out by a number 
of immunoassay formats (ELISA & RIA). In the absence of competing antigen 
(or analyte) the titre of an antibody was determined as being that concentration 
at which 50 % of the maximum labelled (or immobilized) antigen binding was 
achieved.
2.3.5 Determination of protein concentrations
i Optical density; the concentration of protein A (SpA) in solution was
determined by ODjgonm {Al% = 1.65; Sjoquist et al., 1972). A  general
estimation of total serum protein content of solutions was assessed also by 
ODjgonm (IgG A l% , 280nm = 14.0, Little and Donahue, 1967; and HSAX1% ,
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279nm = 5.3, Blombâck and Hanson, 1979).
ii Coomassie dye binding; Coomassie Brilliant Blue G-250 (60 ± 1 . 0  mg. Sigma 
Chem. Co. N o. B-0630) was dissolved in a 3% solution of perchloric acid (50 
ml Analar Perchloric acid 60%, BDH N o. 10175: 950 ml ROW and added to 
a IL volumetric flask through a plug of glass wool. This solution was stored at 
4°C (cold tray) and aliquots filtered prior to use. To samples/standard 
(containing up to 100  ftg/ml of protein), an equal volume of prefiltered 
Coomassie reagent was added and the solutions vortexed for 10 seconds. The 
solutions were then allowed to stand for 5 minutes and the optical density read 
at 595 nm.
This dye forms electrostatic bonds with NH^ "^  groups and non-covalent bonds 
with non-polar regions of proteins. This results in a uniform staining of proteins, 
indicated by a colour shift from red/brown to blue. This dye-binding technique was 
sensitive in the range 0.1  - 100  jwg/ml.
iii Miscellaneous small quantities of protein (<  10 /^ g); these were detected by 
spiking samples with iodinated protein prior to an operation and evaluating the 
presence or absence of protein by gamma counting. Another approach to 
determining the concentration of protein component in a mixture of proteins 
was to serially dilute samples in water to discover the point at which 
components were no longer visible on staining electrophoretic gels. The 
presence of proteins with bioselective activity was determined by means of 
immunoassay techniques.
2.3.6 Evaluation of sample protein components
The protein make-up of affinity purified fractions was detected by gel electrophoresis 
(lEF and SDS-PAGE), using the Phamacia PhastSystem™. Proteins were separated by 
isoelectric focussing (lEF) and were compared against calibration standards (GOLD, lEF 
calibration kit pH 3-10; N o. 17-0471-01), using a PhastGel 3-9 for separating proteins with a 
pi between 3 and 9 (Separation Technique File N o. 100) (Appendix III); and by sodium dodecyl
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sulphate polyacrylamide gel electrophoresis (SDS-PAGE) comparing calibration standards 
(RED, electrophoresis low molecular weight calibration kit; N o. 17-0446-01), using the 
PhastGel gradient 10-15 for separating proteins with a molecular weights ranging from 10 ,000  
to 250,000 (Separation Technique File N o. 110) (Appendix IV). The location of isolated 
proteins on gels was detected by Coomassie staining (Development Technique file N o. 200 ), 
sensitive to 20 to 30 ng protein/band; and/or silver staining (PhastGel Silver Kit Instruction 
Manual), sensitive to 1 to 5 ng protein/band for lEF gels and 0.3 to 0.5 ng protein/band (or 
jLtg/ml as the volume applied was 1 fA) for SDS-PAGE gels (Pharmacia Ltd.).
2.3.7 Determination of radioactivity
Radioactivity was determined using RackBeta counters (1017 and a Wallac System 
1410) and a 1260 Multigamma II counter. These were originally purchased from LKB Ltd (1017 
and 1260) and at by the time of the end of writing this thesis a new machine (the 1410) had 
been purchased and the suite of machines (the "counting room") were serviced by Pharmacia 
Ltd. (address as above). These machines were all calibrated by external radioactive sources and 
regularly maintained as part of an ongoing service contract. The radioactivity of tritiated 
compounds was measured in plastic scintillation vials (6 ml). Routine within-lab determinations 
of gamma radiation (P^ % were assessed by using a Mini-1 Series 900 mini monitor, (Mini- 
Instruments Ltd, 8 Station Industrial Estate, Burnham-on-Crouch, Essex CMO 8R N, UK).
2.3.8 Radioimmunoassay (RIA)
i Clenbuterol assay; the "3H-Clenbuterol R.I.A.-Kit (5 X 100 tubes)" assay kits 
were purchased from Laboratoire d’Homonologie, Rue du Point du Jour, 8 - B- 
6900 Marloie, Belgium.
ii Zeranol assay; the FAVL/GUILDHAY zeranol RIA kits were a kind gift from 
Dr Steve Dixon (FAVL, address as above).
iii Anabolic agent assays; RIA was performed in a similar method to that described 
by Dixon and Russell (1983). Unknown samples (or recovered extracts) were 
added in duplicate to new soda-glass tubes in 500 jA of PBSGT. 100  fA of
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standards (0 Std to NSB), or controls were then added to additional tubes also 
in duplicate and 400 jxl of PBSGT added. 100  fxl of tracer (labelled analyte) was 
then added to all the tubes (510 Bq/ml; sufficient to give 2000 cpm in a 
Rackbeta 65% efficient for H )^. 100 fA of antiserum (at the predetermined 
working titre) in PBSGT was then added to all but the NSB tubes and 100  f A  
of PBSGT added to the NSB tubes. The tubes were then covered in clingfilm 
and then with aluminium foil and incubated overnight at 2-4°C (cold room). 
The tubes were then incubated in a tray of ice for 2 0  minutes and 500 f A  of 
dextran/charcoal was then added (omitting the total cpm tubes, to which 500 
f A  of water was added). The tubes were then centrifuged for 10 minutes at 2500 
g and the supernatant decanted into scintillation vials. 4 mis of scintillation fluid
were then added and the tubes counted for 4 minutes. The resulting cpm values
for the unknown samples were then compared with those of the standards and 
estimations of their analyte content printed out automatically by the Rackbeta 
controlling computer software package RiaCalc.
2.3.9 Enzyme-linked immunosorbent assay (ELISA)
The development and evaluation of analyte specific ELISA techniques constituted a 
considerable proportion of this study the details of which are described in later chapters.
2.3.10 Peroxidase labelling of second antibodies
A primary antibody (IgG-CPG) column was purged with 5 vols of citric acid (0.1 M) 
and 5 vols of PBS. Second antibody serum (1 vol) was then applied and allowed to percolate 
through under gravity flow. The column was then washed with PBS (5 vols) and adsorbed 
antibodies eluted by the addition of citric acid (O.IM pH 3.5, 5 vols) and HCl (30 mM, 2 X 5  
vols). The three eluted fractions were dialysed for 16 hour (overnight) against 3 changes of 
1 ,000  vols of carb/bicarb buffer. The affinity purified antibody concentration was then
determined by optical density (OD2gonm; 1% = 14).
Sodium periodate (0.1 M, 0.5 ml) was added to HRP (same quantity as Ab to be
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labelled, in 1 ml of water) and the solution roller-mixed for 30 minutes at room temperature. 
This solution was then dialysed for 16 hours (overnight) at 4°C, against 1 litre of acetate buffer 
(10 mM, pH  5.6; SpA buffer 1 in 100  containing NaBH^CN 10 mM).
The antibody and enzyme solutions were then combined and roller-mixed for 4 hours 
at room temperature. Remaining active sites were then blocked by adding 0.1 vols of a 
blocking solution (ethanolamine, IM; glycine, 0 .2  M; and NaBH^CN 10 mM; pH  7.6) and 
roller-mixing for a further 30 minutes. The conjugate was then dialysed for 16 hours at 4°C  
against 2 0 0 0  vols of enzyme label preserving solution.
2.3.11 Column flow characteristics
i Void volume determination; a solution of Rivanol (10 mM, in 1:100 diluted SpA 
buffer) was applied to columns and the OD^ gonm monitored. The void volume 
(Vo) was determined as being the volume of buffer required to reach half the 
OD of the rivanol solution applied (C/Cg = 0.5). Vq was also estimated by 
weighing columns of water-damp, solid phase,pre- and post-drying overnight at 
80°C. The Vo (ml) was then estimated as being equal to the loss in column mass 
(g). Using this technique, the void fraction of Prosep A HC was assessed as being 
0.81.
ii The nature of the flow within a packed bed of solid phase was assessed by 
calculation of its associated particles Reynolds number, defined as:
Re -  -  (17)
where /y  was the density of the fluid applied to the packed bed; u was the 
superficial velocity of solvent flow through the packed bed; was the diameter 
of the solid phase particles and fi was the viscosity of the liquid applied to the 
packed bed. If the value of Re was less than 10 , the nature of solvent flow  
through a column was assessed to be laminar; if the number was assessed to be 
between 10 and 10 0 ,the flow was considered to be mixed and if the number was
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found to be greater than 100, the nature of solvent flow through the column was 
considered turbulent.
2.3.12 Statistical analysis of data
i Linear regression; this was used to describe the best line of fit where appropriate 
and was used only when one of the parameters assessed was determined by a 
technique developed in this study.
ii Student’s t-test; this was used in order to judge the similarity or dissimilarity of 
groups of results from sample evaluations conducted in this study.
iii Bartlett’s test for homogeneity of variances; this test was used to compare the 
variation of the means of groups of analytical results conducted in this study. 
These values were calculated as follows:
M - 2.3026/[(Hog,„(ES^/fe)) -  (DogjoS^)] U»)
where S was the standard deviation of the means; k was the number of groups; and /  
was the number of degrees of freedom (for n - 1 observations). M  was then given as 
being the od statistic for k - 1 degrees of freedom at the P = 5% level. When M  was 
lower than the od value, then the similarity in the values for the groups may be 
considered statistically significant, indicative of the same underlying <A.
Linear regression and t-test analysis of data was performed using the OXSTAT II 
computer programme (Microsoft Corporation, 1985). Analytical results comparing in-house 
and brought-in samples or test kits were compared using the PC software Fig P (Biosoft Ltd., 
22 Hills Road, Cambridge CB2 IJP. UK) for biological data. Data reduction of ELISA 
evaluations was performed using the Titresoft computer software package supplied by Flow  
Laboratories Ltd. (UK). This software was replaced later by the MultiCalc software supplied 
by Labsystems (UK) Ltd., Unit 5 The Ringway Centre, Edison Road, Basingstoke, Hants RC21 
2YH. RIA evaluations were performed using the RiaCalc computer software.
Other statistically determined values were given by locating the assigned values in a 
book of four figure statistical tables (Murdoch and Barnes, 1986).
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CHAPTER THREE 
AN ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR 
STAPHYLOCOCCAL PROTEIN A (SpA) PRESENT IN SpA PURIFIED MURINE
IMMUNOGLOBULINS
3.1 SUMMARY
In order to compare matrices commonly used as supports in the affinity purification 
of proteins, a technique was developed for screening an affinity-purified protein for the trace 
presence of a ligand leaked from solid phases. To achieve this, a specific non-competitive 
enzyme-linked immunosorbent assay (ELISA) was developed. This assay detects and quantifies 
protein A (SpA) levels, present as a trace contaminant in therapeutic murine monoclonal 
antibodies (MAb), purified on immobilized SpA solid phases. The assay employs a 
microtitration plate system, in which affinity-selected chicken anti-SpA antibodies from the egg 
yolks of immunized hens provide a specific capture antibody; followed by the addition of 
standards or sample with a MAb concentration of 1 mg/ml, in conditions unfavourable for Fc 
binding; and finally an affinity-selected rabbit anti-SpA peroxidase label. The working range 
of this assay is between 0.5 and 10.0  ng/m l (CV <  5%), with a lower limit of detection of 0 .2  
ng/m l (CV <  10%).
With this assay typical SpA leakage (usually in the range 0.5 - 10 ng/m l of irrigating 
buffer) from solid phase preparations may be assessed. This assay enables screening of murine 
monoclonals for the presence of SpA. Thus, it provides a means of quality controlling the mass 
production of immobilized SpA affinity preparations; and more importantly here, a means of 
comparing the matrices used in the production of the solid phase.
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3.2 INTRODUCTION
The utility of immobilized protein A (SpA) preparations for the affinity purification 
of antibodies for therapeutic applications is widely acknowledged. However, the potential 
physiological effects of injecting SpA present in such antibodies due to ligand leakage remains 
of some concern, and has prompted this investigation. An attempt was therefore made to 
develop an ELISA capable of detecting SpA in the presence of stoichiometric excess of murine 
IgGi, and provide a means comparing the performance of affinity matrices, and quality 
controlling the production and use of immobilized SpA affinity preparations.
SpA is a cell wall protein found in the bacteria Staphylococcus aureus, covalently linked 
at one end (containing the C-terminus) to the wall’s peptidoglycan layer. It may be found in 
the cell walls of a number of staphylococci strains; these pathogens are wide spread and not 
species specific as first believed (Blackmore and Francis, 1970). Commercial preparations of 
native-SpA are made by isolating the SpA from cell cultures of S. aureus, by lysostaphin 
hydrolysis of its glycosidic bond to the cell wall, and an ion exchange chromatography clean 
up (Forsgren and Sjoquist, 1966; and Hjelm, H. etal., 1972). Recombinant SpA prepared from 
genetically engineered colonies of E. coli strain have also be developed and are commercially 
available (Porton Products Limited; Warnes et al., 1986).
The SpA molecule consists of a single polypeptide chain that is 31% a-helix, 13% fi- 
pleated sheet, and 56% randomly coiled and contains little or no carbohydrate component. SpA 
has a molecular weight of 42,000 Daltons; a pi 4.85 - 5.15; and UV maximum at 275 nm, 1% 
= 1.65. Amino acid analysis of SpA’s polypeptide make-up has revealed that it has 4 tyrosines 
and no tryptophan residues, which has been implicated in its irregular SDS-PAGE position. 
The SpA globular protein has a marked extended shape and is very resistant to denaturing 
agents such as 6M guanidine HCl, 70% ethanol, and O.IM HCl (Coding, 1978; Lindmark et al, 
1983).
The SpA molecule has four homologous regions of around 50 amino acid residues, each 
containing a single receptor site capable of binding an immunoglobulin molecule with high 
affinity. This binding is greatest for human IgC  ^ (Sjodahl, 1977), which has a binding affinity
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constant of 4.8 x 10  ^1/mole (Lindmark et al., 1983), limited binding also occurs with the IgM 
and IgE of some species, recognition occuring solely in the Fc region of the antibody molecule 
(Forsgren and Sjoquist, 1966; Kronvall, 1967).
The nature of the SpA-Fc interaction may be revealed by the technique of 
crystallographic refinement. These studies suggest binding is due to the formation of a major 
hydrophobic link between residues of the SpA molecules active site and the antibodies’ CH2 
and CH3 domains in the Fc region. In addition, there is a minor polar link in which CH3 
residues are involved in a sulphate ion link (Deisenhofer, 1981).
The use of SpA as a biospecific ligand has many applications in biomedical research; 
when radio-labelled it has been used to detect antigenic sites on the surface of intact cells; it has 
also been used as a precipitant in immuno-detection (RIA, secreting cells, and anti-idiotypic 
isolation of receptors; Forsgren etal., 1983). SpA has also been studied as a treatment in cancer 
therapy as a mediator of the body’s removal of circulating immune complexes carrying tumour- 
associated antigens (Salinas et al., 1985). Detailed reviews of the immunological applications of 
SpA include those of Coding (1978); Langone (1982), Forsgren et al (1983), and Lindmark et 
al (1983). Its major application, as addressed here, has been its use as a ligand in the affinity 
purification of immunoglobulins from sera, ascites, and tissue culture media.
A number of non-competitive ELISA screening techniques for SpA have been 
developed. These include those of Olsvik and Berdal (1981), non-specific Fc recognition 
followed by sample, rabbit anti-SpA, and goat anti-rabbit label; Dertzbaugh et al (1985), a 
rabbit anti-SpA used as capture antibody and labelled for detection; Warnes eta l (1986), human 
IgC used as a plate coat followed by sample, rabbit anti-SpA, and finally goat anti-rabbit label; 
Lucas et al (1988), an adaptation of that of Dertzbaugh using rabbit anti-SpA F(ab) ’2 fragments 
to eliminate Fc recognition; and Bloom eta l (1989), where rabbit anti-SpA provided the capture 
antibody and labelled F(ab) ’2 fragments the detector.
The final assay protocol proposed here follows attempts to reproduce and improve 
upon those described above. In doing so an attempt was made to avoid those inherent hazards 
associated with the use of extracts from human sources (hIgC); those of precision loss, increased 
costs, and time due to large numbers of assay stages; and in particular those effects due to the
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presence of stoichiometric excesses of Fc regions in purified murine monoclonal samples.
These problems have largely been avoided in keeping the number and length of assay 
stages to a minimum, while introducing three novel features in the assay. Firstly samples and 
standards were presented to the capture antibody in molar ammonium sulphate pFI 5.6 
favouring SpA-Fc dissociation, and secondly the capture antibody was an affinity-selected 
chicken anti-SpA antibody with no non-specific SpA-Fc recognition (chicken antibodies do not 
normally bind SpA; Lindmark et aL, 1983; and Fahnestock, 1987). Finally antibodies were 
affinity-selected for high affinity SpA binding by a stepped pH gradient elution from an 
immobilized SpA preparation, and antibodies eluted in the pH 3.5 - 1.8 fraction used in the 
assay.
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3.3 MATERIALS AND METHODS
3.3.1 Isolation of IgY’s from egg yolk
Four laying hens were immunized with SpA following standard immunization protocols 
(Chuwa, 1983). A number of techniques for the isolation of immunoglobulins from the yolks 
of immunized were assessed. Theses included the use of dextran sulphate, concentrated 
ammonium sulphate, and freeze-thawing (Jensenius et al, 1981); Aerosil and dextran (Chuwa, 
1983); magnesium chloride and phosphotungstic acid (Vieira, 1984); propanol and PEC 
precipitations (Hassl et al., 1987); and a series of PEC precipitations (Pepper, 1990). N one of 
these worked entirely satisfactorily; as a result the isolation protocol adopted contains elements 
of a number of protocols, but is mainly a variation of that of Vieira (1984).
Separated egg yolk was diluted with 10 volumes of phosphate-buffered saline (PBS: 
disodium hydrogen phosphate, 0.02 M; sodium chloride, 0.14 M; potassium phosphate, 1.5 mM; 
and potassium chloride, 2.7 mM; pH 7.4), and roller mixed for 2 hours at room temperature. 
On equilibration at 4°C the mixture was centrifuged for 10 minutes at 1000 X  g. The 
supernatant was stirred and 0.01 volumes of magnesium chloride (3 M) and 0.05 volumes of 
phosphotungstic acid (20 mM) were added dropwise. The mixture was incubated at 37°C for 
90 minutes and then centrifuged for 30 minutes at 2500 X g, and the supernatant dialysed at 
4°C against PBSThim (PBSThimerosal, 0.02 %; 3 X 100 volumes). Isolated IgYs were then 
stored at -40°C.
3.3.2 Affinity-selection of chicken anti-protein A (CceSpA)
A Prosep A, High Capacity column (10ml, 10 mm diameter), was purged with 10 
column volumes of molar citric acid, and equilibrated with 10 column volumes of PBSThim 
under gravity flow (0.5 ml/min). IgY isolate was applied (20 volumes; equivalent to a single 
yolk) and the column washed with 10 volumes of disodium phosphate (0.2 M). Elution was 
carried out by three additions of 5.5 volumes of citrate/phosphate solutions (citric acid, 0.1 M; 
and disodium phosphate, 0.2M) at pH ’s 4.8, 3.5, and 1.8 respectively, the first 0.5 volumes 
being discarded in each case. Eluates were dialysed against 100 volumes of PBSThim and the
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IgG content evaluated by optical density (Abs 280 nm, 1% = 14.0; Little and Donahue, 1967).
3.3.3 Preparation of chicken anti-SpA-HRP
Affinity-selected CœSpA (1.5 mg) was labelled with an equal amount of HRP, by 
periodate activating the enzyme (Beyzavi et al, 1987). This process was repeated activating the 
IgY component. The periodate based labelling protocol of Nakane and Kawaoi (1974) was also 
attempted.
In addition, the conjugating properties of the heterobifunctional reagent N-succinimidyl- 
3-(2-pyridyldithiol) propionate (SPDP), for making IgY-HRP conjugates was also assessed. 0.2 
ml of 30 mM SPDP was added to HRP (1 mg, in 1 ml PBS) and IgY (500 /ig, in 1 ml PBS), in 
two new clean glass vessels, and the solutions roller mixed for 30 minutes at room temperature. 
Dithiothreitol (0.1 M, 100 fA) was then added to each solution, and the solution roller-mixed 
for a further 30 minutes. These solutions were then dialysed in the same vessel for 16 hours 
(overnight) at 4°C, against 3 changes of 1000 vols of PBSThio. These solutions were then 
combined and roller-mixed for 16 hours at 4°C.
The conjugate was then purified by gel filtration down a 20 ml Sephadex G50 column 
and the eluted fractions (1 ml) assessed for enzyme activity and coomassie dye binding. The 
success of the conjugation procedure was checked by ELISA titration analysis of the peroxidase 
activity on D aC  coated plates. The labels were also evaluated in the SpA ELISA.
3.3.4 Preparation of rabbit anti-SpA-HRP (RceSpA-HRP)
Lyophilized rabbit anti-SpA (RaSpA, 50 mg), was resuspended in 2 ml of water. 
Affinity-selection of those antibodies with the highest affinity for SpA was carried out 
following the same procedure as for CaSpA. 1 mg of the pH 1.8 eluate was diluted to 1 ml 
with water, and dialysed for 16 hours (overnight) at 4°C, against 500 vols of carb/bicarb buffer 
pH 9.8. Sodium periodate (0.1 M, 0.5 ml) was added to HRP (1 mg, in 1 ml of water), and the 
solution roller-mixed for 30 minutes at room temperature. This solution was then dialysed for 
16 hours (overnight) at 4°G, against 1 litre of acetate buffer (10 mM, pH 5.6). The antibody 
and enzyme solutions were then combined and roller-mixed for 4 hours at room temperature.
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Remaining active sites were then blocked by adding 0.5 ml of a blocking solution 
(ethanolamine, IM; glycine, 0.2 M and sodium cyanoborohydride 10 mM; pH 7.6), and roller 
mixing for a further 30 minutes. The conjugate was then dialysed for 16 hours at 4°C against 
2000 vols of PBSThim.
3.3.5 Assay validation
Optimal concentrations of plate coat antibody (CaSpA, 9/90; 0.125 /xg - 2 jLtg; @ 200 
jul/well) and tracer antibody (RaSpA-HRP, 1/91; 1:125 - 1:64,000) were assessed by a two 
dimensional titration determination, keeping the SpA level constant at 10 ng/ml. The effects 
on the standard curve of murine monoclonal antibodies (IgGj, 0.01 - 1 mg/ml), pH  (4.6 - 6.6), 
and of incubation time ( 1 - 3  hours at 37°C) were also evaluated.
3.3.6 Preparation of standards
The concentration of protein A in solution was determined by optical density (Abs 280 
nm, 1% = 1.65; Sjoqist et al, 1972), and evaluated for purity by polyacrylamide gel 
electrophoresis (Pharmacia PhastSystem).
3.3.7 Sample preparation
The IgG content of affinity purified antibodies was determined by optical density (Abs 
280 nm, 1% = 14.0), and 1 ml aliquots diluted to 1 mg/ml in IM sodium acetate, pH  5.6 for 
assaying.
3.3.8 ELISA protocol
Microtitration plate(s) were coated with capture antibody in coating buffer (CaSpA; 200 
fA, at 5 /ig/m l in sodium carbonate, 15 mM; sodium bicarbonate, 35 mM; pH 9.8), for an hour 
at 37°G. Any remaining active sites were blocked by washing three times and finally incubating 
for 30 minutes with PBSGT (300 iA\ PBS 0.14 M, gelatin, 0.1%; and Tween 20, 0.05%). Plates 
were then used in the ELISA, or incubated with lactose/Thimerosal (300 fA-, 5 % and 0.05% 
respectively) for 30 minutes at room temperature. The preserving solution was then decanted
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off and the plates then desiccated and stored at 4°C. Sample(s) and standards were then added 
(200 fil in sodium acetate, IM: pH 5.6; so as murine IgGj = 1 mg/ml) and the plate incubated 
for 1 hour at 37°C. The plate was then washed (4 X 300 fA of PBSGT), enzyme label added 
(RofSpA-HRP. 1/90; 1:10 ,000  in PBSGT) and incubated for an hour at 37°C. The plates were 
again washed (4 X  300 f A  of PBSGT), substrate buffer added (tetra-methylbenzidine 2 0  m g/m l 
in dimethylsulphoxide, 100  f A;  7 f A  of hydrogen peroxide (60%) in 2 0  ml of disodium 
phosphate, 50 mM; citric acid, 25 mM; pH 4.9) and incubated for 30 minutes at 37°C. The 
reaction was then stopped by the addition of hydrochloric acid (IM, 50 jul), and the optical 
density measured at 450 nm. These results were then subjected to Titersoft analysis.
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3.4 RESULTS
A summary of those ELISA protocols assessed is given in table V. Though many of 
these may appear sensitive enough to be of use, they were unable to tolerate the presence of 
contaminating mlgG^. The protocol of choice was number 11 , and was therefore further 
developed. This assay (fig. 5), proved quick, sensitive, and reproducible, even in the presence 
of contaminating monoclonal antibodies.
TABLE V. SUMMARY OF SpA ELISA’s EVALUATED
Assay Protocol mean LLD 
(ng/ml, 
n = 6)
GV
(%)
mlgGj
tolerance
(mg/ml)
1 dIgG:SpA:dIgG-HRP 4.0 ± 2 2 .0 <  0 .0 1
2 hIgG:SpA&SpA-HRP 25.0 + 2 0 .0 <  0 .0 1
3 hIgG:SpA:SpA-HRP 5.0 ± 8 .0 <  0.05
4 RaSpA:SpA:SpA-HRP 8.0 ± 11.3 <  0.05
5 RofSpAiSpAzsIgGzDaS-HRP 1.6 ± 43.6 <  0 .0 1
6 hIgGzSp AiRaSp A(AS) :DaR-HRP < 0 .0 2 ± 21.5 <  0.05
7 RaSp A(AS) :Sp AzhlgGzSah-HRP 2 .0 ± 51.9 <  0 .1 0
8 hIgGzSpAzRaSpA-HRP 2 .0 ± 3.7 <  0.05
9 Ro:SpA:SpA:RceSpA-HRP 2 .0 ± 27.6 <  0 .1 0
10 KLHbio:StAv-Co:SpA:SpA:RaSpA-HRP <  0 .0 2 ± 17.6 <  0 .1 0
11 GaSp A(AS) :Sp AzRceSp A-HRP(AS) <  0 .2 ± 2.1 >  1 .00
SpA ELISA protocols attempted (LLD = lower limit o f detection).
A typical egg yolk preparation produced 29 mgs of affinity-selected chicken anti-SpA 
(CaSpA, 9/90; pH 3.5 - 1.8 fraction, 50ml @ 89 jug/ml). IgYs from these hens prior to 
immunization were found not to bind SpA (as determined by the ELISA protocol). HRP 
enzyme labelled CaSpA preparations gave very poor results when used in the ELISA instead
66
of RaSpA-HRP. However, these antibodies produced good peroxidase titration curves when 
serially diluted and applied to a microtitration plate coated with donkey anti-chicken 
antibodies. This would suggest successful conjugation of the enzyme to IgY.
<
II HRPIII
HRPIV
Subs tra te  (colourless)
Product (coloured)
Figure 5. Diagrammatic representation of an ELISA protocol for SpA. (I) 
Plates (Nunc Immuno Plate Maxisorp F96) are coated with 
affinity-selected chicken anti-SpA IgY from the egg yolks of 
immunized hens as a capture antibody (CcuSpA, 200 fA, @ 
5/xg/ml); (II) Staphylococcal protein A standard or diluted 
sample is added (SpA, 200 /xl in sodium acetate, IM pH  5.6 
containing murine IgG  ^monoclonal, Img/ml); (III) Rabbit anti- 
SpA horse radish peroxidase enzyme label (RaSpA-HRP), and 
(IV) colorimetric detection with tetramethylbenzidine, O D  
measured at 450 nm.
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From a vial of lyophilized rabbit anti-SpA, 10 ml of high affinity-selected antibodies 
were isolated (RaSpA, 1/91; pH fraction 3.5 -1.8 at 783 /xg/ml), and from 1 mg of this, 5 ml 
of enzyme label was produced.’ A two-dimensional titration assay of these reagents suggests a 
plate coat concentration of 1 /ig/well and enzyme label dilution of and 1:10 ,0 0 0  as optimal (fig. 
6).
OD (450 nm) 
3 r
0.125
Plate coat 1C anti-SpA, fig/well) 
0 2
1.25 12.5 125
Label dilution (:lx1000)
Figure 6 . Two dimensional titration of chicken anti-SpA (CaSpA, 9/90) 
plate coat, and rabbit anti-SpA peroxidase label (Ro;SpA-HRP, 
1/91); at an SpA standard level of 10 ng/ml.
Standard curves in buffers commonly used in SpA affinity purification (PBS, citric acid, 
high and low salt buffers) suggest that the assay remains largely unaffected by changes o f buffer 
(as reflected in the OD/OD^^^ curves), though the maximum optical density achieved may vary 
(fig. 7). Recombinant SpA had a 100 % cross reactivity in the ELISA (fig. 8).
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0.156 1.56 15.6
SpA (ng/ml)
b)
Figure 7. The effect of buffering conditions on an ELISA for SpA: a) 
optical density, and b) binding profile.
69
OD (450 nm)
P ro te in  A
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Figure 8 . Cross reactivity of rPro A in an ELISA for SpA.
Standard curves in the presence and absence of murine IgG  ^monoclonal antibodies (fig. 
9), and in varying pH conditions in the presence of murine IgGj (1 mg/ml) suggest that the 
assay remains largely unaffected by monoclonal antibody concentrations below 1 m g/m l, with 
the effect minimal at a pH of 5.6 (fig. 10). In these conditions, standard curves (0 ng/m l - 51.2 
ng/ml) would suggest saturation at SpA levels above 10 ng/ml. The within-batch precision 
profile (CV plot) indicates a working range 0.5 ng/ml-lOng/ml (CV <  5%), with a lower limit 
of detection of 0.2 ng/ml (LLD ± 3SD >  0.0 ng/ml), which was unimproved by increasing 
the sample incubation time (fig. 11).
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Figure 9. The effect of murine IgGj levels on an ELISA for detecting and 
quantifying the present of SpA in immobilized SpA purified 
MAbs.
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1.4
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Figure 1 0 . The effect of pH on an ELISA for detecting and quantifying 
SpA present in immobilized SpA purified murine monoclonal 
antibodies at a concentration of Img/ml.
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Figure 11.
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Standard calibration curves, and precision profiles; for an ELISA 
detecting and quantifying SpA present in immobilized SpA 
purified murine monoclonal antibodies (diluted to a 
concentration of, Img/ml), achieved over an hour (a), and 3 
hours (b) assay time (n = 6).
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Using this assay, the SpA content of murine monoclonal purified on a Prosep A, High 
Capacity column, and also on a Protein A Sepharose CL-4B wasj evaluated. Contamination 
of murine monoclonals purified on these preparations would appear to be in the region of 1 - 
10 (1.8 - 2.7, and 5.0 - 8 .8 , respectively) parts per million, within an area of the standard curve 
found to be most sensitive. The levels of SpA leakage for protein A Sepharose found in this 
study would appear to be consistent with those detected by Füglistaller (1989).
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3.5 DISCUSSION
The assay described here is a specific non-competitive ELISA capable of detecting and 
quantifying levels of SpA (leakage), present as a trace contaminant of murine monoclonal 
antibodies purified on SpA affinity columns. The assay exploits the ability of a chicken anti- 
SpA antibody capable of high affinity SpA binding (as reflected in the strong dissociating 
conditions required for its affinity-selection, pH 3.5 - 1.8), to displace a stoichiometric excess 
of relatively low affinity SpA binding murine IgG  ^ molecules in conditions of high salt 
concentration (molar sodium acetate) and low pH (5.6, closer to their elution pH  from SpA 
preparations; pH 3-5) .  Samples are diluted in assay buffer prior to evaluation; this reduces the 
stability of murine IgG SpA-Fc binding thereby favouring dissociation, whilst offering little 
resistance to association with the high affinity capture antibody. At equilibrium the sequestered 
SpA molecules are therefore immobilized by the capture antibodies of the plate coat and the 
dissociated MAbs washed away.
The use of immunoglobulins from the yolks of immunized hens in immunological 
techniques has previously been reported by Jensenius et al (1981), Chuwa (1983), Hassl et 
al.{19S7), Pepper (1990), and Bauwens et al (1987 and 1988). Unlike mammalian IgG, chicken 
IgYs do not demonstrate Fc recognition when in the presence of SpA or mammalian Fc 
receptors (Jensenius et al.^  1981; Lindmark et al., 1983; and Fahnestock, 1987), suggesting the 
hen as an ideal source of specific SpA antisera. Unfortunately, all attempts at peroxidase 
labelling these IgYs resulted in poor SpA tracer reagents. This would suggest enzyme 
conjugation of the IgY results in steric hindrance of the Fab regions binding sites.
In choosing eggs from immunized hens as a source of immunoglobulins,provideda non- 
invasive means of collecting large amounts of stock antibodies. Their ease of extraction and low  
cost of production was of particular relevance when considering the production of a batch 
reagent for routine analysis. Utilizing the protocol suggested here, 10 batch isolates of chicken 
anti-SpA are possible from an egg (as for assay CceSpA, 9/90; producing sufficient antibodies 
for coating in excess of 4000 microtitration plates).
The rabbit anti-SpA serum used in this assay (RaSpA, as employed by Warnes et al,
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1986; Lucas et al, 1987; and Bloom et al, 1989) is capable of non-specific binding to the Fc 
receptor site in addition to the antigenic sites of the SpA molecule. In the assay, non-specific 
Fc and low affinity epitopic recognition of the Ro:SpA were limited by the affinity-selection 
of only those antibodies with a high-affinity for SpA, prior to enzyme-labelling with 
peroxidase.
On subsequent evaluations. Nunc Maxisorp microtitration plates were selected for the 
assay above the use of the cheaper Falcon plates, as the Nunc plates were found to have the 
best binding for chicken antibodies. Horseradish peroxidase was chosen as the labelling-enzyme, 
and tetramethylbenzidine/peroxide as the substrate as these reagents provide the greatest colour 
development per unit of immobilized enzyme (Beyzavi et al., 1987). The use of an equilibrated 
humidifier (sealed container, with a layer of damp tissues) and only the inner 60 wells of the 
microtitration plates was in order to minimise any possible "Edge Effects" (Esser, 1985).
The assay protocol described here does not represent that which was found most 
sensitive, but was selected to give the best working range and precision best around 1 to 20  
ng/ml, levels of SpA was found common for column leakage. Additional amplification stages 
using either DceR-HRP, or a biotin-avidin system produced an increase in the assay sensitivity 
(steeper curve), and a ten fold lowering of the lower limit of detection of 0.02 ng/ml. However, 
typical leakage levels observed would suggest that this level of sensitivity is not currently 
required.
The presence of IgGs forming soluble complexes with SpA (such as murine IgGj) of 
levels up to 1 m g/m l produce little alteration in the standard curve achieved. However, the 
presence of IgGs forming insoluble complexes (such as human IgG) causes a severe depression 
of the standard curve on approaching levels of 1 mg/ml. In order to use this assay to quantify 
SpA contamination of monoclonal antibodies other than IgG^s the effect this particular 
immunoglobulin isotype has on the assay may require evaluation, and standards run in the 
presence of control levels of monoclonal where necessary.
The usefulness of this assay was evaluated by assessing the SpA content of murine 
monoclonal antibodies purified on two commercially available immobilized SpA preparations 
(Prosep A, High Capacity, based on a controlled pore glass matrix; and protein A  Sepharose
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CL-4B, an agarose based matrix). The levels of SpA leakage for protein A Sepharose found 
using this ELISA were consistent with those detected by Füglistaller (1989).
SpA affinity chromatography may provide a one step clean up of antibodies to a 
near therapeutic grade of purity. However, in order for it to become the technique of choice 
for the production of therapeutics, one would expect rigorous monitoring of the ligand 
stability of affinity preparations and the contamination of those antibodies purified on them. 
The assay described here may provide a quick, sensitive, and inexpensive answer to the 
problem of routine screening of SpA.
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CHAPTER FOUR
ASSESSMENT OF THE SUITABILITY OF AFFINITY SOLID PHASE MATRICES 
FOR THE PURIFYING PROTEINS AT PROCESS SCALE
4.1 SUMMARY
The controlled pore glass (CPG) based SpA affinity chromatography solid phase Prosep 
A "High Capacity", was compared against seven other commercially available SpA solid phases, 
selected to demonstrate a number of matrix materials, and ligand immobilization chemistries. 
These solid phases were evaluated to establish their potential for the large-scale purification of 
a murine monoclonal antibody (MAb, m lgC j. The antibody was produced in-house, serum- 
free, in a hollow fibre bioreactor. Solid phases were tested for the effects of salt concentration, 
pH, and the presence of MAb on ligand leakage and flow rate. These effects were compared 
using the solid phases in stirred-tank (roller-mixing) and flow-through (packed-bed) modes of 
operation. In addition, six SpA solid phases were evaluated to determine the effect of buffer 
composition on the non-specific binding, and hence co-purification of plasma proteins (albumin 
and transferrin), in purified antibodies.
Ligand leakage in the absence of MAb was generally at its lowest when the solid phases 
were used in a flow-through mode. In this mode of operation increasing the inorganic salt 
concentration and pH of the washing/adsorption buffer from 150 mM at pH 8 .6 , to 3M at pH  
8.9, typically produced a 10% increase in MAb capacity of the solid phases (20% for the agarose 
based Sepharose CL-4B). However, contamination of the purified antibodies was also greatly 
increased due to an elevated level of background ligand leakage from the matrices. Residual 
contaminating levels of SpA, and non-specific binding of albumin and transferrin, in affinity 
purified antibodies were lowest with a low salt (NaCl, 150 mM) glycine (IM) 
adsorption/washing buffer.
Maximal antibody capacity was achieved for all matrices on frontal analysis 
(breakthrough curves), as opposed to a pulse mode of use. The largest capacity was found for 
the CPG based solid phase Prosep-A "High Capacity" (12 -15 mg/ml col vol), where capacity 
approached its experimentally determined theoretical capacity (C/Co = 0.5) regardless of its 
mode of use. The relatively high MAb capacity of Prosep-A "High Capacity" was further 
reflected in a superior dynamic isotherm. Frontal analysis, however, generally resulted in a 
greater SpA contamination of the purified MAbs. Under these conditions the lowest levels of
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SpA contamination were found for the Prosep-A "high Capacity" (CPG), and Repligen (6% 
cross-linked agarose) solid phases (12 ppm) on purifying 12.8 and 4.3 mg of MAb respectively.
For the large scale downstream processing of antibodies for therapeutic applications, 
Prosep-A "High Capacity" would appear the most appropriate of the solid phases tested.
79
4.2 INTRODUCTION
The large scale down-stream processing of antibodies destined for therapeutic 
applications requires a rapid (probably chromatographic), automated protocol. Affinity 
chromatography lends itself to this application in that it is about an order of magnitude more 
effective than comparable techniques which may be adapted to an industrial scale (Clonis, 
1987). Staphylococcal protein A (SpA) has largely become the ligand of choice for the affinity 
purification of monoclonal antibodies. In adapting the use of immobilized SpA solid phases to 
process scale, the main concerns are mechanical stability, flow rate, dynamic capacity, cost, 
purity of end product, and reusability. Amongst the SpA affinity solid phases currently 
available there is no obvious choice which appears to fulfil all the criteria of an ideal solid 
phase. In this chapter silica based matrices are proposed, and evaluated, as an alternative to the 
more conventionally used affinity matrices for the production of affinity solid phases for use 
at process scale.
Eight commercially available SpA solid phases were selected for evaluation, particular 
attention being paid to their matrix composition and ligand-binding chemistries. SpA solid 
phases were packed into disposable columns and assessed in stirred-tank (roller-mixing), and 
flow-through modes of operation, for the effect of buffer composition (pH and ionic strength) 
on ligand leakage, and flow rate. Solid phases were also evaluated for MAb capacity and trace 
SpA contamination of purified MAbs, when used in pulse and frontal modes of column use. 
The SpA levels of the samples in this investigation were assessed by sandwich ELISA, for 
measuring SpA in the presence of murine immunoglobulins. Six commercially prepared solid 
phases were were also evaluated for the non-specific purification of HSA and BT, in the 
presence or absence of hIgG.
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4.3 MATERIALS AND METHODS
4.3.1 Matrices
The following SpA solid phases were tested:
i Fast Flow Immobilized rProtein A, RepliGen Corp. 1 Kendall Sqr, Building 
700, Cambridge, Massachusetts, 02139, USA.
ii SpA-Agarose, iii Prosep-A "Low Capacity, iv Prosep-A "High Capacity", v 
Prosep-rA "Low Capacity", and vi Prosep-rA "High Capacity", Bioprocessing 
Ltd. N o. 1 Industrial Est., Consett, Co. Durham, England. D H 8 6 TJ.
vii Protein A  Sepharose CL-4B ' Pharmacia Biosystems Ltd., Biotech. Div., Davey 
Ave., Central Milton Keynes, England, MK5 8PH.
viii Protein A  Sepharose 4 Fast Flow, Pharmacia (as above).
ix NYGene MASS 10 mg IgG, NYGene Corp. NY, supplied by Receptor 
Technologies Ltd., 3 Church End, Radford Semele, Leamington Spa, CV31 
ITA.
X Protein A agarose 4XL, Affinity Chromatography Ltd., Freeport, Bailasalla, Isle
of Man, British Isles.
xi Protein A agarose 4XL, Affi-Prep Protein A, Bio-Rad Labs. Ltd., Bio-Rad 
House, Maylands Ave, Hemel Hempstead, Herts, HP2 4BR.
xii Protein A immobilized on Sepharose 4B Fast Flow, Sigma Chem.Co., Fancy 
Road, Poole, Dorset. BH17 7BR.
4.3.2 Preparation of buffers
The following buffer solutions were prepared: Borate, pH 8.5; Citrate, pH  6 ; Eluting 
buffer, pH 3.0; Glycine, pH 2 ; HCl, pH 1.5; High salt, pH 8.9 (Pharmacia, 1992); Low salt, 
pH 8 .6  (Bioprocessing Ltd., 1991); and PBS, pH 7.2 (Chapter 2). All buffers were filtered, and 
then degassed for an hour prior to use.
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4.3.3 Preparation and conditioning of columns
Solid phases (supplied as slurries, except the NYGene prepackaged cartridge) were 
suspended in PBS; the fines were removed by decanting the supernatant, and the remaining 
material was poured into two disposable columns, to form duplicate columns with 1ml settled 
bed volumes. Columns were then conditioned by purging with 10 column volumes (vols.) of 
eluting buffer and re-equilibrated with an equal volume of the buffer under evaluation. Between 
uses, columns were capped off and stored at 4°C in PBSThim.
4.3.4 Ligand leakage in the absence of MAb
The level of SpA leakage from the solid phases (ACL, Bio-Rad, NYGene, Pha. Fast 
flow, Prosep-A HC, Repligen, Seph CL-4B and Sigma F .Flow), on washing in stirred-tank and 
flow-through modes of use in four of the above buffering conditions (eluting. High salt. Low 
salt, and PBS), was assessed as follows:
i Leakage in stirred-tank mode of operation; columns were purged with 10 vols, 
of eluting buffer and re-equilibrated with 5 vols, of PBS. The solid phases were 
then resuspended in 5 vols, of PBS, the columns capped off and roller-mixed for 
30 minutes at room temperature (the NYGene cartridge was left soaking in 
buffer). After allowing the solid phases to form settled beds once more, the 
buffer was run off under gravity flow and collected. This was repeated for four 
cycles, for each of four buffering conditions (PBS, Citric acid, low, and high 
salt). All samples were stored at 4°C prior to assay.
ii Leakage in frontal analysis (breakthrough) mode of column operation. Each 
column was conditioned as above, then 5 vols, of buffer passed through and the
breakthrough collected. This process was carried out for four cycles for each of
four buffering conditions. Flow through times were also noted, and matrix flow  
rates were calculated. The SpA content of these fractions was determined by 
ELISA, against standard curves run in the same buffers.
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4.3.5 Leakage of SpA on affinity purification of MAb
Following conditioning (as described above), 20 vols, of serum-free bioreactor 
supernatant (20 ml, MAb of approximately 1.5 mg/ml) was applied to each column (gravity 
flow), and the columns washed with 10 vols, of buffer. Adsorbed antibody was eluted in 5 vols, 
of eluting buffer. This was repeated for four cycles, for all three of the adsorption buffers (PBS, 
Low, and High salt).
4.3.6 Dynamic and working capacities of columns
Pooled affinity purified MAb (in eluting buffer) from leakage studies was neutralized 
by adding 0.1 vols, of ten times concentrated PBS (1.5 M), and sodium hydroxide (1.0  M) to 
pH 7.2. This solution (850 jtig/ml, MAb) was applied in 10 X 5 ml fractions to the columns 
and each breakthrough fraction collected. Columns were then washed with 10 vols, of PBS, and 
adsorbed MAb eluted in 5 vols of eluting buffer. The MAb concentration of breakthrough 
fractions, and SpA contamination of eluted MAbs was evaluated. From these results, the 
dynamic and working (eluted) MAb capacities for the solid phases was calculated. The effect 
of residual SpA, in the pooled MAb used in this experiment, was eliminated from the ELISA 
determinations by running standard curves in the pooled MAb applied to the columns.
4.3.7 Evaluation of the MAb content of eluted samples
Eluates were evaluated for immunoglobulin content by optical density (Abs 280 nm, 
1% = 14.0; Little and Donahue, 1967).
4.3.8 ELISA for SpA
Leakage SpA samples obtained on applying buffer to the columns in the absence of 
MAb, were assayed against standard curves made in the buffers under evaluation. Eluted MAb 
samples were diluted with 4 vols, of assay buffer, and evaluated for MAb content prior to 
assaying for SpA. All ELISAs were conducted in accordance with the protocol reported in the 
previous chapter, using a Denley Wellprep II instrument.
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4.3.9 Non-Specific binding of albumin and transferrin to SpA columns
Following conditioning of the columns (Pha. Fast Flow, Prosep-rA LC and HC, Prosep- 
rA LC and HC, and SpA-Agarose), 10 vols of borate adsorption buffer containing plasma 
protein (albumin (10  mg/ml) or transferrin (1 mg/ml)) spiked with freshly iodinated plasma 
protein (200 kBq; with a specific activity 22  - 25 kBq//xg; Kwasowski, 1986) was applied to each 
column (gravity flow), and the columns irrigated with a further 10 vols of Citrate adsorption. 
Glycine adsorption, and HCl elution buffers. This process was repeated for plasma proteins in 
the presence or absence of hlgC (0 , 1, and 6 mg/ml), for two cycles. The plasma protein 
content of these fraction was evaluated by gamma counting, and the hlgC content by optical 
density (adjusted for plasma protein content).
4.3.10 The effect of ionic strength on HSA, and BT non-specific binding to Prosep-A HC  
As above Prosep-A H C preparations were contacted with spiked plasma protein ((HSA-
or BT-T^ ;^ 10 vols at 1 mg/ml), and the columns washed with a further 10 vols of 
adsorption buffer. Adsorbed proteins were eluted with 10 vols of eluting buffer (glycine; 0.1 
M, pH 2), and evaluated for protein content by gamma counting. This process was carried out 
for HSA and BT, in the borate and Low salt adsorption buffers.
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4.4 RESULTS
TABLE VI. THE COM POSITION OF COMMERCIAL SpA SOLID PHASES 
EVALUATED
Solid phase Matrix
composition
Active group SpA Capacity 
MAb (mg).
4=
ACL 4% cross-linked 
agarose
Triazine "Unknown" 5.3
Bio-Rad "Polymer" "Unknown" Native 3.5
NYGene cellulose "Unknown" Recombinant 5.1
Pha. Fast Flow 4% cross-linked 
agarose
Cyanogen
bromide
Native 5.0
Prosep-A HC Controlled pore 
glass
Aldehyde/ 
Schiff base
Native 15.0
Repligen 6% cross-linked 
agarose
Aldehyde/ 
Schiff base
Recombinant 2 .2
Seph. CL-4B 4% cross-linked 
agarose
Cyanogen
bromide
Native 4.3
Sigma F. Flow 4% cross-linked 
agarose
Cyanogen
bromide
Native 5.6
Average capacity of duplicate 1 ml columns (and a NYGene cartridge) over four cycles with a low 
salt washing/adsorption buffer (glycine IM, sodium chloride 150 mM; pH  8.6).
4.4.1 Background leakage of SpA in the absence of MAb
The specifications of the solid phases evaluated are summarized in table VI. Ligand 
leakage from these solid phases over four cycles in PBS, citric acid, low and high salt buffers 
are summarized for stirred-tank (roller-mixing) mode of operation in table VII, and for flow-
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through mode in table VIII. A flow-through mode of operation was adopted for the MAb 
capacity studies; as this resulted in lower levels of background ligand leakage. The effect of 
buffering conditions on column flow rates is given in table IX.
TABLE VII. THE EFFECT OF BUFFER COM POSITION O N  THE TOTAL SpA 
LEAKAGE (ng) FROM COMMERCIAL SpA AFFINITY CHROM ATOGRAPHY  
SOLID PHASES IN  STIRRED-TANK OPERATION
Solid Phase PBS (pH 7.2) CIT (pH 3.0) Low (pH 8 .6) High (pH 8.9)
ACL 1.74 ± 0.82 >  100 8.24 ± 7.26 > >  100
Bio-Rad 1.41 ± 1.79 1.84 ± 2.45 4.73 ± 5.70 9.01 ± 4.13
NYGene 20.01 ± 20.65 47.86 ± 34.89 39.34 + 54.65 6.4 ± 6.13
Pha. Fast Flow <  0.50 <  0.50 4.76 + 3.92 16.41 ± 5.29
Prosep-A HC 7.14 ± 3.28 34.87 + 10.05 48.06 ± 11.37 >  100
Repligen < 0.50 1.33 + 2.37 0.57 ± 0.23 1.06 ± 0.57
Seph' CL-4B <  0.50 <  0.50 2.23 ± 3.23 25.65 ± 1.83
Sigma F. Flow 0.49 ± 0.19 1.39 ± 1.69 1.64 ± 1.90 15.69 ± 2.19
SpA leakage from commercial immobilized SpA preparations (n = 8, duplicate 1 m l columns over 
4  cycles) on roller-mixing for 30 minutes with 5 col vols, in various buffering conditions.
Ligand leakage from all solid phases was highest in the high salt/pH buffer suggested 
as optimal for the binding of murine immunoglobulins by Pharmacia (1992), but was 
minimized by using the columns in a flow-through mode. Under these conditions the amounts 
of leakage were greatest for the solid phases Protein A agarose 4XL (Affinity Chromatography 
Ltd.) and Prosep-A "High Capacity" (Bioprocessing Ltd.), and the lowest for the solid phase 
Fast Flow Immobilized rProtein A (RepliGen Corp.). The cellulose NYGene cartridge 
demonstrated a fall from an excessively high level of ligand leakage (>  >  2 0  ng/ml), to a below
86 except the NYGene solid phase*
average value (2.3 ng/ml) over four cycles.
TABLE VIII. THE EFFECT OF BUFFER COM POSITION O N  THE TOTAL SpA 
LEAKAGE (ng) FROM  COMMERCIAL SpA AFFINITY CHROM ATOGRAPHIC  
SOLID PHASES IN  FLOW -THROUGH OPERATION
Solid phase PBS (pH 7.2) CIT (pH 3.0) Low (pH 8 .6) High (pH 8.9)
ACL 13.01 ± 6.46 >  100 > 100 >  100
Bio-Rad 4.04 ± 1.30 <  0.50 4.55 i  2.24 10.84 ± 1.20
NYGene >  100 38.23 ± 17.69 73.67 ± 30.59 29.15 ± 47.36
Phai Fast Flow 1.09 ± 0.79 0.75 ± 0.55 1.69 ± 0.54 13.97 ± 4.52
Prosep-A HC 15.50 ± 2.36 20.78 ± 2.88 25.87 ± 5.30 >  100
Repligen 0.34 ± 0.14 <  0.50 <  0.25 0.51 ± 0.02
Seph. CL-4B 1.56 ± 0.94 3.33 + 4.64 3.44 ± 1.38 39.56 ± 11.24
Sigma F. Flow 0.94 ± 0.46 <  0.50 1.84 ± 0.75 14.94 ± 5.45
SpA (SpA) leakage from commercial immobilized SpA preparations (n = 8, duplicate 1 m l columns 
over 4 cycles) on application of 5 col vols, in various buffering conditions.
In the presence of eluting buffer, all columns had consistently low levels of ligand 
leakage over four cycles of operation. Appreciable levels of leakage were only detected in three 
of the eight preparations evaluated (ACL, and the non-agarose solid phases Prosep and 
NYGene), suggesting this buffer is most suited to agarose based solid phases.
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TABLE IX. FLOW RATES OF COMMERCIAL SpA AFFINITY  
CHROM ATOGRAPHY SOLID PHASES (m l/m in)
Solid phase PBS (pH 7.2) CIT (pH 3.0) Low (pH 8 .6) High (pH 8.9)
ACL 0.47 0.39 0.35 0 .2 2
Bio-Rad 0.14 0 .12 0 .12 0 .1 0
NYGene 1.01 0.82 0.57 0.38
Pha. Fast Flow 0.43 0.34 0.35 0.23
Prosep-A HC 0.52 0.42 0.41 0.24
Repligen 0.35 0.30 0.29 0.18
Seph. CL-4B 0.34 0.29 0.27 0.17
Sigma F. Flow 0.55 0.46 0.45 0.27
Mean flow rates o f commercial immobilized SpA preparations, on applying 5 col. vols, o f buffer (n 
-  8, duplicate columns run under gravity flow for 4 cycles).
4.4.2 Leakage of SpA on purification of MAb
The effect of equilibrating/washing buffer composition on MAb capacity of the SpA 
solid phases, and the SpA contamination of MAbs purified on these solid phases in a pulse 
mode of operation are given in table X. Varying buffering conditions appeared to have little 
(or no) effect on the amount of MAb purified, but significantly affected the level of SpA 
contamination of the purified MAbs. Residual SpA levels in purified MAb were at a minimum  
for all solid phases when using a low salt glycine equilibrating/washing buffer. However, a 
marked stabilizing effect was observed for Prosep-A "High Capacity" (over four cycles), the 
average SpA contamination of purified MAb falling over three cycles to a steady 7 ppm.
TABLE X. THE EFFECT OF W A SH ING /A DSO RBING  BUFFERING  
C O N D IT IO N S O N  THE PULSE AFFINITY PURIFICATION OF A  SERUM- 
FREE M URINE IgGi MAb (SUPERNATANT; AFP27 J.28; 20 mL, UNTREATED), 
O N  COMMERCIAL SpA SOLID PHASES
Solid phase Buffer
MAb
Eluted
(mg)
SpA
Eluted
(ng)
SpA/ 
MAb 
(X 10 -  )^
ACL PBS 3.3 ± 1.1 356.3 ± 107.0 121.4 ± 20.1
Low 3.1 ± 0.2 236.5 ± 111.6 76.5 ± 36.6
High 3.1 ± 0.1 496.0 ± 47.0 149.3 ± 14.7
Bio-Rad PBS 3.8 ± 0.8 101.0 ± 31.7 27.4 ± 9.2
Low 3.3 ± 0.2 23.9 ± 3.9 7.25 ± 1.3
High 3.3 ± 0.1 29.6 ± 3.5 9.0 ± 1.1
NYGene PBS 4.7 ± 0.6 196.0 ± 23.2 42.5 ± 8.3
Low 5.2 + 0.6 30.3 ± 9.4 6 .0  + 1.8
High 5.1 ± 0.2 176.8 ± 215.6 36.3 ± 45.8
Pha. Fast Flow PBS 5.8 ± 1.8 72.3 ± 15.5 13.3 ± 3.9
Low 4.8 ± 0.5 23.3 ± 5.1 4.9 ± 1.0
High 5.0 ± 0.3 33.8 ± 4.8 6 .6  ± 0.9
Prosep-A HC PBS 27.2 ± 9.1 224.9 ± 43.7 9.4 ± 4.3
Low 14.1 ± 0.9 252.1 ± 171.1 18.4 ± 12.6
High 11.8 ± 0.7 485.8 ± 27.3 >  45
Repligen PBS 1.2 ± 0.3 <  11 <  10
Low 2.4 ± 0.7 < 11 <  5
High 2.8  ± 0.1 < 2.5 <  1
Seph. CL-4B PBS 5.7 ± 2.0 70.3 ± 11.2 14.1 + 5.6
Low 4.3 ± 0.3 34.6 + 6.5 7.9 ± 1.4
High 5.1 ± 0.1 54.8 ± 8.5 9.4 ± 4.2
Sigma F. Flow PBS 8.3 ± 3.5 91.9 ± 21.2 12.1 + 3.4
Low 5.9 ± 0.5 23.4 + 4.2 4.0 ± 0.8
High 6 .0  ± 0.1 36.8 ± 6.5 6.3 + 1.2
The following buffers were assessed PBS (disodium phosphate (20 mM), sodium chloride (137 mM), 
potassium chloride (2.7 mM), and potassium phosphate (1.5 mM) pH  7.2); Low (salt buffer; glycine 
(1 M), sodium chloride (150 mM), sodium hydroxide to pH  8.6; Bioprocessing Ltd.), and High (salt 
buffer; glycine (1.5 M), sodium chloride (3 M), and sodium hydroxide to pH  8.9 (Pharmacia), n — 
8, duplicate columns run under gravity flow.
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Increasing the adsorption/washing buffer salt concentration from 150 mM to 3 M 
typically produced a 10 % increase in capacity of these solid phases (20 % for Sepharose CL- 
4B). However, contamination of the purified MAbs due to ligand leakage also increased by 
between 10 and 80%.
4.4.3 Leakage of SpA on frontal analysis of columns
Figure 12 shows the results of frontal analysis (breakthrough curves), of the 
immobilized SpA solid phases in the low salt buffer. The dynamic and working capacities of 
these solid phases, and the SpA contamination of MAbs purified on them are summarized in 
table XI. In these conditions, maximal capacity was achieved for all solid phases as opposed to 
the pulse mode of use. Under these conditions Prosep-A "High Capacity" had the highest MAb 
capacity of the solid phases evaluated, purifying 12.5 mg of MAb (98% of the experimentally 
determined theoretical capacity) with equally the lowest contaminating SpA content (12  parts 
per million).
C/Co
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Figure 1 2 , Frontal analysis of SpA affinity chromatography solid phases on 
application of a murine monoclonal (C = breakthrough 
antibody concentration; Co = initial antibody concentration; 
and dynamic capacities C /Co = 0.5).
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TABLE XL DYNAMIC CAPACITIES OF COMMERCIAL SpA SOLID PHASES
FO R MAb
Solid phase
Dynamic 
Capacity 
(C/Co = 0.5)
MAb
Eluted
(mg)
SpA
Eluted
(ng)
SpA/ 
MAb 
(X 10-")
Prosep-A HC 12.8 12.5 150 12
Repligen 4.3 4.2 50 12
Pha. Fast Flow 6.1 5.6 84 15
Sigma F. Flow 6 .0 5.8 93 16
Seph. CL-4B 4.9 5.3 106 20
NYGene 6.8 5.7 120 21
Bio-Rad 4.7 4.2 105 25
ACL 4.1 4.0 780 195
Dynamic capacity and ligand leakage on frontal analysis of commercial SpA affinity solid phases. 
35 col vols o f MAb (at 850 fig/ml) applied to each column in low salt glycine buffer (solid phases 
ranked in order of increasing MAb SpA contamination).
Comparing the values of SpA leakage from the columns in the low salt adsorption 
buffer (table VIII) would suggest little correlation between leakage and MAb capacity (from 
table VI; r = 0.772), or the SpA content per unit purified MAbs (table XI; r = 0.770). On 
extended frontal analysis of a Prosep-A "High Capacity" column in the low salt glycine buffer, 
the level of SpA leakage fell from that expected of leakage in buffer alone ( > 2 0  ng/ml), to a 
lower level (<  2 ng/ml). Approaching column capacity this level of leakage appears again to 
slowly rise at a rate of 60 pg/m l per mg of MAb applied (fig. 13).
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Figure 13. SpA leakage from a Prosep-A HC column on frontal analysis 
with a murine monoclonal (MAb, AFP27 J.28, 1.5 mg/ml).
4.4.4 Non-specific binding (NSB), and co-purification of plasma proteins to SpA columns 
The NSB’s and co-purification results of affinity purifying HSA or BT on immobilized 
SpA solid phases in pulse mode, in the presence or absence of hIgG, are summarized in tables 
XII and XIII. In these conditions, the plasma protein content of affinity purified antibodies was 
the order of <  1 to 26 parts per thousand. Maximal plasma protein contamination of purified 
antibodies was found for the Prosep "Low capacity" solid phases. The plasma protein content 
of the eluted fraction (Glycine) remained at a more of less constant level irrespective of the 
antibody content.
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TABLE XII. THE HSA CONTAMINATION OF HSA-T'^ SPIKED GAMMABULIN 
(hIgG) POST AFFINITY PURIFYING O N  IMMOBILIZED SpA SOLID PHASES (mg 
HSA (mg hIgG))
Solid phase Borate Citrate Glycine HCl
Purification ofhIgG (10 ml, 6 mg/ml), containing HSA-H^ (10 mg/ml).
Pha. Fast Flow 99.95 ( - ) 0.01 (0.3) 0.02 (59.9) 0.01  (0 .1)
Prosep-rA LC 98.93 ( - ) 0.02 (2.7) 0.04 (60.0) <  0.01  (0 .1)
Prosep-rA HC 99.92 (1.1) 0.05 (0.2) 0.03 (58.1) 0.01  (0 .1)
Prosep-A LC 99.95 ( - ) 0.02 (2.9) 0.03 (60.0) <  0.01  (0 .1)
Prosep-A HC 99.95 (2.4) 0.02 (0.3) 0.02 (57.3) <  0.01  ( - )
SpA-Agarose 97.92 (20.4) 0.01 (5.0) < 0.01 (34.6) <  0.01  (0 .1)
Purification ofhIgG (10 ml, 1 mg/ml), containing HSA-H^ (10 mg/ml).
Pha. Fast Flow 99.90 (3.7) 0.02  (0 .2) 0.06 (6 .0) 0.01  (0 .1)
Prosep-rA LC 99.82 (4.4) 0.03 (0.2) 0.14 (5.3) 0.01  (0 .1)
Prosep-rA HC 99.89 (2.6) 0.02  (0 .2) 0.07 (7.0) 0.01  (0 .1)
Prosep-A LC 99.81 (2.5) 0.07 (0.2) 0.11 (7.3) 0.01  (0 .1)
Prosep-A HC 99.90 ( - ) 0.03 (0.2) 0.07 (9.8) <  0 .01  (<  0 .1)
SpA-Agarose 99.96 (2.7) 0.01 (0 .2) 0.02(7.0) <  0.01  (0 .1)
Purification ofhIgG (10 ml, 0 mg/ml), containing HSA-P^  ^ (10 mg/ml). ‘
Pha. Fast Flow 99.95 ( - ) 0.02  ( - ) 0.01  ( - ) 0 .02  ( -  )
Prosep-rA LC 99.58 ( - ) 0.25 ( - ) 0.12  ( - ) 0.04 ( - )
Prosep-rA HC 99.48 ( - ) 0.45 ( - ) 0.05 ( - ) 0 .0 2  ( - )
Prosep-A LC 99.87 ( - ) 0.02  ( -  ) 0 .10  ( -  ) 0 .01  ( - )
Prosep-A HC 99.93 ( - ) 0 .02  ( - ) 0.03 ( - ) 0.01  ( - )
SpA-Agarose 99.61 ( - ) 0.38 ( - ) < 0.01 ( - ) 0 .01  ( - )
HSA-P^  ^spiked Gammahulin was added to solid phases in 10 ml of Borate buffer (disodium borate (0.1 
M), sodium chloride (0.15 M) pH  8.5); followed by 10 ml of Citrate (trisodium citrate (0.1 M), citric acid 
(0.1 M), pH  6), Glycine (glycine (0.1 M), pH  2), and Hcl (hydrochloric acid (30 mM), pH  1.5) buffers, n 
= 4, duplicate columns run for 2 cycles under gravity flow.
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TABLE XIII. THE BT CONTAMINATION OF BT-T"" GAMMABULIN (hIgG) POST 
AFFINITY PURIFYING O N  IMMOBILIZED SpA SOLID PHASES (mg BT (mg 
hIgG))
Solid phase Borate Citrate Glycine HCl
Purification ofhIgG (10 ml, 6 mg/ml), containing BT-P^  ^ (1 mg/ml).
Pha. Fast Flow 9.99 ( - ) < 0.01 (0.4) <  0.01 (62.1) <  0.01  ( - )
Prosep-rA LC 9.94 (2.3) 0.04 (3.0) 0.02 (54.1) <  0.01  ( - )
Prosep-rA HC 9.93 (3.5) 0.06 (0.5) < 0.01 (58.2) <  0.01  ( - )
Prosep-A LC 9.96 (20.1) 0.02 (3.0) 0.01 (37.1) < 0.01  (0 .1)
Prosep-A HC 9.99 (15.1) < 0.01 (0.3) < 0.01 (48.1) <  0.01  (0 .1)
SpA-Agarose 9.99 (24.0) < 0.01 (7.8) < 0.01 (29.3) <  0.01  (0 .2)
Purification ofhIgG (10 ml, 1 mg/ml), containing BT-P^  ^ (1 mg/ml).
Pha. Fast Flow 9.97 { - ) 0.03 (0 .2) <  0.01 (10.5) <  0.01  (<  0 .1)
Prosep-rA LC 9.97 ( - ) 0.03 (0.2) <  0.01  (11 .0) <  0.01  ( - )
Prosep-rA HC 9.97 ( - ) 0.02  (0 .2) < 0.01 (11 .6) <  0.01  ( - )
Prosep-A LC 9.99 ( - ) < 0.01 (0.3) < 0.01  (11 .1) <  0.01  ( - )
Prosep-A HC 9.99 ( - ) < 0.01  (0 .2) < 0.01 (11.9) <  0.01  ( - )
SpA-Agarose 9.97 (1.1) 0 .02  (<  0 .1) < 0.01 (9.4) <  0.01  (0 .22)
Purification ofhIgG (10 ml, 0 mg/ml), containing BT-P^  ^ (1 mg/ml).
Pha. Fast Flow 9.99 ( - ) <  0.1  ( - ) <  0.01  ( - ) <  0.01  ( - )
Prosep-rA LC 9.98 ( - ) < 0.01  ( - ) 0.02  ( - ) <  0.01  ( - )
Prosep-rA HC 9.99 (-  ) < 0.01  ( - ) 0.02  ( - ) <  0.01  ( - )
Prosep-A LC 9.98 ( - ) < 0.01  ( - ) 0.01  ( - ) <  0.01  ( - )
Prosep-A HC 9.98 ( - ) < 0.01 ( - ) 0.01  ( - ) <  0.01  ( - )
SpA-Agarose 9.99 (- ) < 0.01 ( - ) < 0.01  ( - ) <  0.01  ( - )
BT-H  ^ spiked Gammahulin was added to solid phases in 10 ml of Borate buffer (disodium borate (0.1 
M), sodium chloride (0.15 M)pH 8.5); followed by 10 ml of Gitrate (trisodium citrate (0.1 M), citric acid 
(0.1 M), pH  6), Glycine (glycine (0.1 M), pH  2), and HGl (hydrochloric acid (30 mM), pH  1.5) buffers, 
n = 4, duplicate columns run for 2 cycles under gravity flow.
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The plasma protein content of the eluted fraction was greatly reduced by lowering the 
inorganic salt content of the adsorption/washing buffer. Switching from a high salt (borate, pH  
8.5) buffer to the low salt (glycine, pH 8 .6) buffer produced a reduction in the plasma protein 
content from an average 2.9 /xg to <  0.1 /xg for HSA, and from 0.8 jitg to <  0.2 /xg for BT, 
per eluted fraction per cycle respectively (Table XIV).
TABLE XIV. THE NON-SPECIFIC ADSORPTION OF PLASMA PROTEINS (HSA
AND BT, 10 mg) TO PROSEP-A HC (mg)
Solid phase Breakthrough Wash Eluate
Purification of HSA (10 ml, 1 mg/ml). in borate buffer pH  8.5.
#1 7.4520 2.1570 0.0030
#2 7.9750 2.0640 0.0033
#3 8.1890 1.8040 0.0024
Purification of HSA (10 ml, 1 mg/ml). in Low salt adsorption buffer pH 8 .6 .
#1 7.4870 2.1320 0 .0000
#2 8.0400 2.8370 0.0001
#3 8.2760 1.7970 0.0001
Purification of BT (10 ml, 1 mg/ml), in! borate buffer pH  8.5.
n 7.3550 2.1620 0 .0 0 1 2
#2 7.7910 2.1140 0.0009
#3 7.9470 1.8870 0.0004
Purification of BT (10 ml, 1 mg/ml), in Low salt adsorption buffer pH 8 .6 .
#1 7.8850 2.7820 0 .0 0 0 2
#2 7.8720 1.1590 0.0004
#3 8.1040 1.6760 0 .0001
10 vols of plasma proteins (iodinated HSA or BT, 200 kBq) were applied to Prosep-A H C columns (1 
ml), in Borate buffer (disodium borate, (0.1 M), sodium chloride (0.15 M) pH  8.5); or Low salt buffer 
(glycine (1.0 M), sodium chloride (0.15 M) ,pH 8.6), washed (10 vols of buffer), and adsorbed proteins 
eluted (10 vols of glycine (0.1 M), pH2). n = 4, 2 columns run for 2 cycles under gravity.
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4.5 DISCUSSION
Cross-linked beaded agaroses are the most commonly employed supports for affinity 
chromatography solid phases (as used in 5 of the assessed preparations). This is due to their 
macroporosity, low non-specific adsorptions, good chemical stability, relatively low cost, and 
availability of functional groups for easy ligand coupling. The drawback of these solid phases 
is that the matrix may biodegrade on storage, and their flow rate tends to get slower over a 
number of cycles due to compaction and fouling. Silica based matrices such as controlled pore 
glass (CPG, as used in Prosep-A "High Capacity") have excellent mechanical stability, though 
poor chemical stability in alkaline conditions. This has resulted in their limited use as a matrix 
in the preparation of affinity solid phases. The polymer based preparation Affi-Prep (Bio-Rad) 
offers an alternative to silica without the poor stability in alkaline conditions. Cellulose based 
matrices are not generally used in the production of affinity solid phases as they are prone to 
high non-specific adsorptions, have low permeability, with low mechanical and thermal 
stability.
The process-scale protein A (SpA) affinity chromatography of immunoglobulins 
demands a high flow rate (for large volumes of liquid), of a system in which both the ligand 
and ligate are macromolecules (42,000 and 150,000 respectively). In such a system, maintenance 
of interparticle porosity of the solid phase is an important factor affecting matrix longevity. 
N o doubt all commercial SpA affinity supports are selected with specifications appropriate for 
the isolation of immunoglobulins. However compaction and/or fouling on application of large 
volumes of media as in process-scale applications may reduce the interparticle porosity and 
hence the permeability to flow. This suggests that rigid matrices, such as those employed in the 
preparations Prosep-A (Bioprocessing) and Affi-Prep SpA (Bio-Rad), are most likely to be 
suitable at process scale.
Another approach to the problem of solid phase compaction is to use columns with a 
large diameter to height ratio. The NYGene Mass 10 mg IgG cartridge achieves this by using 
a fixed disc of solid phase. O f the eight solid phases evaluated the NYGene cartridge had the 
highest initial flow rate. On repeated purification of a monoclonal (MAb) this flow  rate fell
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from its initial value to less than one fifth of this rate over 4 cycles (0.57 to >0.1  ml/min, in 
IM glycine buffer, pH 8 .6). In terms of flow rate the preparations Prosep-A, Sepharose 4B Fast 
Flow, and the NYGene cartridge proved best. Of these, Prosep-A appeared most suited to 
process-scale applications as the other two showed reduced permeability on continued use, 
leading to decreasing flow rates.
It has been suggested that recombinant receptor proteins such as rPro A  do not have 
as high an affinity for their binding compound as do their native receptor proteins. This would 
suggest a greater degree of non-specific protein co-purification due to the presence (at antibody 
capacity) of more free non-specific interaction sites. In this survey no significant difference 
between the use of native or recombinant protein A was found.
Immobilization chemistries used in the commercial SpA solid phases tested included 
cyanogen bromide (CNBr), triazine, aldehyde/Schiffs' base and a number of unrevealed 
chemistries. Peng et al (1986) reported finding that the most stable binding for immobilizing 
proteins to a matrix was via amine or amide bonds, as opposed to a cyanogen bromide linking 
which slowly degrades. This observation was further supported by those of Fuglistaller (1989) 
who found, on comparing SpA affinity matrices, that ligand leakage was lowest for those 
employing alkylamine or ether immobilizing linkages. Similarly, in this chapter of the study 
presented, the level of contaminating SpA in affinity purified MAbs on frontal analysis was 
lowest for the two solid phases employing aldehyde/SchifPs base ligand bonding (Prosep A and 
Repligen).
Ligands immobilized on CNBr-activated Sepharose may become unstable at pHs <  5 
or >10. In addition, these preparations may contain residual cationic charges leading to the 
non-specific binding and co-purification of contaminants in antibody preparations (Narayanan 
and Crane., 1990). This effect may be reduced by the inclusion of nucleophilic compounds such 
as glycine in the adsorption and washing buffers, though its presence may also result in an 
increase in background SpA leakage from agarose preparations (Dertzbaugh et al., 1985). 
Furthermore, activating agents such as CNBr and triazine are highly toxic, and may leach out 
together with purified antibodies from SpA solid phases, suggesting that these immobilization 
chemistries are inappropriate for the purification of therapeutics.
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The MAb capacity of SpA solid phases is at a maximum with a buffer containing a high 
concentration of inorganic salts (NaCl >  IM); however eluted MAbs contain higher levels of 
co-purified SpA, albumin, and transferrin, due to their elevated non-specific bindings. Lower 
adsorption/washing buffer salt concentrations result in less contamination of eluted MAbs, as 
a result of reduced ligand leakage, and non-specific binding of plasma proteins. This finding 
would suggest the NSB’s of plasma proteins occurs largely as a result of hydrophobic binding.
On affinity purifying MAbs, the level of contaminating SpA was greatest for the 
adsorption/washing buffering conditions suggested by Pharmacia Ltd. (high salt and pH). In 
these conditions Fuglistaller (1989) found murine IgG  ^purified on a Prosep-A "Low Capacity" 
column to have an SpA contamination level of 88 ng SpA/mg of IgG  ^ These findings would 
indicate degradation of the solid phase due to excessive exposure to alkaline conditions ^ H  8.9; 
flow rate 0 .2  ml/min), in which controlled pore glass preparations may be slowly dissolved. 
Similarly, with a Prosep-A "High Capacity" column MAb (mlgGj 2 0  ml, 1.5 mg/ml) was 
affinity purified in conditions of low salt as suggested by Bioprocessing, thereby not infringing 
the United States Patent of Juarez-Salinas et al (1987, for inorganic salt concentrations above 
0.5 M) and allowed it to drain under gravity (0.5 ml/min). Over four cycles this process 
resulted in an SpA contamination of the purified MAbs, which decreased from an initial level 
> 35 ng SpA/mg MAb to a maintained lower level of 7 ng SpA/mg MAb by the third 
purification. This leakage stabilizing effect was also noted by Francis et al (1990), who found 
that SpA leakage from a protein A Sepharose column falls on consecutive column uses to a 
lower level, remaining constant after four subsequent cycles.
The properties of an affinity solid phase affecting the level of ligand leakage in the 
absence of ligate are mainly binding chemistry stability, the stability of the supporting matrix, 
and the amount of ligand immobilized. Background ligand leakage from the SpA solid phases 
assessed in this study was independent of column capacity, indicating a dependence on solid 
phase nature and binding chemistry alone. The contaminating level of SpA in purified MAbs 
on frontal analysis appears to be the most accurate indication of solid phase stability.
On frontal analysis of the SpA preparations, SpA leaching from solid phases is 
prevented from being washed away with the free MAb in the mobile phase by the relatively
98
higher concentration of MAb immobilized on the solid phase. This results in a fall in the level 
of SpA leaving the column. On approaching column capacity (q = Q) the level of SpA leakage 
appears to increase again slowly to the normal rate. This would suggest a dynamic replacement 
of immobilized SpA associated MAb for free MAb. The leaking SpA saturates the binding sites 
on the immobilized MAb, emerging as a peak of leakage on elution of the antibody. An 
optimal elution point would therefore be at the point of inflection in the SpA leakage curve 
on frontal analysis, which approximates to q /Q  = 80% (fig. 13).
Frontal modes of column use are most appropriate for process-scale isolation of 
proteins, where the maximum usage of the column for the isolation of adsorbate is desirable. 
In doing so, sites which may otherwise non-specifically bind contaminants resulting in their 
co-purification are kept to a minimum. As a result, the level of contaminating SpA in purified 
antibody samples should indicate the nature of the affinity of the SpA-Fc binding of the 
antibodies.
For process-scale applications sorbent stability (chemical and mechanical) may be the 
most significant factor determining the overall cost of the separation method, followed closely 
by specificity and binding capacity (Narayanan and Crane, 1990). The initial outlay for the 
matrix must be weighed against those factors affecting column longevity, its compressibility, 
non-specific adsorption, ligand leakage, and matrix stability, and hence the matrix cost per 
batch separation. Resistance to 1 M sodium hydroxide (used in depyrogenation) has been 
considered a prerequisite of affinity media for use in this area, excluding CPG preparations 
(Hodgson, 1990). Alternative sanitizing conditions applicable to SpA solid phases and more 
suitable for silica based matrices include: guanidine HCl (6M), chloroform/methanol/water 
(5:4:1), urea (6M), acetic acid (10%), formic acid (10%), chloroform, and ethanol.
O f the matrices evaluated, the glass based solid phase Prosep-A "High Capacity" would 
appear to have those properties most suited to the large scale downstream processing of 
antibodies. In particular it has a high permeability, and good mass transfer properties, essential 
for process scale volumes of dilute media. In addition it had the largest capacity of all the 
matrices tested with the lowest contamination of purified product on optimal use.
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CHAPTER FIVE
PURIFICATION OF BIOLOGICALS ON SILICA BASED AFFINITY SOLID
PHASES
5.1 SUMMARY
The use of rigid silica-based matrices for the preparation of AC solid phases to extract 
constituents of biological samples in a highly selective and rapid way was investigated. The 
porous silica preparation Matrex™ Si (particle size, 90 - 130 fim; pore size 1000 Â  Amicon 
Ltd.), was used as the starting material for the development of a number of silica-based solid 
phases. In particular, the grade of Matrex chosen had a pore accessability suited to affinity 
chromatographic applications involving the purification of biological macromolecules from 
biological matrices (filtered tissue homogenates, serum, whole blood, and bile) on immobilized 
bioligands.
The introduction of functional groups onto the surface of silica-based matrices by 
silanization was assessed. This technique has been used for preparing epoxide and aminopropyl 
derivatives of PS as the initial stages in matrix activation. The bis-oxirane 1,4 -butane diol 
diglycidyl ether also evaluated, to determine its merit as a bifunctional agent for immobilizing 
ligands. The most appropriate technique for coupling ligands to porous silica or glass matrices 
appeared to be by aldehyde activation of the matrix surface followed by Schiff base bond 
formation with the free amine groups of the ligand. The ligand binding Schiff’s bonds could 
then be reduced to form stable covalent bonds. This proved the quickest of the techniques 
investigated, and resulted in the greatest degree of ligand immobilization. The nature of the 
reduction process employed was then chosen depending on stability of the ligand in question.
The activation procedures developed were used in order to immobilise a number of 
proteins (BSA, MAb, PAb, SpA), charged molecules (DEAL, QAM), a hapten (Tb-CMO), and 
a dye (Rivanol). Particular attention, was paid to the robustness of the resulting solid phases, 
their reusability, and stability of ligand binding. These solid phases were used to assess the 
success of immobilizing chemistries, and were further evaluated for their use in the AC 
purification of components of biological samples (proteins and organic residues). In addition, 
solid phases were evaluated for their AC properties when used in column, stirred-tank (Roller- 
mixing), and HPLAC formats. When optimized for pilot-scale, or rapid separation applications 
(as in later chapters), solid phases were produced using the more costly, robust CPG beads, of
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regular (defined) pore sizes and particle diameter.
Strategies to limit the level of bioligand leakage from silica-based solid phases during 
normal purification and hydroxide sanitising operations were investigated using BSA and SpA 
and as model bioligands (proteins). One approach to limiting the level of ligand leakage from 
protein-PS solid phases investigated was to experimentally optimise their preparation and 
operating conditions. The best level of ligand loading (degree of substitution) of the matrix 
appeared to be around half the maximum matrix capacity. The most appropriate adsorption 
conditions appeared to be at alkali pH (8 - 9), with a low inorganic salt (<  2 0 0  mM) glycine 
buffer at flow rates between 50 and 100 col vols per hour. Desorption was best achieved at 
acidic pH ’s (<  2) and ionic strengths below 0.2 M with flow rate above 100 col vols per hour. 
Packed-bed modes of column operation proved to result in minimal ligand contamination of 
purified products, though stirred-tank approaches to solid phase use resulted in the greatest 
yield of purified ligate.
Treating columns with molar N aO H  has largely become the method of choice for 
sanitizing and depyrogenation of affinity solid phases, which would seem inappropriate for use 
with silica-based solid phases. However, Ab-PS and SpA-PS columns prepared in this study 
when exposed to pH ’s of greater than 8 between subsequent AC cycles showed no degradation 
in performance. Incorporating metal ions into AC buffers or onto the surface of affinity solid 
phases proved of limited success. Both approaches were able to reduce the degree of dissolution 
of silica-based matrices in alkali conditions, but at the cost of decreased ligate capacities or 
increased ligand contamination of purified ligates respectively.
Alternative sanitising conditions to molar NaOH, which have been used to clean up 
SpA-(PS or CPG) solid phases without any ill effects have included GuHCl (6 M), Urea (6 M), 
chloroform/methanol/water (5:4:1), acetic acid (10%), formic acid (10%), chloroform, 
methanol, and acetone. Prosep A solid phases were also subjected to heat sterilization processes 
(autoclaving and 80°C dry for 72 hours), and maintained 30% of their original MAb capacity.
PS based Ab solid phases were used in the lAC clean-up of analytical samples prior to 
quantitative assessment. Conversly, by immobilising a hapten to PS a bovine MAb was affinity 
purified on a hapten column. Also the feasibility of rapid protein fractionation on rigid silica-
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based ion exchange matrices has been demonstrated. By conecting PS based solid phases up to 
an HPLC, HPLAC on immobilized bioligands was also investigated. Under these conditions 
silica/glass solid phases were used at flow rates 20 to 30 times greater than those normally 
employed for the use of conventional AC matrices (agarose, dextran), with no appreciable loss 
of separation efficiency.
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5.2 INTRODUCTION
The nature of the surface of glass is largely a reflection of its thermal history, heat 
greatly affecting the number of adjacent hydroxyl (silanol; =  Si-OH) groups (Equation 19). In 
the production of silica based solid phases, controlled pore glass (CPG) and porous silica (PS) 
matrices are usually derivatized via their surface silanol groups. A common initial step in 
creating CPG or PS based solid phases is therefore the reconstitution of their hydroxylated 
surfaces, by boiling in concentrated nitric acid (Weetall and Filbert, 1974; Dean et al, 1986; and 
Ernst-Cabrera and Wilchek, 1988).
•SiO H (H j3\ ± heat -SiOH + (= S i\0  * ± heat (1@)
During the heat and leaching processes of the production of CPG, surface boron (B2O 3) 
levels are increased, as revealed by infrared studies. Though boron constitutes only 3% of 
CPG’s bulk (the B:Si ratio being 1:20), the surface boron is at a concentration of 2.4 X 10^ ° 
atoms/g glass, with 8 silanol groups per nanometre square (Weetall and Filbert, 1974). 
Consequently, excessive surface boron allows the formation of Lewis acid sites, by accepting 
an electron pair (Equation 20)- Lewis acid sites together with the silanol groups account for the 
net negative surface charge of glass in aqueous media.
As a consequence of their net negative surface charge, native CPG and PS matrices are 
able to adsorb nucleophiles (proteins, amines, and ammonium ions). Thus, the non-specific 
adsorption of proteins to CPG has been found to be greatest for those with a high isoelectric 
point, and the degree of protein binding inversely proportional to their molecular weight 
(Messing, 1969). When CPG matrices are used for gel filtration these interactions may be 
reduced by pre-treatment with polyethylene glycol (PEG), glycerol, albumin (bonded), and 
silanizing agents.
O3B- ; NHl (20)
The silica-based matrices used in high-performance liquid chromatography (HPLC) 
range in pore size from 60 to 4000 Â. When pore sizes are below 150 Â, the performance of
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a high-performance liquid ajfinity chromatography (HPLAC, Ohlson et al., 1978) column may 
suffer due to poor solute diffusion and unavailability of the surface. Conversely, with pores 
above 1000  Â the ligate capacity of affinity solid phases is often very low, and the matrix has 
a tendency to break-up into smaller fragments (or fines) due to reduced mechanical stability. 
Therefore, pore sizes between 500 and 1000  Â are most commonly used.
In conventional HPLC, small particle sizes (<  10 jum) tend to be used in order to 
minimise diffusional band spreading, and maximise solute resolution. Only small amounts (1 - 
10  mg) of analyte may be loaded onto these columns; hence HPLC is often only used as an 
analytical technique. In HPLAC, resolution depends on selectivity, not efficiency (plate count); 
thus, there are few advantages to the high plate counts achievable with smaller particle sizes 
in HPLAC (Philips, 1991). Affinity columns may be considered to selectively adsorb solute 
loading from their inlet to outlet, with elution occuring as a result of solvent switching; it may 
therefore be said that affinity columns operate using a single theoretical plate (Philips, 1989). 
Hence, particle sizes between 30 and 300 /rm are most commonly used, both to accomodate 
the immobilization of bioligands and to allow the passage of biological samples.
5.2.1 Preparation of silanized CPG and PS
Functional groups (R) may be introduced onto the surface of silica based matrices in 
one of two ways:
i directly, forming an =  Si-R bond; by chlorination followed by the addition of 
an organometallic compound; 
or ii indirectly, via a bridging atom X  to yield a =  Si-X-R group (eg. =  Si-O-R, on 
condensation of an alcohol; =  SiNH-R, on condensation of an amine and 
chlorinated surface; and s  Si-O-Si-R, on condensation of organosilanes).
The most widely used technique in the production of functionalized silica/glass matrices has 
been silanization, with trialkoxysilanes (Walters, 1985).
Bifunctional organosilanes, containing an organic functional group at one end and a 
silylalkoxy group at the other, may react with the silanol groups on the surface of PS and CPG
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matrices producing a hydrophilic organic surface layer. By using trialkoxysilanes, 
polymerization of adjacent groups may also be achieved, producing a monolayer (-SiR-O-SiR-)^ 
coating the surface of a matrix. In addition to providing functional groups suitable for ligand 
attachment, these monolayers also have the added advantage of reducing non-specific protein 
adsorptions by removing the matrix surface charge and eliminating hydrophobic moieties 
(Equation 21).
^SiOH + {HfiO)^SiR^ -» {{^ S iO \S iR \ (21)
Functional groups introduced to the surface of silica/glass matrices for the immobilization of 
proteins have included epoxide (Chang et al, 1976), aldehyde, isothiocyanate, carboxyl, diol, 
primary hydroxyl and amino groups (Kozlov et al, 1984; and Weetall and Filbert, 1974).
The degree to which the surface of a silica/glass matrix has been functionalized on 
silanizing with the trialkoxysilane glycidoxypropyltrimethoxysilane (OPTS), may be 
determined by hydrolysing the introduced surface epoxide groups to diols with H 2SO4, 
followed by thiosulphate titration (Equation 22; Dean et al, 1985).
RCH OH .CH fiH  + HIO^ -  ECHO  + HIO^ + H f i
HIO  ^ + 5KI + 5H^ -> 3/2 + 5K^ + (22)
HIO  ^  ^ IKI + 4/2 + IK  + A H p
I2 + 2A(fl2«S^2^3  ^ 2NaI + Na^Sfi^
The surface diol concentration of an activated matrix may then be obtained by calculating the 
diol content and dividing by the sample weight (Equation 23).
\i.mol diol = (ml blank -  ml sample) X X — ; X1 litre
1000 ml " (23)
«1 mol diol ^  10 [imol 
2 mol thiosulphate mol
5.2.2 Immobilizing proteins
Epoxide silica can be used as the starting material for the preparation of a number of 
immobilized protein affinity solid phases. Under very mild conditions, epoxide groups may 
form covalent bonds with primary amines, hydroxyl, polysaccharide and thiol groups on the 
surface of proteins (Equation 24).
106
-O-CH^-CH.O.CH^  + (R-NH^, R -O H , or R-SH ) ^  (24)
-C H O H -CH ^-N H -R, -C H O H -C H ^-O -R , or -C H O H -C H ^-S-R
Eupergit C (Rohm Biopharm GMBH), is a well known commercially available epoxide 
activated support for immobilizing protein (enzymes in particular), based on polyacrylamide. 
Epoxide binding of enzymes to this matrix is a very slow process (typically 16 hours) and is 
intolerant to the presence of many protein preserving agents. For the reported optimal 
production of an Eupergit C immobilized 5’-phosphodiesterase solid phase, the enzyme had to 
be incubated with the activated matrix for 3 days, in an acetate buffer (pH 4.5) at room  
temperature (Keller et al., 1987). Generally, the production of epoxide groups is used as the 
starting point for the synthesis of other functional groups, to which proteins may be bound 
with greater ease (aldehydes, -CHO; isothiocyanates, -N =C =S; carboxyl, -COOH; diol, - 
CHOH-CH2OH; hydroxyl, -OH; and amino, -NH2; groups).
The covalent coupling of proteins to activated silica/glass matrices is usually achieved 
by the formation of Schiff’s base (or imine) bonds (Equation 25).
(25)
R-NH^ + R 'C H fH O  ^  R-N -C H -C H ^R ' Schijf's base +
Schiff’s base bonds tend to be unstable and will slowly hydrolyse to free reactants in aqueous 
conditions. The bonding of ligands immobilized to matrices by Schiff’s base attachment can 
be stabilized by reduction with a general reagent such as sodium borohydride (NaBH j, or 
more selectively with sodium cyanoborohydride (NaBH^CN).
(26)
R -N -C H -C H ^R ' S ch ig s  base + NaBH^CN ^  R-NH-CH^-CH^R
The use of NaBH^ as a reducing agent also has the added advantage of preventing any 
unwanted irreversible solid phase binding, by reducing any aldehyde groups remaining on the 
activated matrix surface to alcohols.
5.2.3 Reduction of ligand leakage from silica/glass solid phases
It has previously been reported that the dissolution of silica/glass solid phases in alkali
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conditions (>  pH 8) may be prevented by a modification of their surface to incorporate the 
oxides, hydrous oxides, hydroxides, carbonates, or silicates of selected transitional metals (Al, 
Fe, Zr and Ti: Barkatt et al., 1987; Stout, 1986). It has also been suggested that the dissolution 
of silica/glass solid phases in alkali conditions is prevented by washing with microfine alumina 
(Her, 1973), or with alkali solutions containing millimolar levels of aluminium salts (Pfankoch 
et al., 1990). In both these operational and synthetic approaches, it was believed that matrix 
dissolution was prevented by the formation of surface metalosilicate groups.
Another approach to limiting the level of ligand leakage from an affinity solid phase 
is to experimentally optimise the preparation of solid phases and the conditions in which they 
are used. Areas of concern may include the ligand loading (degree of substitution) of the 
matrix, adsorption (pH, ionic strength), desorption (pH, ionic strength), storage conditions, 
matrix cleaning, mode of solid phase use (stirred slurry or packed bed) and flow rate.
5.2.4 The production and use of PS and CPG immobilized ligands
In this study, the PS matrix Matrex Si (particle size, 90-130 /xm; pore size 1000 Â; 
Amicon Ltd.) has been used extensively as the starting material in the development of silica 
based solid phases. This chapter documents attempts made at the preparation of a number of 
silica based solid phases and initial investigations into their wider applications. Firstly, methods 
for preparing epoxide and aminopropyl derivatives of PS were investigated. By introducing 
epoxide groups onto the surface of silica (epox-PS) or glass (epox-CPG), diol, aldehyde, 
carboxyl and primary hydroxy groups may be easily prepared by further chemical 
modification. Aminopropyl derivatives of silica (AP-PS) and glass (AP-CPG) were also 
produced. These may provide the starting material for a number of syntheses including 
arylamine, by addition of p-nitrobenzoylchloride and subsequent reduction with sodium 
dithionite; carboxyl, on reacting with succinic anhydride; and aldehyde groups, by coupling 
gluteraldehyde.
The bis-oxirane 1,4-butane diol diglycidyl ether (H-,C'^°^CHCHi-0 -CHiCHo-L was also 
evaluated, to determine its merit as a bifunctional agent for immobilizing ligands. The bis- 
oxirane molecule has epoxide groups at both ends, which may react readily with a matrix’s
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surface hydroxyl, thiol and amine groups at alkaline pH. In doing so, a long hydrophilic spacer 
with an active epoxide at one end is formed, which may react with the same groups when 
present on the surface of a ligand.
The activation procedures developed were used in order to immobilise a number of 
proteins (BSA, MAb, PAb, SpA), charged molecules (DEAE, QAM), a hapten (Tb-CMO) and 
a dye (Rivanol). These solid phases were evaluated for their AC properties when used in 
column, stirred tank (Roller-mixing) and HPLAC formats. Particular attention, was paid to the 
robustness of solid phases, their reusability and stability of ligand binding. When optimized for 
pilot scale, or rapid separation applications (as in later chapters), the final solid phases were 
produced using the more costly, robust CPG beads, of regular (defined) pore sizes and particle 
diameter.
Methods of limiting solid phase degradation due to use, cleaning and storage were also 
invesigated. A synthetic approach to reducing ligand leakage from silica/glass solid phases by 
incorporating metal ions was assessed by aminopropyl activating PS in the presence of kimal, 
microfine alumina and aluminium ethoxide. The activated solid phases were evaluated for their 
resistance to the dissoluting effects of alkali conditions. In addition, silica matrices activated in 
the presence or absence of aluminium ethoxide were used to immobilise SpA. These SpA- 
(Al%)-PS solid phases were evaluated for MAb capacity and SpA leakage, pre- and post- 
sanitizing with molar NaOH.
An operational approach to limiting the dissolution of a protein ligand from silica based 
affinity solid phases was investigated, by studying the effect the presence of metal ions when 
present in purification buffers has on the MAb capacity and N aO H  resistance of Prosep A  HC  
(an SpA-CPG solid phase; Bioprocessing Ltd.). Using this solid phase, operating parameters 
(flow rate, pH, mode of use and ionic strength) were also assessed for their effect on ligand 
leakage.
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5.3 MATERIALS AND METHODS
5.3.1 Activation of silica/glass matrices
5.3.1.1 Preparation of epoxide silica/glass matrices.
The introduction of diol groups onto the surface of silica/glass matrices was achieved 
by silanization. This was carried out in batch (50 g) preparations, in aqueous or organic 
conditions as follows:
i Aqueous epoxide activation of silica/glass: to PS (50 g) nitric acid (0.5 M, 5 vols; 
500 ml) was added and the mixture incubated for 2  hours at 90°C. The matrix 
was then washed with water (5 x matrix volume) and incubated with 
glycidoxypropyl-trimethoxysilane (GPTS; 10 % v /v  in 0.1 M sodium acetate, 
pH 5; 250 ml) for 16 hours (overnight) at 90°C. The matrix was then washed 
over a sintered glass filter, with dimethylsulphoxide (DMSO, 1 X  300 ml), 
methanol (2 X  300 ml) and water (3 X 500 ml).
ii Organic epoxide activation of silica/glass: the PS (50 g) was first treated with 
nitric acid and washed as above and dried for 16 hours (overnight) at 90°C. 
GPTS (10 % v/v , in DMSO, 500 ml) and triethylamine (200 jul) were then 
added and the matrix again incubated for 16 hours (overnight) at 90°C. The 
matrix was then washed over a sintered glass filter, with methanol (2 X  300 ml) 
and water (3 X  500 ml).
Epoxide activated matrices were then either, converted to diol activated matrices, or 
again washed with acetone (3 X 500 ml), dried (overnight, 90°C) and stored at room  
temperature.
5.3.1.2 Preparation of diol silica/glass matrices (PS-(OH)2)
Epoxide activated matrix was suspended in H 2SO4 (0.1  M, 5 vols) and incubated for 2 
hours at 90°C. The matrix was then washed over a sintered glass filter with 3 X 5  vols of 
water, methanol and acetone. The diol activated matrix was then dried at 90°C for 16 hours
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(overnight) and stored at room temperature.
On subsequent manipulations, the preparation of epoxide and diol activated matrices 
was optimized for their appropriate reaction conditions (pH, reaction time, silanizing agent 
concentration).
5.3.1.3. Preparation of aminopropyl silica/glass matrices (AP-PS and AP-CPG)
To PS nitric acid (0.5 M, 5 vols) was added and the mixture incubated (with periodic 
agitation) for 2  hours at 90°C. The matrix was then washed with water ( 3 X 5  vols) and dried 
for 16 hours (overnight) at 90°C. Aminopropyltriethoxysilane (APTS; 2.5% v/v , in DMSO; 
5 vols) was then added and the mixture incubated for 16 hours at 90°C. The silanized matrix 
was then washed over a sintered funnel with 3 X 3  vols of DMSO, isopropanol and water. The 
aminopropyl-silica (AP-PS) was then dried by drawing off any remaining liquid by passing air 
through for an hour, then incubating for 16 hours (overnight). Glutaraldehyde (125 mM; 5 
vols) was then added and roller-mixed for an hour at room temperature. The mixture was then 
incubated for a further 3 hours at 37°C, the matrix being periodically resuspended. The 
aldehyde activated matrix was then washed over a sintered funnel with 3 X 3  vols of 
NaBHjCN (0.1  M), water and acetone. The aldehyde activated matrix was then dried by 
passing air through for 16 hours (overnight) and stored in an air tight container.
5.3.1.4 Determination of the diol content of (PS-(OH)2) (Dean et al, 1985)
To diol-activated matrix (70 mg) NalO^ (0.1  M, in 80% v /v  acetic acid; 0.5 ml) was 
added and the solution sonicated for 1 minute. The solution was then incubated at room  
temperature for a further 30 minutes and KI (0.6 M, 0.25 ml) added. The solutions were then 
vortexed and titrated with Na2S2 0 3 .5H 2 0  (20 mM, volumetrically prepared in 0.4 mM 
Na2C0 3 ). Unactivated matrix was titrated as a blank for the degree of activation calculations.
5.3.1.5 Determination of the trialkoxysilane (GPTS) concentration for aqueous silanizing silica 
based matrices.
Matrex (2 g) was silanized as above in aqueous conditions by adding GPTS (10 ml, at
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0, 0.625, 1.25, 2.5, 5 and 10 % v/v; in 0.1  M sodium acetate, pH 5) and incubating for 16 
hours (overnight) at 90°C. Activated matrices were washed thoroughly, then assessed for 
surface diol content and protein (BSA) capacity. The level of protein leakage from these solid 
phases was assessed by a batch process. Batches of solid phase (200 mg) were roller mixed for 
15 minutes at room temperature in citric acid (0.1 M, 5 ml) and the supernatant assessed for 
BSA content by Coomassie dye binding.
5.3.2 Ligand binding to activated silica/glass matrices
5.3.2.1 The ligand (protein) binding to activated bonded silica
In order to immobilise proteins, surface diol groups on silanized silica/glass matrices 
were first converted to aldehyde groups. This was achieved by incubating the matrix for 2 
hours at 90°C with 5 vols of NalO^ (10 mM). The resulting aldehyde activated matrix was then 
washed with water ( 5 X 5  vols) and either used immediately or dried and stored in a sealed 
container.
To dry periodate activated diol-silica (200  mg), BSA (10 mg/ml; or 10 m g/m l spiked 
with BSA-/^^ ;^ in 3 ml of carb/bicarb) was added and the mixture roller-mixed for 16 hours 
(over-night at 4°C). The supernatant (1 ml) was then drawn off and tested for protein content 
by Coomassie dye binding, or gamma counting. This method was used as a means of gaining 
a rough quantitative comparison of protein capacity and leakage from activated matrices. 
Residual ligand leakage from these solid phases was assessed by gamma counting eluates for the 
presence of BSA-/^^ .^
5.3.2 .2  Epoxide coupling of ligands to activated silica/glass matrices.
i Direct ligand coupling to epoxide-PS: epoxide silica/glass was produced by 
silanizing PS or CPG with GPTS. The ligand was then coupled by roller mixing 
with the epoxide silica in 5 vols of SpA buffer (1 in 10 diluted), for 16 hours 
(overnight) at room temperature.
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ii Bis-oxirane epoxide activation of AP-PS, followed by ligand coupling: PS and 
the bifunctional bis-oxirane coupling agent 1,4 butanediol diglycidoxy ether 
were roller mixed for 16 hours (overnight) with 5 vols of bis-oxirane (1,4 
butanediol diglycidoxy ether, 10 % v /v  in SpA assay buffer; 1:100 diluted: 
C2H 3 0 2Na, 10 mM; NaCl, 1.5 mM; pH 5.6). Excess bis-oxirane was then 
removed by washing the matrix with SpA assay buffer (1 in 100, 3 X 5 vols) 
over a sintered glass filter. Ligand was then immobilized by diluting (if 
concentrated) or dialysing (if at a low concentration) in diluted SpA assay buffer 
(1 in 100) and roller mixing with 0 .2  vols of epoxide activated solid phase.
iii Bis-oxirane coupling of AP-PS and ligands; ligand and AP-PS were roller-mixed 
bis-oxirane (5 vols; 1,4 butanediol diglycidoxy ether, 10 % v /v  in SpA assay 
buffer; 1:100 diluted: C2H 3 0 2Na, 10 mM; NaCl, 1.5 mM; pH 5.6) for 16 hours 
at room temperature.
Epoxide ligand immobilizing procedures were compared by a batch procedure. Weighed 
quantities (4 X 2 0 0  mg) of dry epoxide-PS, bis-oxirane activated AP-PS and AP-PS were mixed 
with BSA (5 ml, 10 mg/ml) in diluted SpA assay buffer (1 in 100, epoxide-PS and bisoxirane 
activated PS), or diluted SpA assay buffer containing bis-oxirane (AP-PS) respectively. These 
mixtures were roller-mixed at room temperature and the supernatant periodically tested for 
BSA content by diluting a 50 /xl aliquot to 1 ml and assaying by Coomassie dye binding. Values 
of immobilized protein (q) were then calculated from the fall in concentration (Co - C) 
levels.
The active epoxide groups remaining after ligand immobilization were then blocked, 
by roller-mixing for 16 hours (overnight) in one of the following solutions:
i H 2SO4 (1 M);
ii mercaptoethanol (2 %, v/v);
iii glycine (1 M);
iv thiourea (1 M); 
or V  water.
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The effectiveness of epoxide blocking solutions was assessed by roller-mixing batches 
(200  mg) of epoxide-PS in the solutions (5 ml) for 16 hours (overnight) at room temperature 
and checking the matrices’ (200mg) remaining capacity for BSA (10 mg/ml, 5 ml; roller-mixing 
for 16 hours).
5.3.2.3. Coupling proteins to aldehyde activated silica/glass matrices
Aldehyde activated silica based solid phases were firstly prepared by periodate oxidation 
of (PS-(0 H)2), or glutaraldehyde activation of the aminopropyl derivative of matrices. Proteins 
were then diluted in, or dialysed against, 1% SpA assay buffer (SpA buffer 1:100 diluted, to 
give: C2H 3 0 2 Na, 10 mM; NaCl, 1.5 mM; pH 5.6). To activated matrix, 5 vols of protein 
solution was added and the mixture roller-mixed for 4 hours at room temperature (or overnight 
at 4°C). NaBH3C N  (0.1  M, 1 vol) was then added and the mixture roller-mixed for a further 
30 minutes. The solid phase was then washed by repeated slurrying and decanting off of 1% 
SpA assay buffer ( 5 X 5  vols). The remaining solid phase active sites were then blocked by 
roller-mixing the solid phase, for 30 minutes, in 5 vols of one of the following solutions:
i Clycine (1 M), NaBH3CN (10 mM), pH 6 .
ii Ethanolamine (1 M), glycine (0.2 M), NaBH3CN (10 mM), pH 7.6.
iii SpA assay buffer containing NaBH^ (10 mM).
5.3.2.4 Immunoaffinity chromatography (lAC) solid phase synthesis.
i Immobilizing crude antiserum: aldehyde silica/glass (gluteraldehyde activated 
aminoproyl silica/glass, or periodate activated diol silica/glass) and 5 vols of 
antiserum solution (100 fi\ per 10 ml of sodium acetate (10 mM), NaCl (1.5 
mM), pH 5.6) were combined and coupled as for other proteins. The remaining 
aldehyde active sites were blocked with a solution of glycine (1 M), containing 
NaBH3CN (10 mM), pH 6 .
ii Immobilizing Ig’s: aldehyde silica/glass and 5 vols of immunoglobulin solution
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(200  jLtg/ml in 10 mM sodium acetate, 1.5 mM NaCl, pH 5.6) were combined 
and coupled as for proteins. The remaining aldehyde active sites were blocked 
with a solution of ethanolamine (1 M), glycine (0.2 M), containing NaBH^CN 
(10 mM), pH 7.6.
iii Immobilizing a MAb: aldehyde silica/glass and an equal volume of MAb 
containing cell culture supernatant (or MAb diluted to 100 /xg/ml), 4 vols of 
sodium acetate (10 mM), NaCl (1.5 mM), pH 5.6, were combined, coupling and 
blocking was carried out as for Ig’s
5.3.3 Purification protocols using silica/glass immobilized ligands
5.3.3.1 lAC purification of zeranol (Zl) and trenbolone (Tb) on immobilized specific antibodies.
The adsorption and recovery of the anabolic agents Zl and Tb from buffer and sera 
solutions were assessed by radio-label studies. lAC columns were assessed for the effect of pH  
and the presence of methanol in buffers.
5.3.3.2. Purification of antibodies on PS immobilized hapten
The steroid testosterone (Ts) was carboxyl activated by addition of a carboxy- 
methyloxime (CMC) bridge (Erlanger et al., 1959). Ts-CMO and CMC were then reacted with 
N-hydroxysuccinamide (NHS) to form "active esters" (Hosodaet<«/., 1979) and bound to AP-PS 
to form Ts and control columns. Bovine PAb;s (BaTs) and MAb’s (B/MT.4A.17.H5.A5; 
Croves et al., 1987) to testosterone were affinity purified on columns (1 ml) of Prosep A HC, 
Ts-CMO and CMC, by adsorbing and washing in PBS (1.5 M) and desorbing with 5 col vols 
of glycerol (10 %, pH 1.5).
In order to determine the most appropriate conditions for eluting antibodies from the 
Ts-CMO-PS column the following elution buffers were assessed: glycine (2 M, pH 1.6), CuHCl 
(6 M), Methanol (80 %, v/v), or glycerol (5 %, v/v). Eluted antibodies were collected and 
immediately dialysed against 250 vols of PBSThio overnight at 4°C.
The specific activities (Ts binding per unit mass of protein) of anti-Ts sera, cell culture
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supernatant and antibody fractions were determined by Coomassie dye binding to assess the 
relative protein content, followed by ELISA assessment of hapten binding (Croves et al., 1987)
5.3.3.3 Ion exchange silica/glass solid phase synthesis
i DEAE-PS preparation; diol-PS was roller-mixed with 5 vols of DEAE (0.1 M, 
30 ml; in C2H 3 0 2 Na, 10 mM; NaCl, 1.5 mM; pH 5.6; containing NaBH3CN, 
10 mM and bis-oxirane, 10 % v/v) for 64 hours (over a weekend) at 4°C.
ii QAM-silica synthesis; silica/glass was silanized with quaternary aminomethyl
triethoxysilane (QAMTS: 3-(Triethoxysilyl)propyl-trimethylammonium
chloride; 2.5% v/v , in DMSO, Fluka, Equation 27), for 64 hours (over a 
weekend) at 4°C.
^SiOH + (CH^CHp\.Si.CH^.CH^.CH^.N\CH^\ CZ" ^  
(=SiO),.Si.CH,.CH,.CH,.N'(CH.) C f
iii DEAE-Dextran-PS synthesis; this was achieved in two ways: firstly, aldehyde- 
activated diol silica and DEAE-Dextran (10 % w /v, 5 vols in C2H 3 0 2 Na, 10 
mM; NaCl, 1.5 mM; pH 5.6; containing NaBH3CN, 10 mM) were combined 
and roller mixed for 64 hours (over a weekend) at 4°C. Secondly, aminopropyl 
silica was mixed with DEAE-Dextran (10  % w /v  in 5 vols of bis-oxirane, 5% in 
carb/bicarb buffer containing NaBH3CN).
The presence of dextran, immobilized on DEAE-Dextran-PS was detected by observing 
irreversible Cibacron blue dye binding (Scopes, 1982; 5 vols of 1% CB F3C-A applied to a 1ml 
column). DEAE-PS, QAM-PS and DEAE-Dextran-PS solid phase preparations were compared 
against DEAE-Sephadex A50 and QAE-Sephadex (Pharmacia), for protein capacity and charge 
density. The protein capacity of ion exchange solid phases was determined by applying excess 
BSA (5 vols, at 10%) in dilute Na2HP0 4  (10 mM) and eluting exchanged BSA with 
concentrated Na2HP0 4  (0.4 M).
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The net surface charge of the ion exchange solid phases was determined by titration 
(Pharmacia, 1980). To 1 g of dry solid phase KCl (1 M, 100  ml) was added and the pH adjusted 
to 12 (NaOH). The mixture was then stirred and HCl (1 M) added in 100  jA aliquots (equal 
to 1 m eq/g solid phase) at 1 minute intervals and the pH recorded.
5.3.3.4 High performance liquid affinity chromatography (HPLAC) on solid phases 
HPLAC was performed by packing solid phases into variable bed length glass (omnifit)
columns and connected to a Varian 5000 HPLC instrument. This was linked to a Varian UV-50 
variable wavelength detector, coupled to a Varian 9175 chart recorder. Solutions (sera, proteins, 
residues) were applied to solid phase columns of different volumes and evaluated for ligate 
binding and resolution under varying conditions of flow rate, pH and ionic strength.
Eluted protein peaks were evaluated for composition and purity by gel electrophoresis 
(lEF and SDS-PACE, Pharmacia PhastSystem).
5.3.4 Reduction of ligand leakage (SpA) from silica/glass solid phases
5.3.4.1 Selection of solid phase operating conditions (pH, flow rate)
The pH  most suitable for operating silica/glass based solid phases was determined by 
applying a pH  (citrate/phosphate) gradient (at 0.17 ml/min) to a 1 ml Prosep A H C  column. 
This was achieved by connecting the column to a gradient mixer (contain A, 2 0 0  ml of citric 
acid, 0.1  M; and B, 200 ml of disodium phosphate, 0.2M) and applying a gradient of acid for 
16 hours (overnight) and collecting the breakthrough in 2  ml fractions.
To determine whether ligand leakage from an SpA-CPC solid phase was time or 
percolating solvent volume dependent, the effect of buffer flow rate on the level of ligand 
leakage was investigated. This was done by applying low salt adsorption buffer to a Prosep A  
HC column (1 ml), at flow rates ranging from 0.33 ml/hour to 13 m l/m in for greater than 5 
col vols (over a period of 60 hours, 3 days and 2 nights at ambient). The SpA content of the 
breakthroughs was assessed and the solvent SpA content plotted against flow rate.
The effect of elution pH on the level and activity of antibodies eluted from silica
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immobilized SpA was determined by a cit/phos buffer stepped elution procedure. To a 
preconditioned Prosep A H C (1 ml) column, a polyclonal sheep anti-trenbolone antibody 
(Tb271b, SOOjLil diluted to 5 ml) was added. The column was then washed with 5 vols of low  
salt adsorption buffer and adsorbed antibodies eluted by adding 5 vols of citrate phosphate 
solutions at pHs 7.8, 6.7, 4.9, 3.3 and 1.8 respectively. The MAb content of eluted fractions was 
assessed by O D 2gonm ^^ d^ the relative antibody activities determined by radioimmunoassay 
(B/Bo, per unit mass of MAb).
5.3.4.2 Selection of the ligand substitution for solid phase production
SpA at levels of 0 to 40 mg in 5 ml of 1 in 100 diluted SpA buffer was added to 1 ml 
of aldehyde activated PS (from CPTS sythetic route, section 5.3.1 .1). These solid phases were 
then stabilized by incubating with a solution of NaBH^ (10 mM). The columns were then 
purged with 20  vols of PBS containing NaN^ (0.05 % v/v) and stored in 5 vols of ethanol (20 
%, containing 0.05 % NaNj) at 4°C. These solid phases were assessed on MAb saturation 
(frontal analysis) for MAb capacity and the SpA contamination of purified MAb’s (n = 4).
5.3.4.3 Incorporation of Al during surface silanization
Three batches of PS (Matrex, 2 g) were silanized with aminopropyltriethoxysilane 
(APTS; 10 % v /v  in 0.1 M sodium acetate, pH 5; 10 ml), in the presence of ground Kimal 
(mortar and pestle), microfine alumina and a control (normal) in carb/bicarb pH  9.8 buffer, 
for 16 hours (overnight) at 90°C. Activated matrix was separated from fines and aggregates by 
sieving (Endecotts, London; 90, 106 and 125 fxm sieves) and the 90-125 /xm fraction collected. 
Matrices were then gluteraldehyde activated and tested for stability at high pH by roller mixing 
in N aO H  (IM 5 vols) and periodic sampling of the supernatant (100 /xl). Samples were then 
assessed by OD^ o^nm rates of dissolution curves (CD/OD^a^ against t) plotted.
PS (Matrex, 2  g) was silanized with glycidoxypropyltrimethoxysilane (GPTS; 10  % v /v  
in 0.1 M sodium acetate, pH 5; 10 ml), in the presence of aluminium ethoxide (0 , 0.25, 0.5, 1 
and 2  %) for 16 hours (overnight) at 90 °C. Matrices were then acid treated and sieved to the 
appropriate size fraction (90-106 fim ; as above). The surface diol contents of activated matrices
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were evaluated, prior to periodate activating to aldehyde silica (48 hours at room temperature). 
To 1 ml of the activated matrices (plus one from an AP-PS synthetic route, section 5 .3 .1.3), 
SpA (10 mg in 5 ml of 1% SpA buffer) was immobilized in disposable columns (as for protein 
immobilizing, section 5.3.2.1) and then blocked with 1 % SpA assay buffer containing NaBH^, 
10 mM). Columns were then purged with 20 vols of PBS (containing 0.05% NaNj) and stored 
in ethanol (5 vols; 20%, containing 0.05% NaN^) at 4°C, prior to and between uses.
SpA-Silica columns were evaluated for ligand leakage in the presence of MAb, by frontal 
analysis, adding the following: eluting buffer (citric acid, 0.1 M; , 5 vols) to prime, low salt 
adsorption buffer (Bioprocessing Ltd, Appendix; 5 X 3  vols) to equilibrate, mlgCj containing 
cell culture supernatant (AFP27 SZ; 8 X 3  vols: at approximately 450 /xg/ml) to load, low salt 
adsorption buffer again to wash ( 4 X 3  vols) and elution buffer to elute ( 3 X 3  vols). All 
fractions were collected and evaluated for protein (breakthrough) and immunoglobulin (elution) 
content by ODjgonm for SpA by ELISA.
The effect of sanitizing these matrices between MAb affinity purifications with 
hydroxide was also evaluated. This was carried out by adding solutions (5 vols) to the SpA 
columns as follows: eluting buffer, low salt adsorption buffer, AFP27 SZ and again eluting 
buffer. This process was repeated a further 7 times, purging with N aO H  (IM, 5 vols) prior to 
each cycle. The level of SpA leakage produced in the NaO H  wash and elution stages was 
evaluated by ELISA the elution stage assessed for MAb content (ODjgonm)-
5.3.4.4 Incorporation of metal ions in affinity chromatography buffers.
The chlorides of Al, Sn and Zn were evaluated for their use as additions to affinity 
chromatography buffers to reduce the degree ligand leakage from silica-based matrices. The 
concentration of ZnCl2 required to lower background level of ligand leakage from a Prosep A  
HC column incorporating SpA-P^  ^ (Bioprocessing Ltd. 170 MBq/mg) was evaluated by an 
automated frontal analysis. Low salt adsorption buffer was applied (at 0.2 ml/min; peristaltic 
pump) to a 1 ml Prosep A HC column, and after 30 col vols a gradient of ZnCl2 in low salt 
buffer was applied (at 1 mM/ml, Pharmacia gradient mixer) for 352 col vols (for 16 hours, 
overnight) at room temperature. Normal low salt buffer was then again applied to the column.
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During this process fractions were collected (2.5 col vols) and assessed for SpA content by 
gamma counting.
The effect of residual ZnCl2 on the affinity purification of a MAb on Prosep A HC  
(SpA-P^^ was assessed by an automated frontal analysis of MAb (AFP27 SZ, 1 mg/ml; >  400 
ml), in low salt adsorption buffer containing ZnCl2 (lOmM). The effect that the presence of 
Zn^ "^  ions has on the affinity purification of a MAb on Prosep A ’high capacity’ (SpA-T^^ was 
also assessed by batch purifications. Batches of buffering solutions (5 X  eluting and washing) 
were made up containing ZnCl2 to varying degrees (0 , 1, 10, 100 and 1000 mM). Affinity 
purifications were then carried out by adding solutions (5 vols) to columns as follows: eluting 
buffer(s), low salt adsorption buffer(s), AFP27 SZ and again eluting buffer(s). The resulting 
eluted antibodies were evaluated for MAb and SpA content (by OD2gonm ^tid ELISA 
respectively).
5.3.4.5 Evaluation of alternatives to molar N aO H  for sanitizing silica-based solid phases
Prosep A "high capacity" columns (1 ml) were roller-mixed for 30 minutes with 5 vols 
of acetone, chloroform/methanol/water (5:4:1), methanol. Low salt adsorption buffer, acetic 
acid (10%), guanidine hydrochloride (6M), urea (6M) and N aO H  (IM). Solid phases were also 
heat treated by autoclaving and also by incubating a column dry at 80°C for 72 hours.
All columns were then evaluated for MAb capacity by frontal analysis and the SpA 
contamination of affinity purified MAbs assessed by ELISA.
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5.4 RESULTS
5.4.1 Matrix derivatization and ligand immobilization
The surface diol content of porous silica matrices silanized with GPTS, in aqueous and 
organic conditions, was found typically to be 71.3 and 121.43 /xmol/g respectively. These solid 
phases had protein capacities (BSA) of 2 2 .2  and 29.9 m g/g respectively, with leakage levels of 
28.0 and 17.5 /xg/g on applying citric acid to columns (0.1 M, 10 vols). By reducing the BSA 
binding Schiff’s base bonds with NaBH^, the levels of protein leakage from aqueous and 
organically activated solid phases on applying citric acid (O.IM, 10 vols) were reduced to 67 and 
19 n g /g respectively.
TABLE XV. THE EFFECT OF TRIALKOXYSILANE CONCENTRATION ON 
PROTEIN CAPACITY AND LIGAND LEAKAGE OF PS-BASED SOLID PHASES 
SILANIZED IN AQUEOUS CONDITIONS
BSA Leakage
GPTS (%) diol (/xmol/g) BSA (mg/g)
unreduced
M à
NaBH^ reduced
(ng/g)
0 4.3 0.3 >  1
0.625 71.4 12.4 146 ± 194 162 ± 1.3
1.25 114.3 31.1 112 ± 164 123 ± 2.7
2.5 128.6 54.1 108 ± 176 118 ± 4.5
5 128.6 80.7 105 ± 170 114 ± 4.4
10 128.6 91.3 82 ± 158 86  ± 3.8
AP-Silica - 19.1 98 ± 30 107 ± 2.1
Matrex silica (2^ silanized with glycidoxypropyltrimethoxy silane (10 ml, in sodium acetate 0.1 M; 
pH5) over night at 90°C.
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The effect of silanizing trialkoxysilane concentration on the degree of matrix 
functionalization, ligand capacity and leakage for diol-PS solid phases is summarized in Table 
XV. The surface diol content of PS silanized with GPTS (2 vols; 2g and 10 ml) in aqueous 
conditions, was at a maximum with GPTS concentrations above 2.5 % (v/v). The level of 
ligand (BSA) leakage from these solid phases on roller-mixing for 15 minutes with citric acid 
(0.1 M, 5 vols) was greatest for those silanized at low concentrations of GPTS. Ligand leakage 
fell by around 20  fold over 10 citric acid treatment cycles, the 10 % GPTS silanized solid phase 
having an exponential decrease in leakage from 522 to 9.7 /xg/g. Ligand leakage from these solid 
phases was reduced still further (>  500 fold) by reduction of the immobilizing Schiff’s base 
bonds with NaBHyacetate blocking solution.
Coomassie dye binding analysis of protein concentration(s) was found to be a quick, 
effective technique. The working range of this assay for BSA was between 0.5 and 500 /xg/ml 
(CV <  5 %), with a lower limit of detection of 0 .2  jtxg/ml (CV <  10 %) (Fig. 14).
CD 5 9 5  nm CV {%)
1.4
0.8
0.6
0.4
0.2
0
0.01 0.1 1 10 100 1,000
BSA ( /ig/ml)
Figure 14. Standard calibration curve for BSA by Coomassie dye binding.
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Figure 15. The effect of time on the covalent binding of protein (BSA, 5 ml 
at 10 mg/ml) to activated porous-silica (200  mg), n = 4. Total 
binding (Q, mg/g) was as follows: diol-PS, 76; AP-PS, 63; Epox- 
PS, 34; Bis-PS, 29; and AP-PS&Bis, 11.
The epoxide coupling of a protein ligand (BSA) to activated PS, by either direct oxirane 
linking or bifunctional bis-oxirane linking was a time consuming process. The direct binding 
of proteins to epoxide-PS, as opposed to the use of a bis-oxirane bridging molecule, produced 
solid phases with the greatest level protein immobilization (^ a^x ot Q for BSA = 34 mg/g). The 
time taken to reach half the solid phase protein (BSA capacity, q /Q  = 0.5) was also shortest 
when protein was coupled directly to epoxide activated PS (Fig. 15).
All of the epoxide removing conditions evaluated appeared to remove the protein 
binding capacity of epoxide-PS. Incubating epoxide activated PS in epoxide removing solutions 
for 30 minutes and testing for BSA binding would suggest blockers (from best to worst) came 
in the order, 1 M glycine pH 1.6 (44 j^g/g) <  1 M thiourea (51 jug/g) <  1 M H 2SO4 (57 /xg/g) 
<  2 % v /v  mercaptoethanol (63 /tg/g) <  and the control water (27 mg/g).
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5.4.2 Immunoaffinity Chromatography (lAC)
Immobilized whole antisera PS solid phases performed best when a glycine based 
(glycine/NaBH^CN pH 7.6) blocking solution was used. However, immobilized 
immunoglobulin solid phases (IgGs and MAbs) performed best when an ethanolamine based 
(ethanolamine/glycine/NaBH^CN pH 7.6) blocking solution was used. Although the use of 
borohydride (NaBHj proved the best means of removing residual aldehyde groups and 
reducing Schiff’s bases, it was also found that it drastically lowered the activity of immobilized 
antibodies (by between 60 and 80%).
Figure 16 presents the chromatography of a crude stock of tritiated trenbolone (Tb- 
H^^), containing the 17 alpha (17o'OHTb) and 17 beta (17BOHTb) hydroxy isomers. Tb-H^^ 
(50 KBq) was immunoaffinity purified and the 17o;OHTb and 17BOHTb isomers separated, 
by lAC on columns of PS immobilized antibodies specific for either the alpha or beta 
component (Ab cross reactivities <  5 % for the other isomer). When the breakthrough 
component of a Tb-H^^ purification on a lAC column specific for one isomer was applied to 
a column specific for the other, all the radioactivity emerged as a single peak in the elution 
phase. When the eluted activity from an isomer specific column was applied to one specific for 
the other, all the radioactivity appeared as a single peak in the breakthrough fraction. By 
comparing the area under the tritium breakthrough and elution peaks, the composition of the 
Tb-H^^ radio label sample was assessed to be 82.5 % 17fiOHTb and 17.5 % 17o:OHTb.
Figure 17 shows the selective recovery of the anabolic agent zeranol (Zl) from clean and 
crude mixtures by lAC, on a solid phase of PS immobilized anti-Zl monoclonal antibody. A  
0.5 ml column of anti-zeranol solid phases had a Zl capacity of 138 ng (C/Co = 0.5). Effective 
elution of Zl and prevention of non-specific hydrophobic binding to the anti-Zl column, 
required the presence of methanol (4 %) in all the purification buffers.
Antibodies have been purified by AC on either PS immobilized antibodies or SpA. 
Antisera raised to antibodies from one species have been purified on columns of antibodies 
from another, or immobilized and used as a the lAC ligand for purifying antibodies from  
another species. Immobilized SpA was used throughout this study as a general purpose ligand 
for recognizing the Fc region of Ig molecules.
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C/Co (CPM)
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A d so rp tio n /w a sh in g E lu tion
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col vols
Tb c o lu m n s
■^DantiTb 
-®-M315
Figure 16. Affinity purification of crude on donkey anti-lZceOHTb
and on sheep anti-lZfiOHTb (M315) (adsorption/washing; PBS 
containing 4% MeOH, Elution; 30 mM HCl containing 20% 
MeOH.
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Figure 17. lAC of the anabolic agent Zeranol on PS immobilized anti- 
zeranol MAb (17C4): a) Zl-H^  ^ breakthrough curve and b) 
purification profile of Zl in PBS and serum.
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In both immobilized Ab and SpA AC purifications, Igs were adsorbed in buffering 
conditions of near neutrality (5.6 <  pH <  8.9) and eluted by a shift to more acid conditions 
(1.8 <  pH <  3.0). When a mlgG^ MAb (20 ml AFP27 J28, at 840 /xg/ml) was affinity purified 
on 1 ml columns of DceMIgG-PS and Prosep A HC under similar conditions, the MAb 
recoveries were 14.3 and 10.6 mg respectively.
5.4.3 Purification of antibodies on PS immobilized hapten
Figure 18 shows the result of purifying bovine anti-Ts antibodies on a Prosep A, 
Ts-CMO-PS and Rivanol affinity column. The effect of eluting conditions on the specific 
activity of an anti-Ts Mab eluted from a Ts-CMO-column is presented in Figure 19.
OD (450  nm)
1.4
0.8
0.6
0.4
0.0078 0.078 0.78
column used
—  Ts-CMO-PS  
-+-CM O-PS  
Antiserum 
Rivanol 
Prosep A HC
Protein (^'E/mi)
Figure 18. Titre of a bovine anti-Ts MAb when purified on PS based solid 
phases.
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Figure 19. The effect of elution conditions on the titer of an anti-Ts MAh 
when purified on a Ts-CMO-PS solid phases.
5.4.4 HPLAC on PS immobilized ligands
Figures 20  to 22  represent the HPLAC of antibody containing biological fluids and 
electrophoretic analysis of the protein peaks isolated. Antibodies eluted from SpA solid phases 
by a gradient of decreasing pH commonly produced 4 elution peaks, indistinguishable by SDS- 
PAGE. The eluted protein peaks produced on HPLAC of biological samples on Prosep A  
"High Capacity" columns contained only antibodies when examined by electrophoresis.
The rate limiting step in the affinity purification of Abs by HPLAC was the time 
dependent adsorption phase. Increasing the flow rate of an HPLAC purification on antibodies 
from serum on a Prosep A HC column resulted in a proportional increase in the breakthrough 
component of the purification profile. All other stages of the affinity separation could 
successfully be speeded up to flow rates of 30 col vols/m in with little effect on the overall 
efficiency of the isolation. HPLAC of serum proteins on the immobilized acridine dye, 
Rivanol, was also investigated and will be outlined in a later chapter.
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Figure 2 0 . HPLAC separation of (NH^)2SO  ^ precipitated MAb on Prosep 
A HC. 200 fA of MAb (mlgGi; at 0.634 mg/ml) was injected at 
a flow rate of 10 ml/min. Eluent: linear gradient from 200 mM 
NazHPO^ pH 7.8 to 100 mM citric acid pH 1.8. Detection: 280 
nm. Fractions about the protein peaks of the 2 m l/m in run were 
collected and assessed by ELISA (for SpA) and SDS-PAGE for 
protein composition.
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Figure 21. HPLAC separation and SpA profile (a) and protein make-up (b) 
of (NH4)2S0 4  precipitated MAb on Prosep A HC. 2 0 0  fA of 
MAb (mlgGi; at 0.634 mg/ml) was injected at a flow rate of 2 
ml/min. Eluent: linear gradient from 200 mM Na2H PQ 4 pH  7.8 
to 100 mM citric acid pH 1.8. Detection: 280 nm.
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Figure 2 2 . Separation of crude CaSpA egg yolk isolate by HPLAC on a 
Prosep A HC (0.5 ml) column. 2 0 0  fA of CaSpA was injected at 
a flow rate of a) 0.5 and b) 2 ml/min. Eluent: linear gradient 
from A; 200 mM NazHPO^ pH 7.8, to B; 100 mM citric acid pH  
1.8, in run C) was the same as b) but the B buffer was molar 
glycine pH 1.6. Detection: 280 nm. Fractions about the protein 
peaks of run c) were collected and assessed by lEF 
electrophoresis for protein composition, d).
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5.4.5 Immobilized anionic exchangers
Table XVI, summarises the results of BSA purifications on PS immobilized anionic 
exchangers. The solid phases produced by immobilizing DEAE and QAM groups on PS 
produced poor ion exchange matrices. When applied to a DEAE-PS column, BSA had an Rf 
the order of 1, protein appearing to breakthrough with the solvent front. When applied to a 
column of QAM-PS the percolation of BSA through the column was retarded and emerged as 
a broad peak at around 7 col vols of phosphate solution. O f the ion exchange solid phases 
produced, the DEAE-dextran-PS anionic exchanger was found to be the best overall performer, 
having a good isolation profile for BSA (Fig. 23). Furthermore, when compared to DEAE- 
Sephadex and QAE-Sephadex, DEAE-dextran-PS had a simple profile titrating over 1 m eq/g 
rather than 3 m eq/g profile of DEAE-Sephadex. This would suggest that the PS preparation 
was a relatively strong exchanger, with fewer charged groups than DEAE-Sephadex and with 
a uniform distribution (Fig. 24).
BSA (mg/ml) phosphate (M)
0.614
BSA Phosphate
0.5
0.4
0.3
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0 10 15 20 25 30 35 40 45 505
vols
Figure 23. Purification of BSA (5 ml at 4 mg/ml in 10 mM N a2HPO^ pH  
8) on a DEAE-dextran-PS column (0.5 ml). Elution: stepwise 
gradient 400 mM Na2HPO^ pH 8 .
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Figure 24. Titration of 1 g of DEAE-dextran-PS, DEAE Sephadex A50 and 
QAE-Sephadex in IM KCl.
TABLE XVI. PURIFICATION OF BSA O N  PS BASED A N IO N IC  EXCH ANGER
SOLID PHASES
Buffer (5ml)
DEAE-
Sephadex DEAE-PS QAM-PS
DEAE-dextran-
PS
Load 500 500 500 100 500 100
Breakthrough 235 117 79 41.5 58.5 3.5
wash #1 97 314 264 39.5 2 0 2 30
wash #2 . 38 6.5 96 14.5 97 0.5
wash #3 14 0.5 - 2 .0 - 18
Elution 117 30 60.5 1.5 142 72.5
BSA (in NaJtlPO^ 10 mM; 5ml) added to 1 ml columns, washed (3 X  N a^P O ^ 10 mM; 5ml) and 
eluted (in Na2 HP 0 4 , 0.4 M; 5ml). BSA determined by ^% = 5.3.
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5.4.6 Reduction of PS solid phase ligand leakage
Figure 25 shows the effect that percolating buffer pH has on the ligand (SpA) leakage 
from a Prosep A HC column. This leakage appeared time dependent, as increasing the 
percolating solvent flow rate caused an exponential fall in the SpA concentration of 
breakthrough solvent (Fig. 26). However, the rate of ligand leakage from the Prosep A column 
(ôSpA/ôt, Fig. 26b.) appeared to peak at around 5 to 10 ml/hour (or 0.37 cmS' )^. This was 
consistent with a change in Reynolds number from below 10 to above 100 and hence a shift 
from "laminar flow" to "turbulent flow".
SpA cone pH grad
SpA (ng/ml) pH
100
0.1
0.01
102.52.5 52.5 152.5 202.5
Col. vols.
Figure 25. The effect of percolating buffer pH on the background level of 
ligand leakage from a Prosep A HC column. Eluent: linear 
gradient from 200 mM Na2HPO.^ pH 7.8 to 100 mM citric acid 
pH 1.8, at a flow rate of 0.25 ml/min. Detection: ELISA.
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Figure 26. The effect of flow rate on the level of ligand leakage from a 
Prosep A HC column. Eluent: glycine (IM), NaCl (150 mM), 
pH 8 .6 . Detection: SpA specific ELISA; a) concentration v time, 
b) leakage rate v time.
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w hen  a polyclonal sheep antiserum raised to the anabolic agent trenbolone was eluted 
from a Prosep A H C  column by a stepped decrease in pH (citrate/phosphate), the majority of 
antibodies were eluted in the fractions with a pH greater than 5. However, the greatest specific 
activity (analyte recognition per unit antibody mass) was found in the pH 3.3 fraction 
containing less than 5 % of the antibodies adsorbed (Fig. 27). This would suggest that when 
purifying such an antibody for pharmaceutical applications, contaminants and the amount of 
protein required to achieve the therapeutic dose may be minimized, by selectively isolating 
only those antibodies eluted about pH 3.3 and discarding all other material.
Activity ( % / k ) pH
PAb (Tb) ^ M A b  (Zl) “ pH
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Ip
100%0 %Gly 25% 50% 75%
Applied solution (cit/phos %)
Figure 27. The analyte binding of sheep anti-trenbolone (Tb271a; 500 /tl in 
5 ml glycine (IM), NaCl (150 mM), pH 8 .6 .) and anti Zl MAb 
(17C4) fractions purified on a Prosep A "high capacity" column 
(1 ml). Elution: Stepwise gradient 0 .2  M Na2HP0 4  pH 7.8, to 1 
M citric acid pH 1 .8 . Detection: Total protein ODjgonm» SpA by 
specific ELISA.
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Silanizing PS in the presence of Kimal or alumina resulted in clumping of the solid 
phase particles, with the matrices requiring selective sieving prior to further activation. The 
matrix silanized in the presence of Kimal produced activated solid phase particles with spots 
of white particulate matter on the surface after glutaraldehyde activation (a uniform salmon 
pink colour usually achieved). The presence of aluminium oxides (kimal and alumina) during 
the PS silanization process also resulted in matrices with reduced flow rates, but with much 
greater resistance to the dissoluting effect of molar N aO H  (Fig. 28).
OD/ODmax (450 nm)
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Figure 28. The dissolution of porous silica matrices in molar N aO H , 
activated in the presence or absence of aluminium oxides.
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TABLE XVII. THE EFFECT OF Al-ETHOXIDE CONCENTRATIONS ON THE 
PERFORMANCE OF GPTS SILANIZED SpA-PS SOLID PHASES
Al-ethoxide (%) diol (/zmol/g) MAb (mg) SpA/MAb
(X 10-^ )
AP-Silica - 2.27 0.59
0 64.3 1.82 0.74
0.25 64.3 2.04 1.03
0.5 56.3 3.21 5.84
1.0 50.0 7.02 5.62
2.0 42.9 8.58 5.03
MAb (AFP27 SZ) capacity determined by frontal analysis (24 vols, 8 X 3  ml fractions), on SpA-Silica
Table XVII shows the effect of Al-ethoxide concentration on the properties of SpA-PS 
solid phases produced by GPTS silanizing PS. Increasing the amount of aluminium ethoxide 
in matrix silanizing solution reduced the degree to which PS matrices were diol functionalized. 
The MAb capacity of SpA solid phases made with these Al-ethoxide matrices was greatest for 
those silanized in solutions with a high Al-ethoxide content.
Table XVHI shows the results of experiments demonstrating the effect of metal ions on 
the alkali dissolution of silica-based solid phases. SpA-PS and SpA-CPG solid phases were 
assessed for MAb capacity and ligand leakage, post sanitizing for 8 cycles. Over 8 cycles, none 
of the diol-PS prepared SpA-PS preparations showed any signs of degradation, while the AP-PS 
prepared SpA-PS solid phases began to show increased ligand leakage and a reduction in MAb 
capacity.
The chlorides of aluminium (AlClj, tin (SnClj and zinc (ZnClj were compared for 
inclusion in buffers to be used for affinity purifying proteins on silica-based solid phases. AICI3 
precipitated protein (BSA) when at concentrations above 50 mM and caused coagulation of 
Prosep A HG when at concentrations above 100 mM. SnClj required acidic conditions in order
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to go into solution, forming a cloudy emulsion at concentrations above 10 mM, the free metal 
eventually falling out of solution. ZnClj appeared best for chromatographic applications, but 
the buffer required much additional alkali to reach the required pH, before making up to the 
working strength.
The inclusion of Zn^ "^  ( > 1 0  mM) ions in the low salt adsorption buffer reduced the 
level of SpA leakage from a Prosep A HC (SpA-/^^  ^ column by more than a hundred fold. 
Increasing the concentration of Zn^  ^ to above 10 mM produced no further lowering in the 
level of ligand leakage. On removing Zn^ "^  from the buffer percolating the SpA-P^  ^column the 
ligand leakage returned immediately to a level slightly lower than the background level prior 
to Zn^ '*’ application (Fig. 29). Figure 30 shows the result of frontal analysis of MAb on a 
Prosep A H C (SpA-P^^ column in the presence and absence of Zn^”^ (10 mM) ions.
SpA (ng/ml) ZnCI2 (mM)
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Figure 29. The effect of Zn^ "^  ion concentration on the background level of 
ligand leakage of a Prosep A HC (SpA-7^ ^^ ) column (1 ml), at 
flow rate of 0.5 ml/min. Eluent: linear gradient from 0 to 400 
mM ZnCl2 in glycine (1 M), NaCl (0.15 M) pH 8 .6 . Detection: 
SpA-/^^ gamma counting.
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Figure 30. Frontal analysis of MAb (AFP27 SZ) in the absence a), or 
presence b) of 10 mM ZnClj, on a Prosep A H C (SpA-/^^ )^ 
column (1 ml), at flow rate of 0.5 ml/min. Eluent: 1; increase 
flow rate to 1 ml/min, 2; wash with glycine (1 M), NaCl (0.15 
M) pH 8.6 and 3; 0.1 M citric acid pH 1.6. Detection: SpA-/^^, 
gamma counting-, IgG; ODjgonm-
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TABLE XVIII. THE EFFECT OF NaOH (IM, 5 VOLS) SANITIZING ON THE MAb CAPACITY AND  
SpA LEAKAGE FROM SILICA BASED SpA SOLID PHASES IN THE PRESENCE OF METAL IONS
Solid phase
MAb (AFP27 SZ) purification cycles.
1 2 3 4 5 6 7 8
MAb purified on each column (mg/ml col vol).
SpA-PS (AP-PS) 1.57 2.21 2.60 2.11 2.45 1.98 2.39 2.11
SpA-PS (Al, 0%) 2.00 4.18 3.43 2.87 2.93 2.91 2.95 2.82
SpA-PS (Al, 0.25%) 2.07 2.96 2.75 2.14 3.18 2.62 3.27 2.87
SpA-PS (Al, 0.5%) 3.11 6.96 3.54 3.64 3.54 3.25 3.37 3.04
SpA-PS (Al, 1%) 6.05 6.86 6.59 6.29 6.07 4.32 4.86 3.77
SpA-PS (Al, 2%) 6.07 7.05 6.27 7.16 5.87 5.39 5.59 3.87
Prosep A HC 8.96 7.91 5.59 4.32 2.96 1.25 1.09 0.70
Prosep A HC 8.62 8.07 6.20 4.27 2.91 1.30 1.14 0.55
Prosep A HC* 8.78 7.70 6.50 5.52 5.21 3.20 3.00 1.89
Prosep A HC* 8.78 8.14 6.57 5.98 5.16 4.46 3.00 1.87
Prosep A HC^ 8.77 8.25 8.19 8.10 8.60 8.02 7.97 7.81
Prosep A HC^ 8.78 8.24 8.18 8.11 8.60 8.05 8.00 7.98
SpA co-purified with MAb from each column (ng/ml col vol).
SpA-PS (AP-PS) 18.42 24.27 41.40 31.87 20.30 17.95 20.38 19.15
SpA-PS (Al, 0%) 40.78 126.97 37.18 36.64 24.95 44.40 20.44 21.18
SpA-PS (Al, 0.25%) 39.71 26.57 26.98 58.60 23.89 36.08 17.73 18.67
SpA-PS (Al, 0.5%) 59.72 81.63 72.51 94.77 71.98 65.86 30.46 21.33
SpA-PS (Al, 1%) 127.81 427.6 324.5 313.8 337.1 211.3 105.9 76.81
SpA-PS (Al, 2%) 132.59 232.4 240.7 209.0 306.4 245.3 107.4 84.04
Prosep A HC 1167 1260 969.3 687.7 741.7 370.1 68.17 24.88
Prosep A HC 1204 1469 1080 877.1 781.4 366.1 57.44 25.99
Prosep A HC* 1374 1527 1046 847.0 1066 589.1 168.1 170.3
Prosep A HC* 1329 1492 1208 890.7 1142 220.2 172.9 148.2
Prosep A HC*" 1311 527 99.1 57.1 51.8 53.7 59.3 53.1
Prosep A HC'’ 1288 503 92.0 59.5 52.2 51.8 52.5 53.8
Ligand contamination of purified MAbs (SpA/MAb X 10- .^
SpA-PS (AP-PS) 11.73 10.98 15.92 15.10 8.28 9.06 8.53 9.07
SpA-PS (Al, 0%) 20.39 30.37 10.84 12.77 8.51 15.26 6.93 7.51
SpA-PS (Al, 0.25%) 19.18 8.98 9.81 27.38 7.51 13.77 5.42 6.50
SpA-PS (Al, 0.5%) 18.20 20.61 20.48 26.04 20.33 20.26 9.04 7.02
SpA-PS (Al, 1%) 21.12 36.09 49.24 49.89 55.53 48.91 21.80 20.37
SpA-PS (Al, 2%) 21.84 32.96 38.39 29.19 52.19 45.51 19.21 21.72
Prosep A HC 130.19 159.29 173.39 159.19 250.57 296.08 62.54 35.54
Prosep A HC 139.68 182.03 174.19 205.41 268.52 281.62 50.38 47.25
Prosep A HC* 156.49 198.31 160.92 153.44 204.61 184.09 56.02 90.09
Prosep A HC* 151.37 183.29 183.87 148.95 221.32 49.37 57.65 79.23
Prosep A HC** 149.50 63.88 12.10 7.05 6.02 6.69 7.44 6.79
Prosep A HC'’ 146.70 61.04 11.25 7.34 6.07 6.43 6.56 6.81
AP-PS; amminopropyl porous silica, Al; Al-ethoxide in silanizing conditions, a; 10 mM in N aO H  solution, b; glycine 
(1 M), N aCl (0.15 M) p H  8.6 sanitized (control).
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TABLE XIX. THE EFFECT OF WASHING AND ELUTING BUFFER IO N  
CONTENT O N  THE SpA AND  MAb CONCENTRATION OF A PROSEP A HC
PURIFIED MAb (AFP27 SZ)
ZnCb (mM) SpA (ng) MAb (mg) SpA/MAb (X 10-")
0 41.9 2.21 18.96
1 44.2 2.16 20.46
10 43.2 2 .20 19.64
100 14.2 1.63 8.71
1000 10.0 0.30 33.33
20 ml of Mab (AFP27 SZ, neat air lift fermenter supernatant), washing and eluting buffers containing 
ZnCL.
TABLE XX. THE EFFECT OF SANITIZING BUFFER COMPOSITION THE SpA 
A N D  Ab CONTENT OF PROSEP A HC PURIFIED MAb (AFP27 SZ).
Buffer SpA (ng) MAh (mg) SpA/MAb (X 10-")
80°C dry (72 hours) 13.5 3.6 3.75
Acetone 94.2 13.6 6.93
CHCI3/C H 3O H /H 2O
(5:4:1)
101.6 12.9 7.88
methanol 101.8 11.5 8.85
Low salt 111.9 12.2 9.17
Acetic acid (10 %) 120.4 11.8 10.20
GuHCl (6 M) 114.2 10.1 11.31
Urea (6 M) 133.4 11.6 11.50
NaOH (1 M) 143.2 12.2 11.74
autoclaving 89.7 3.7 24.24
20 ml of MAb added to columns after roller-mixing column(s) in 5 vols of the above buffers, or heat 
sterilizing, ranked in order of increasing SpA contamination of MAbs.
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By adding ( > 1 0  mM) ions to the washing/adsorption and elution buffers used in the 
affinity purification of a MAh on a Prosep A HC column, SpA leakage was reduced and as a result 
the ligand contamination level of purified MAh (Table XIX). This lowering of SpA contamination 
was at the cost of MAh capacity, the amount of eluted MAh being decreased by 7 fold at molar 
concentrations of Zn^ .^
Alternatives to the use of molar NaOH for sanitizing affinity solid phases have been used 
to clean-up Prosep A HC solid phases and evaluated for their effect on solid phase performance. 
Percolating 5 col vols of acetone through a Prosep A HC column appeared to be the most 
appropriate sanitizing technique (Table XX).
The effect of ligand density on the ligate capacity and ligand contamination of purified ligate 
has been demonstrated for SpA-PS solid phases in figure 31.
MAb (Q) SpA/MAb (ppm)
25025
“ mean — SpA/MAb
20020
150
100
50
4010 2052.50
SpA (mg/col. vol)
Figure 31. The effect of SpA concentration on binding SpA to CHO PS on 
the MAh capasity and SpA leakage of SpA-PS.
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5.5 DISCUSSION
The porous silica preparation Matrex™ Si (particle size, 90 - 130 fxm; pore size 1000  Â 
Amicon Ltd.) was used as the starting material for the development of a number of silica-based 
solid phases. Solid phases were eventually made (as in later chapters) from more mechanically 
stable CPG matrices, of well defined particle size and pore characteristics. The particle size and 
porosity of Matrex was particularly suited to affinity chromatographic applications involving 
biological matrices (filtered tissue homogenates, serum, whole blood and bile). In particular, 
the grade of Matrex chosen had a pore accessability applicable to the purification of biological 
macromolecules, such as antibodies on SpA.
The introduction of functional groups to the surface of silica-based matrices by 
silanization proved a very effective process. The degree to which PS with an average pore size 
of 1000  A when GPTS silanized in aqueous conditions was surface epoxide activated was 
typically 70 to 75 fim ol/g. This level of surface activation was consistent with the findings of 
Walters (1985). Activation was increased still further, commonly to around 110 to 150 jLtmol/g, 
by performing silanizations in organic conditions. The protein capacity of AP-PS preparations 
was greatest for solid phases prepared in organic solvents, this was conceivably due to the 
relatively low solubility of APTS in aqueous conditions. In the large scale manufacture of silica- 
based solid phases for process scale applications, the choice of silanizing conditions may depend 
upon weighing up the degree of matrix derivatization required, against the cost of the analytical 
grade solvents and stability of the ligand required for their preparation.
Increasing the trialkoxysilane concentration when silanizing PS in aqueous conditions, 
resulted in matrices with an improved degree of surface activation (diol /xmol/g; with GPTS, 
up to 2.5 %). Consequently, the protein (BSA) capacity of activated matrices silanized with 
high levels of trialkoxysilane was also increased. However, excessive surface ligand 
concentrations may lead to reduced performance of affinity solid phases, due to ligand stearic 
hindrance, ligate peak broadening and elevated levels of co-purificants due to non-specific 
adsorptions.
Matrices activated to high surface functional group concentrations may immobilise 
ligands by multi-point attachment, increasing the stability of ligand attachment. On binding
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BSA to diol derived PS protein capacity was highest and ligand leakage lowest when BSA was 
attached to matrices with high surface diol concentrations. The biological activity of protein 
ligands immobilized to highly derivatized matrices may be reduced due to distortion of their 
tertiary configuration; hence, immobilizing chemistries must be tailored to suit the ligand in 
question, maximizing ligate purification, with minimal ligand leakage.
The binding of proteins to a matrix via amine or amide bonds has previously been 
reported as being the most stable means of their immobilization (Peng et al., 1986; and 
Fiiglistaller, 1989). The binding of proteins via Schiff’s base formation with aldehyde groups 
on activated PS was a quick (q/Q = 0.5, t <  20 minutes) and easy (salt <  0.2 M, with 5 <  
pH <  7) process. Epoxide coupling of ligands to activated PS matrices was by comparison a 
very slow process (q/Q = 0.5, t >  7 hours). Immobilizing BSA to PS by epoxide bonding 
took more than 24 hours at ambient temperature to reach column capacity. Epoxide bonding 
might therefore be considered unsuitable for coupling labile ligands to silica/glass matrices, such 
as enzymes and antibodies.
Where low levels of bound ligand are adequate for an AC application, epoxide binding 
may be appropriate as levels of ligand leakage were very low. However, blocking the remaining 
surface epoxides also proved a slow process, suggesting long blocking times or harsh conditions 
are required. Epoxide silica/glass matrices may therefore prove most appropriate for binding 
non-labile ligands such as dyes or haptens.
Comparing protein (BSA) solid phases made with AP-PS and diol-PS (both made with 
10% trialkoxysilane), the diol-PS based preparation had a higher degree of protein 
immobilization, with a lower level of ligand leakage. This was possibly due to the unstable 
nature of the protein’s immobilizing Schiff’s base bonds, two of which were required for 
glutaraldehyde bonding to AP-PS and a protein.
For large proteins, a monolayer represents a solid phase surface concentration of the 
order of 0.01 jumol/m^ (Philips, 1991). Assuming the surface area of silica particles with a pore 
diameter of 1000  A to be 2 0  mVg (Walters, 1985), the amount of BSA immobilized on 
aqueously silanized diol-PS represents 64.3 % of the potentially available matrix capacity.
The type of blocking chemistry used to remove functional groups remaining on
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activated solid phases after ligand immobilization was dictated by the nature of the ligand 
immobilized. Reduction of an activated -PS matrix’s surface aldehyde groups and ligand 
immobilizing Schiff’s base bonds was most complete when using NaBH^ as the reducing agent. 
However, NaBH^ reduction proved too vicious for use with labile proteins (typically reducing 
the antigen binding of immobilized antibodies by 60 - 80%), but had little or no effect on the 
activity of a more robust protein ligand such as SpA.
The highly selective reducing agent NaBH^CN, was able to reduce antibody 
immobilizing Schiff’s base bonds without affecting their biospecific activity, while leaving active 
aldehyde groups intact. NaBHjCN was therefore often included in protein immobilizing 
buffers to promote the formation of stabilized Schiff’s base bonds. The remaining aldehyde 
groups were then saturated by incubating solid phases in an excess of free amino groups 
(glycine or ethanolamine).
Solid phases produced by immobilizing biologically active proteins were made under 
conditions so as to limit degradation of their biological activity. For immobilized whole 
antiserum lAC solid phases, a glycine blocking solution proved most suitable. In the case of 
immobilized immunoglobulins (PAbs or MAbs), a slightly more hydrophobic ethanolamine 
based blocking solution proved best. On the whole, immobilized whole serum antibody 
columns appeared to have a longer shelf life than those made from isolated antibodies alone. 
This observation was perhaps due to the accompanying serum proteins immobilized along with 
the antibodies in whole serum offering antibodies mechanical and physicochemical support, 
while provWing alternative sites for protein degrading microbial attack.
In this study immunoaffinity chromatography (lAC) has been used for the pre­
treatment (or clean-up) of residues of anabolic agents in biological samples prior to analysis and 
will be fully discussed in a later chapter. The 17 alpha and beta isotopes of trenbolone were 
resolved by lAC on PS immobilized antibodies, indicative of the extremely selective nature of 
lAC separations. It would appear that haptens demonstrating very slight differences in their 
surface configuration may be extracted from sample matrices by, in effect, a chiral separation. 
The specificity of antibodies would suggest lAC techniques for specific isolation procedures 
may be developed for any molecule, limited only by the quality of antibodies.
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The binding of the anabolic agent zeranol (Zl, 6 ’ ce-zeralanol) to immobilized antibodies 
(PAbs; R114 and L332 and a MAb, 17C4, Carter et al, 1984), was largely as a result of 
hydrophobic interactions. Consequently, the extraction of Zl from buffers and biological 
samples and elution from lAC columns depended largely on the polarity of the percolating 
solutions. Low recoveries of the order of 30% were achieved with hydrophobic samples, such 
as whole serum which has a high lipid content. A shift in pH to more acidic conditions alone 
was not sufficient to desorb Zl from lAC solid phases. Elution required the presence of 
methanol (4%) or ethylene glycol (12 %) in an acidic (pH 1.8) eluting buffer. When preparing 
lAC solid phases, 100 y \ of antisera was immobilized per g of activated solid phase, the 
equivalent to 5.3 - 11.3 jwmol/g (as serum Ab is 8 - 17 g/1). For a 200 mg (wet weight) SPE 
cartridge for a drug residue (of around 300 mol wt), this was consistent with an analyte 
capacity of 200-500 ng/column.
A bovine IgG  ^ monoclonal raised to the steroid testosterone (Groves et al, 1987), did 
not bind to Prosep A when attemping to purify it by means of protein A  affinity 
chromatography. This MAb could be resolved from its culture media solid phase consisting of 
PS immobilized testosterone-carboxymethyloxime (Ts-CMO). The binding of the anti-Ts MAb 
to a Ts-CMO-PS column, like immobilized Zl MAb to Zl^  again appeared largely hydrophobic. 
The specific activity (Ts binding/protein mass) of anti-Ts MAb purified on immobilized Ts 
(Ts CMO-PS) was increased by more than 50 fold. However, the anti-Ts specific activity of 
MAbs, was also increased 10 fold by purification on a column of bridging moiety alone (CMO- 
PS), due to the hydrophobic nature of ofTs-BMAb hapten recognition. The protein capacity 
(Q) of CMO-PS for anti-Ts MAb was 80 % that of Ts-CMO-PS. In order to eliminate the non­
specific (hydrophobic) binding of anti-Ts MAb to CMO-PS required the use of hydrophobic 
conditions such as 40 - 50 % methanol, in which proteins are usually denatured.
DEAE groups commonly have a pKa (pH giving 50% neutral and 50% charged groups) 
the order of 9.0 to 9.5. DEAE-Sephadex is normally used at pHs ranging from 6  to 9 and has 
a complex titration curve, due to the electrostatic repulsion of adjacent protons at lower pH  
values. The DEAE-dextran-PS solid phase produced in this study had a simple titration curve, 
indicative of it being a strong ion exchanger, such as was the case with the titration of QAE-
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Sephadex. Having a simple titration curve, the surface of an exchange matrix should remain 
charged over a wide pH range, therefore the binding of proteins to DEAE-dextran-PS may be 
expected to be stabilized by multi-point attachment. In order to purify labile proteins, weak 
exchangers operating at pH ’s between pH 6  and 9, with mild eluting conditions, are best. 
Stronger exchangers may be chosen when the p i of a protein falls outside the operating pH ’s 
of weak exchangers and therefore extremes of pH  would be required to promote adsorption. 
Ion exchange matrices with simple titration profiles allow the elution of proteins in less diffuse 
bands’, hence they may be collected in fractions devoid of protein contaminants.
Initial findings from experiments conducted using PS solid phases in an HPLAC format 
would suggest them appropriate for the production of extracts for quantitative analysis or large 
quantities of isolate of a quality required for therapeutic use. It was also possible to vastly 
increase the speed of column washing and elution stages, without compromizing the overall 
eluate purity and yield. The rate of mass transfer from the mobile to the stationary phase 
during the adsorption phase of an affinity purification process appeared to be the rate limiting 
step. Consequently, it would appear that lAC may be integrated into an HPLC based analytical 
system, allowing the processing and quantitative evaluation of analytes by a process of column 
switching (Shepherd, 1992).
A problem which was often encountered in earlier attempts at HPLAC purifying 
antibodies on Prosep A HC was one of "ghosting". After affinity purifying a sample, the same 
purification profile (though reduced by 5 - 10 fold) was achieved by running the purification 
system again with a blank sample immediately afterwards. On subsequent investigations it was 
found that these ghost peaks could be eliminated by applying greater than 10  col vols of eluting 
buffer over a period of 30 minutes. Chosting proved to be a "time of clean-up" dependent 
phenomenon and not "clean-up solution volume" dependent as previously expected.
The physical stability of PS-based SpA affinity solid phases remained unaffected by 
changes in pH between 1 and 7.6 (protein leakage remaining below 10 ng/m l, percolating low  
salt adsorption buffer). Above pH 8 , a marked increase in the level of ligand leakage from  
Prosep A "high capacity" columns was observed, due to the dissolution of the silica-based 
matrix. Prior to using Prosep A HC columns to purify antibodies for the first time (or after
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a long period of storage), columns always appeared to have far greater than expected level of 
background SpA leakage in eluting buffer. Desorbing antibodies from these columns increased 
the level of SpA leakage still further, often by more than a hundred fold. Experimentally, this 
effect was only ever observed on antibody purification; non-ligate proteins (BSA, or transferrin) 
had little or no effect on the level of SpA leakage. Peng and his colleagues (1986) reported a 
similar finding, noticing that the level of ligand leakage form CNBr-activated Ab-Sepharose 
solid phases was only ever significant on purifying antigen.
Furthermore, on repeated affinity purifications, the high level of SpA contamination 
of Prosep A H C purified Abs was seen to fall dramatically ( > 2 5  fold), to a steady maintained 
level after 4 consecutive cycles. This observation was consistent with that of Francis et al. 
(1990) for protein A Sepharose. Preconditioning SpA affinity solid phases by a pilot antibody 
purification prior to a production purification may prove the best regime for the clean-up of 
therapeutics.
In addition to matrix stability, the condition of the antibodies eluted from an SpA- 
silica/glass solid phase must be considered. Due to the labile nature of antibodies, a column 
feed stock may contain antibody fragments (Fc and Fab), as well as intact antibodies. The pH  
at which these constituents are adsorbed and desorbed from an SpA solid phase and the pH  
stability of these constituents, will determine the specific activity of eluted antibody fractions.
Due to differences in the binding affinity of SpA for Ig sub-classes, HPLAC on silica 
immobilized SpA has previously been reported as a means of isolating and determining the Ig 
make-up of blood serum samples (Crowley and Walters, 1983). This may also affect the specific 
activity of antibody fractions eluted stepwise from an SpA matrix, clonal selection favouring 
the production of fewer clones of a single isotype.
In this study, the stepped elution of both PAbs from an immobilized SpA column 
resulted in eluted fractions with vastly different specific activities for the antigen in question. 
On conducting the same experiment using a MAh almost all the specific activity eluted was 
found in a single fraction. In both cases the non-Ab contaminants of the purified fractions were 
the same when viewed by SDS-PAGE. These findings would appear to support the suggestion 
of a difference in the isotype make-up of antibody fractions step eluted from an SpA solid
149
phase as has previously been reported (Sada et al., 1988).
By purifying bovine anti-testosterone on an immobilized testosterone column in a 
gradient HPLAC process, it was hoped that the polyclonal antibodies could be fractionated 
into smaller populations and characterized. As a MAb secreting heterohybridoma cell line was 
made from the peripheral lymphocytes of the immunized cow was also available, it was 
envisaged that the Ab clone selected in culture could be resolved from the PAb by HPLAC. 
Unfortunately, the elution of anti-Ts antibodies from Ts-CMO-PS produced a diffuse elution 
peak which could not be sharpened without denaturing the antibodies.
Fractionation of polyclonal antibodies by a stepped gradient elution from an antigen 
column was possible when purifying crude egg yolk extract from SpA immunized hens on 
Prosep A "high capacity". This process typically produced a four peak elution profile, 
consistent with that found by Ohlson and Niss (1988) using this technique to isolate 
populations of circulating immune complexes from the blood of patients with immune complex 
associated diseases.
Incorporating increasing levels of Al-ethoxide into the silanizing solution used to 
activated PS, reduced the effective surface area available to GPTS for diol functionalizing, 
resulting in a lowering of the concentration of surface diol groups. However, the MAb capacity 
of SpA solid phases made with these matrices was greatest for those silanized in solutions with 
a high Al-ethoxide content. The decrease in the degree of matrix activation associated with high 
levels of surface Al may also have decreased the possibility of SpA steric hindrance, or shift in 
shape due to excess multi-point attachments. Consequently, SpA may be less firmly bound to 
a matrix and able to leach from the surface more easily. Experimental result with SpA-(Al)-PS 
solid phases would appear to support this assumption, since although the MAb capacity for 
those solid phases silanized in high Al concentrations had increased, so too had the SpA 
contamination of the eluted antibodies.
In all experiments in which SpA-PS solid phases were produced, those with a relatively 
low MAb capacity (Q of about 8 mg/ml col vol) produced less contaminated affinity purified 
products than those with much higher or lower levels of Q. Therefore, when used for the 
purification of Abs destined for therapeutic applications, large SpA-PS columns of lower
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capacity used at high flow rates may prove most appropriate.
Sanitizing SpA-PS solid phases produced by immobilizing SpA on AP-PS and diol-PS, 
over eight cycles with N aO H  had little or no effect on either the solid phase MAb capacities 
or ligand leakage. The SpA/MAb ratio improved on repeated N aO H  sanitizing, possibly due 
to the stabilizing process of multi-cycle purifications alone. During cyclic sanitizing process no 
alteration in solid phase volume or flow rate was observed, suggesting mechanical breakdown 
was minimal. Dissolution of SpA-silica/glass solid phases on repeatedly sanitizing with molar 
N aO H  appears to reduce their MAb capacities to 3 mg/ml, or have no effect when their initial 
capacities are lower then 3 mg/ml. This low capacity appears to be maintained until eventual 
matrix collapse.
The rate of reduction in MAb capacity of Prosep A HC columns produced by 
sanitizing with molar NaO H  between each purification cycle was markedly reduced by the 
presence of Zn^ "^  ions in the sanitizing solution. Simularly, on sanitizing with N aO H  prior to 
MAb purifications, none of the SpA-(diol)-PS solid phases showed any signs of degradation, 
while an SpA-(aminopropyl)-PS solid phase begun to show an increase in ligand leakage and 
a fall in the level of purified MAh achieved.
Treating solid phases with molar NaO H  has largely become the method of choice for 
sanitizing and depyrogenation of affinity solid phases (Hodgson, 1990). This technique would 
seem inappropriate for use with silica based solid phases, as pH ’s above 8 have been shown to 
cause matrix dissolution on prolonged exposure. However, Ab and SpA columns with which 
have been repeatedly exposed to pH ’s greater than 8 have shown no degradation in 
performance. Alternative sanitizing conditions to using molar NaOH, which have been used 
to clean up SpA-(PS or CPG) solid phases without any ill effects have included GuHCl (6 M), 
Urea (6 M), chloroform/methanol/water (5:4:1), acetic acid (10%), formic acid (10%), 
chloroform, methanol and acetone. By pre-treatment with 5 col vols of acetone it was possible 
to restore performance to old Prosep A columns (to near their origional MAb capacity and 
flow rate) when removed from storage, or after repeated use.
Prosep A solid phases have also been subjected to heat sterilization processes 
(autoclaving and 80°C dry for 72 hours) and were shown to maintain 30% of their MAb
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capacity. This process may allow the aseptic purification of antibodies for therapeutic 
application, but may result in a reduced clean-up efficiency due to the increased presence of 
denatured SpA able to non-specifically bind co-purificants.
Ligands may be bound to porous silica-based matrices using a number of chemistries 
to form stable solid phases with minimal ligand degradation and high ligate capacities. 
Biologically active proteins may be purified on silica/glass immobilized ligands or themselves 
used as ligand with no appreciable loss of bioactivity. By virtue of their rigid nature, silica- 
based solid phases can withstand greater backpressures, allowing for separations at high flow  
rates, thus allowing shorter analysis times and the processing of large volumes in preparative 
chromatography. The perceived alkali dissolution problem associated with the use of silica- 
based solid phases may be overcome by incorporating Zn^ "^  or AT"*" ions in the sanitizing 
buffers or the matrix coating.
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CHAPTER SIX
RIVANOL-SILICA: A DYE-LIGAND SOLID PHASE FOR AFFINITY PURIFYING
PROTEINS
6.1 SUMMARY
The antiseptic acridine dye Rivanol was immobilized onto PS matrices (Riv-PS) and 
investigated for use as a solid phase for the dye-ligand affinity purification of plasma proteins. 
Under the appropriate conditions of pH and ionic strength Riv-PS was able to bind all plasma 
proteins except for thoses with p i’s greater than 9. Riv-PS also appeared to be particularly good 
at binding glycoproteins. Elution of adsorbed proteins from a Riv-PS column could be effected 
by an increase in buffer salt content, by a reduction in buffer pH, or by the inclusion of 
organic solvents in the percolating buffer. By selective adjustments to the adsorption and 
desorption conditions the concentration of specific plasma proteins in a breakthrough or eluted 
fraction could be increased. However, using Riv-PS complete resolution of a protein from other 
proteins was not achieved. In Conclusion, it would appear that Riv-PS may be of most value 
when used upstream as a semi-selective fractionation technique, or downstream as a final 
polishing stage in a protein purification procedure.
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6.2 INTRODUCTION
6 .2 .1  Rivanol chemistry
NH
" 2 10
O ^ C H j  COOH 
CHOH
C H 3
Figure 32. Rivanol
Rivanol (Fig. 32); 6,9-d.iamino-2-etlioxyacridine lactate (Merck
11,3668), is a bright yellow crystalline compound with a molecular weight of 343.39, mp 243- 
245°C. It fluoresces under UV irradiation with a maximum in the region 260-280 nm, and is 
soluble in water (67 mg/ml) and alcohol (9 mg/ml). This compound is commonly classified in 
the therapeutic category "antiseptic".
6 .2 .2  Rivanol bioactivity
Rivanol (a trade name of Farbwerke Hoescht), was first prepared in 1921, along with 
a number of related 9-aminoacridines, for their use as potent antiseptics. These compounds 
were first used as wound disinfectants during World War U. Presently, Rivanol may still be 
found used as a surgical antiseptic (Dean, 1973), a general purpose antiseptic wound aerosol 
(Giurov, 1984), and in small doses as an intestinal disinfectant (Rivanolette, Hoechst).
Albert, Rubbo, and their associates over a period of many years (1941-1966), evaluated
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the anti-microbial activity of over a hundred acridines in comparable conditions against five 
different species of bacteria (cited in Acheson, 1973). From their findings, four general 
conclusions may be drawn. Firstly, efficient bacteriostases occured only with those acridine 
compounds 50% cationic at pH 7; secondly, the nature of the acridine nucleus was 
unimportant; thirdly, the mode of action was competitive where 500 acridine cations compete 
with each hydrogen ion for a vital anionic site on the bacterial cell; and finally, ionic and Van 
der Waals bonds were responsible for fixing the acridine to the vital receptor.
Rivanol is 100% cationic at pH 7.3 and 37°C and, of the acridines reviewed by Albert 
and his collègues, Rivanol proved very effective at preventing the growth of all 5 microbial 
species evaluated {Cl. welchii, Strep, pyrogenes, Staph, aureus  ^E. coli, 2inà Proteus). It is also noted 
for precipitating some viruses, such as the tobacco mosaic virus, and is used as the standard test 
reagent for the detection of Brucella abortis. Intraamniotic injection of Rivanol (0.1%) has also 
been demonstrated to terminate midtrimester pregnancies in humans (Zauva et al.., 1989, and 
Gardo and Nagy, 1990).
6.2.3 Rivanol protein interactions
6.2.3.1 Precipitation of proteins
Rivanol was first used in protein fractionation by Horejsi and Smetana (1956), who 
precipitated the protein in human serum by adding 3.5 vols of Rivanol (0.4%). Precipitated 
proteins were then discarded and the Rivanol remaining in solution was extracted by 
adsorption onto charcoal. This produced a fraction of almost pure y-globulin (80-90%, thought 
at the time to be 100%). This process was later refined, and used in conjunction with an 
alcohol precipitation in the US patent for the general fractionation of blood proteins by West 
and West (1968).
Though few proteins are soluble in a neutral solution of 0.4% Rivanol, this situation 
may be altered by changes in pH, the amount of Rivanol present, and the ionic strength of the 
buffer used. Transferrin, haemoplexin, IgA, cholinesterase, and Bz-glycoproteins I and II are 
Rivanol soluble proteins at pH conditions higher than neutrality. In contrast, by adjusting the
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pH of protein solutions to between pH 5 and 7 it is possible to make Rivanol precipitation 
more restrictive, and thus precipitations can be made more specific (Neurath and Brunner, 
1969).
Another approach to the fractionation of serum into its component proteins is by the 
fractional addition of Rivanol. This process has been adopted for the large scale purification 
of o!2-macroglobulin from plasma. First, proteins precipitated at low concentrations of Rivanol 
are removed, and the enriched (%2-macroglobulin fraction is then precipitated at higher Rivanol 
concentrations (Steinbuch et al., 1965, and Steinbuch and Blatrix, 1970).
6.2.3.2  Mechanism of Rivanol precipitation
Lactic acid is liberated when rivanol-protein complexes are formed (equation 28). Hence, 
to prevent the purification of undesirable proteins in batch purification processes (due to a 
lowering of pH), the pH should be continually monitored and maintained by the addition of 
an alkali such as N aO H  (Steinbach, 1980).
^15^ 15^ ^  Cg/fgOg" + Protein ^  C.^^H^^Nfi^Protein~ +
Rivanol is a basic (cationic) organic compound, which would appear to support the 
belief that Rivanol-protein complex formations should occur largely as a result of electrostatic 
interactions between the dye and negatively charged proteins. This assumption is further 
supported by the observation that the degree of protein precipitation of serum is greatest at 
alkali pH. However, a naturally negatively charged cK2-globulin such as cholinesterase is more 
or less Rivanol soluble, whereas one with a lesser negative surface charge such as the fii-globulin 
IgA precipitates. This observation is probably due to cholinesterases excessive repulsive forces. 
Furthermore, not all IgG’s are precipitated by Rivanol, suggesting electrostatic attraction is not 
the exclusive force in the interaction mechanism.
Rivanol is an effective serum precipitating agent when at strengths below 1%, under 
conditions such that the ionic strength of plasma is reduced and the pH remains in the range 
7 to 8.2 throughout the purification, and the dielectric constant is not altered. Under these
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conditions, most of the lipoproteins present are precipitated by Rivanol, promoting aggregation 
of the precipitate and aiding its separation (Stastny and Horejsi, 1961). However, as the 
concentration of Rivanol used is increased, components of the serum protein content begin to 
reappear in solution (particularly albumin). The pH at which optimal precipitation of plasma 
proteins by Rivanol occurs has been reported to be 8 . A difference of only 1 pH  unit either 
side will more than treble the amount of Rivanol required to achieve the same degree of 
protein precipitation (Stastny and Horejsi, 1961).
6.2.3.3 Recovery of precipitated proteins
The use of Rivanol precipitation as a preparative technique for the fractionation of 
plasma proteins has two inherent problems; firstly the removal of the excess dye, and secondly 
the detection of the purified protein. The first of these problems may be overcome by 
adsorption onto charcoal, salt precipitation, or gel filtration (though Rivanol adsorbs to 
Sephadex and Sephacryl gels; Franek, 1986). The second problem occurs due to the ability of 
Rivanol to absorb ultraviolet light strongly; it therefore interferes with any protein 
determinations by adsorption between 260 and 280 nm. Consequently, in order to develop a 
protocol for the isolation of a particular protein, a technique for accurately assessing the total 
protein and specific protein content of fractions may be required.
In the earlier experiments of Horejsi and Smetana (1956), and Deitzel and Geiger (1964), 
Rivanol precipitated proteins were recovered by dissolving precipitates in acetate buffer at acid 
pH, followed by an ethanol precipitation. Later the dissociation of complexed proteins with 
NaCl (5 - 7%) became the most widely used technique. This method had the advantage of 
simultaneously solubilizing precipitated proteins while precipitating any Rivanol remaining in 
solution. Hence, for successful Rivanol protein fractionation, the salt content of protein 
samples must be low enough to allow complex formation, but with some electrolytes present 
for optimal precipitation. Under these conditions, Rivanol precipitations may be carried out 
at room temperature, the antiseptic properties of Rivanol preventing microbial growths 
(Steinbuch and Tavernier, 1979).
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6.2.3.4 Purity of Rivanol precipitated proteins
Plasma protein fractionation by the slow addition of ethanol is achieved due to the 
solubility of proteins slowly decreasing, thus allowing the formation of aggregates through 
electrostatic attraction. Therapeutic grade y-globulin preparations prepared by a combination 
of ethanol fractionation and Rivanol precipitation have been shown to be devoid of Hepatitis 
B, and surface Antigen (HB^Ag). This procedure would appear to be a safer means of their 
preparation rather than the normal ethanol fractionation alone (Pennell, 1957).
Rivanol precipitation has been suggested as the ideal method for preparing isolated 
MAbs from ascitic fluid, as it removes all of the subcellular debris, lipids, lipoproteins, 
emulsified residues or hydrocarbons (Pristane, mineral oil), albumin, IgM, and aggregated 
proteins, in a single step (Franek 1986). However, when rivanol precipitation alone was used 
in the commercial preparation of IgG for therapeutic applications, isolates were unfortunatly 
found to contain high levels of prekallikrein activator activity, and as a result were found to 
be markedly hypotensive (Medgyesi et al., 1988).
Rivanol fractionation may be considered largely a semi-preparative technique, best used 
in conjunction with others in order to increase the target protein content of a plasma protein 
isolate. A number of protein isolation protocols incorporating Rivanol along with other semi- 
selective precipitations have been published, many of which were reviewed by Steinbuch (1980).
In this chapter, Rivanol was immobilized on PS, and evaluated as a potential dye-ligand 
solid phase for the isolation of proteins (particularly immunoglobulins) from plasma. In doing 
so, it was hoped to further exploit the advantages offered by rigid silica based matrices, and 
provide a tool for the the rapid isolation of plasma proteins.
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6.3. MATERIALS AND METHODS
6.3.1 Preparation of Rivanol-Silica (Riv-PS) solid phases
6.3.1.1 Immobilisation of Rivanol on aminopropyl-PS
50 g of amino-activated PS was suspended in 2 0 0  ml of glutaraldehyde (1.5 %) and 
roller-mixed for two hours at room temperature. The solid phase was then washed by repeated 
slurrying and decanting off the supernatant with 5 x 200 ml of water. 200 ml of saturated 
Rivanol solution was then added and the slurry roller-mixed for 2  hours at room temperature.
6.3.1.2  Immobilisation of Rivanol on PS-CHO
30 g of PS-(0 H )2 (diol; 121.43 jitmol/g) was suspended in 250 ml of periodate solution 
(sodium periodate, 240 mM; sodium acetate, 1 mM; and glacial acetic acid to pH 4.5), and
roller-mixed for 1 hour at room temperature. The PS was then dried by pouring onto a 100
ml sintered glass filter funnel to which a small vacuum was applied. The PS was then washed 
in the funnel by repeated resuspending in water (1 L), followed by methanol (500 ml), and 
finally acetone (600 ml). The activated (PS-CHO) PS was then allowed to dry by passing air 
through it for an hour. 0.5 g samples of the dried silica PS-CHO were weighed into 15 clean 
(new) 5 ml screw cap glass vessels. Rivanol at concentrations of 131.3, 26.3, 5.3, 1.1, and 0 .2  
m g/m l in 4 ml of PBS (Rivanol to diol molecular ratios of 25, 5, 1, 0.2, and 0.04 to 1, with 
respect to the diol content) was then added to the vessels in batches of 3. The vessels were then 
roller-mixed overnight at room temperature.
6.3.1.3 The effect of Rivanol immobilizing pH on the binding of Rivanol to PS-CHO 
Rivanol (5 ml, at 10 mg/ml), in cit/phos buffering solutions at pHs’ 7.6, 6 .6 , 5.6, 4.6,
and 3.6 respectively, was added to batches of PS-CHO (500 mg). These mixtures were roller- 
mixed for five minutes, then incubated for 3 hours at 90°C (with periodic mixing), followed 
by overnight at 80°C. NaBH^CN (4 ml, at 100 mM) was then added, and the reaction mixtures 
allowed to cool, whilst roller-mixing for an hour at room temperature. The solid phases were
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allowed to settle and the supernatant drawn off. Solid phases were then washed over a sintered 
glass filter to which gentle suction was applied, with 3 x 10 ml of NaBH^ (10 mM), lactic acid 
(100 mM), water, methanol, and acetone successively. Finally the solid phases were poured into 
clean (brown) glass bottles and dried overnight at 80°C. The bottles were then capped and the 
Riv-PS solid phases stored at room temperature.
6.3.1.4 The preparation of Riv-PS (optimized for pH and Rivanol concentration)
To 10 g of PS-CHO (90/3), Rivanol (Ig) in 80 ml of 100 mM lactic acid was added and 
the mixture incubated for 3 hours at 90°C agitating regularly. The mixture was then incubated 
for a further 16 hours (overnight) at 60°C. NaBH^CN (4ml at 100  mM) was then added, and 
the reaction mixture allowed to cool by roller-mixing for an hour at room temperature. The 
solid phase was then allowed to settle and the excess liquid drawn off with a Pasteur pipette. 
The Riv-PS solid phase was then washed with 3 x 10 ml of NaBH^ (100 mM), lactic acid (100  
mM), water, methanol, and acetone successively, by repeated slurrying and drawing off of 
liquid. Finally the solid dye-ligand solid phase was poured into a tin foil lined metal tray and 
dried overnight at 80°C.
6.3.1.4 Determination of the dye content of Riv-PS solid phases
Riv-PS samples were washed with 3 x 4 ml of water, methanol, and acetone 
successively, by repeated slurrying and drawing off of liquid, then dried overnight at 80°C. 50 
mg of solid phase(s) were weighed into new 5 ml glass vessels and 2 ml of 2 M N aO H  added. 
Dye standards were prepared by adding 2 ml of Rivanol solution in N aO H  (2 M) to 50 mg 
samples of the PS-CHO (prepared as above). Standard and sample solid phases were incubated 
in a water bath at 90°C for an hour. Dissolved sample solid phases were compared against 
standards for dye content by optical density at 450 nm (Rivanol v41% = 35), and the Rivanol 
contents given by OXSTAT II analysis of the results.
6.3.1.5 Titration of Riv-PS solid phases
Riv-PS (1 g) was suspended in 100 ml of KCl (1 M) and stirred with a magnetic stirrer
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at room temperature. To the slurry 100 fA quantities of molar HCl (equivalent to 1 meq/g 
solid phase) was added every minute and the pH recorded after 30 seconds (Pharmacia, 1980).
6.3.2 Protein binding of Riv-PS
6.3.2.1 The effect of pH on the serum protein binding of Riv-PS
Rivanol solid phases (100 mg) with different levels of immobilized ligand were weighed 
into disposable columns to give settled bed volumes of approximately 250 f A .  These columns 
were then primed with 80 vols of water, under gravity flow, and equilibrated by adding 2 0  vols 
of pH buffer (cit/phos pHs’ 7.6 to 3.6). A further 20 vols of pH buffering solution was applied 
to the columns, followed by 20 vols of protein in buffer solution (HSA or hIgG, at serum 
concentrations; 40 m g/m l and 17 mg/ml respectively; Blomack and Hanson, 1976). Columns 
were then washed with 20 vols of pH buffer, and adsorbed proteins eluted in 20 vols of NaCl 
(2 % ) containing lactic acid (0.1  M). This was repeated three times for all five pH  conditions. 
The protein content of the eluates was determined by optical density at 280 nm and correlation 
analysis of the results.
6.3.2.2 The effect of ionic strength on protein binding of Riv-PS
Rivanol columns were evaluated for the effect of salt concentration on serum protein 
(HSA & hIgC) binding as above for pH, in solutions of Na2HP0 4  at concentrations of 0, 20, 
and 2 0 0  mM.
6.3.2.3 The effect of contact time on Riv-PS protein binding
Protein solution (HSA; 4 ml at 40 mg/ml in 200 mM Na2HP0 4 ) was added to five 
batches of Riv-PS (100 mg, RS#3/90/3.6; the pH 3.6 batch, with the highest HSA binding). 
These were roller mixed for 3.25, 7.5, 15, 30, and 60 minutes respectively. The protein solution 
was then decanted and the solid phases washed four times by roller-mixing with 5 ml of 200 
mM disodium phosphate for 5 minutes, and decanting the liquid. Immobilized HSA was eluted 
by roller mixing for 5 minutes with 5 ml of molar NaCl containing lactic acid (1 0 0  mM). This
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process was repeated for four cycles in all, and the protein content of the eluted fractions given 
by Coomassie dye binding and OXSTAT II analysis of the results.
6.3.2.4 Determination of the protein capacity of Riv-PS by batch isothermal analysis (Harris
and Angal, 1989)
Riv-PS (25, 50, 100, 200, and 400 mg) was weighed into clean (new screw cap 5 ml) glass 
vessels, in duplicate to form two batches. To one batch 5 ml of HSA (2 mg/ml) was added, and 
to the other 5ml of hIgG (2.1  mg/ml), both in PBS (15 mM, 10% normal concentration). The 
vessels were then capped and roller-mixed for 3 hours at room temperature. After three hours 
the level of protein remaining in solution was assessed by optical density (280nm), and 
Coomassie dye binding. From these results the amount of protein adsorbed per unit weight of 
solid phase was calculated and plotted against the concentration of protein at equilibrium 
(adsorption isotherm) in order to calculate the solid phase capacity (Q or for HSA and 
hIgC.
The Aj and (definitions given in chapter one) values for the interactions of HSA and 
hIgC on Riv-PS was determined from straight-line plots of c /q  against c .  From this plot the 
intercept on the c axis was taken as being at -Aj, and the gradient of the line as l/q ^  (Chase, 
1984).
6.3.2.5 The effect of pH on Riv-PS separation of plasma proteins
Riv-RS (2 g) were washed in a 500 ml glass vessel (D uran^  with 100  ml of methanol, 
0 .1  M citric acid, and water successively, by repeated slurrying and drawing off of liquid. The 
solid was then partially dried over a sintered glass filter funnel by drawing through air. 100  mg 
of the damp Riv-PS was weighed into LP3 tubes, and then equilibrated in duplicate in cit/phos 
buffering solutions (pH range 4 - 8  with 0.5 unit intervals). 2 ml of the various pH  buffers 
containing plasma protein (HSA, 3 mg/ml; or hIgC, 5 mg/ml respectively) were then added. 
The LP3’s were then capped and roller-mixed for 30 minutes. The degree of protein binding 
was assessed by measuring the concentration of protein remaining in solution byCoomassie dye 
binding (BSA), and by optical density at 450nm (hIgC), and subtracting from that < o r ig i nally
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added.
6.3.2 .6  The effect of ionic strength on Riv-PS separation of plasma proteins
This was carried out as above for the effect of pH evaluations, except that the pH  
solutions were substituted for Na2HP0 4  (10 mM) pH 7.6, containing NaCl at levels from 0 to 
512 mM.
6.3.2.7 Assessment of the hydrophobic interactions on Riv-PS
Hydrophobic interaction chromatography (HIC) was attempted using Riv-PS following 
the method described by Roe (1989). A 1 ml Riv-PS column (RS#4/90) was conditioned by 
purging under gravity with 10 vols of NaH 2P0 4 ; 100 mM (buffer B), followed by 10 vols of 
NaH 2P0 4 , lOOmM containing (NH4)2S0 4 ; 1.5 M (buffer A). 5 vols of (NH 4)2S0 4  precipitated 
MAb (13 m g/m l in buffer A) was then added, and column washed with 5 vols of buffer A. 
Adsorbed MAb was then eluted by the stepped addition of 3 vols of increasing ratio of buffer 
B to A  in 10 steps by 10% increments. Eluted fractions were checked for MAb content by 
OD280nm-
6.3.3 Applications of Riv-PS
6.3.3.1 High performance liquid affinity chromatography (HPLAC) of proteins on Riv-PS 
Serum, protein, and MAb solutions, were injected into a Riv-PS HPLAC system and
evaluated for solid phase binding, and protein resolution under various buffer conditions (pH 
and ionic strength). Protein separations were then performed in order to assess the effects of 
column length, solvent flow rate, and gradient development.
6.3.3.2 Purification of MAbs on Riv-PS
A 1 ml Riv-PS column was primed under gravity flow with 5 vols of NaCl (2 M, 
eluting buffer), and equilibrated with cit/phos buffer. 5 vols of MAb (diluted 1 in 10  in 
cit/phos pH buffer) was then applied, and allowed to drain through under gravity. The column
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was then washed with 10 vols of cit/phos buffer and adsorbed proteins eluted with 5 vols of 
eluting buffer. This process was carried out 5 times in all, in cit/phos buffering solutions at 
pHs 7.8, 6.7, 4.9, 3.3, and 1 .8 . Eluted fractions and 5 vols of the original material (diluted 1 in 
10) were dialysed against 5 L of carb/bicarb buffer. Samples were then assessed by SDS-PAGE 
analysis on the Pharmacia PhastSystem.
6.3.3.3 Riv-PS reduction of contaminating SpA in Prosep A "high capacity" purified MAbs 
500 ml of MAb (dialysed against 1 in 100 SpA assay buffer pH 5.6) was applied to a 1 
ml Prosep A-T^  ^ column from a conical flask, via a peristaltic pump at a flow rate 0 .2  m l/min  
at room temperature. The breakthrough from the Prosep column (500 ml of mlgGj, 1.41 
mg/ml; containing SpA-7^ ^^  324 ng/ml) was collected and applied in a similar manner to a 1 ml 
Rivanol column and the breakthrough collected in 3 ml fractions. Fractions were evaluated for 
MAb content (ODjgonm) SpA (gamma counting), from which their respective adsorption 
profiles were plotted.
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6.4 RESULTS
Rivanol was easily immobilized on PS-CHO, the degree of binding best when the dye 
concentration was at a molecular ratio of greater than 3 to 1 with respect to the surface diol 
density (table XXI), and the buffer pH greater than 5 (table XXII). Riv-PS was able to bind 
HSA and hIgG at pH 7, the affinity being greatest for HSA. The superior binding of HSA to 
Riv-PS with respect to that of hIgG was further increased by lowering the pH to more acidic 
conditions.
TABLE XXI. IMMOBILIZATION OF RIVANOL O N  C H O  PS
Rivanol
( m g / m l ,  (mol.  
ratio))
Immobilized Rivanol 
mol. ratio (mean ± SD)
Comments on synthesis.
131.3 (25) 1.717 ± 0.326 A thick orange syrup.
26.3 (5) 1.037 ± 0.061 yellow emulsion and ppt.
5.3 (1) 0.140 ± 0.010 Yellow ppt in opaque solution.
1.1 (0 .2) 0.061 ± 0.021 Clear yellow liquid and yellow  
ppt.
0.2 (0.04) 0.016 ± 0 .002 clear liquid and yellow solid 
phase.
Rivanol (3 ml) immobilized on PS-HO (500m^.
TABLE XXII. THE EFFECT OF RIVANOL IMMOBILIZING pH  O N  THE HSA  
B IN D IN G  OF Riv-PS
Solid phase Rivanol binding of RS#2  solid phases immobilized at pH:
7.6 6 .6 5.6 4.6 3.6
HSA (mg/g, mean ± SD) 2.4 ± 0.2 4.4 ± 0.1 5.5 ± 0.2 5.8 ± 0.3 5.8 ± 0.4
Mean HSA binding (5 ml, 40 mg/ml) of 100 mg Rivanol columns over 3 cycles.
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Figure 33. The effect of pH (a) cit/phos) and salt concentration (b) NaCl, 
pH 7) on the plasma protein capacity of Riv-PS.
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Equilibrium studies on fixed bed volumes of Riv-PS suggested the hIgG capacity was 
pH dependent, but remained largely unaffected by variations in salt concentration. However, 
the HSA capacity of Riv-PS appeared to be dependent on both adsorption pH, and ionic 
strength (Fig. 33). The capacity of Riv-PS for albumin was also greatly affected by the time 
allowed for adsorption (table XXIII). The serum protein (HSA and hIgG) binding of Riv-PS 
columns was highest at less acidic pH ’s (tables XXIV and XXV).
TABLE XXIII. THE EFFECT OF TIME O N  THE B IN D IN G  OF HSA TO  Riv-PS
Solid phase HSA (mg/g, mean ± SD) immobilized on Riv-PS after (minutes):
3.25 7.5 15 30 60
RS#2/90 1.5 ± 0.2 4.0 ± 0.1 8.9 ± 0.4 19.0 ± 0.1 28.0 ± 0.3
Mean HSA binding (5 ml, 40 mg/ml) of 100 mg Rivanol columns over 3 cycles.
TABLE XXIV. THE EFFECT OF pH AND LIGAND DENSITY ON HSA 
BINDING TO Riv-PS
Substitution HSA (mg/g, mean ± SD) binding of Rivanol solid phases at pH:
(Riv/PS-HO)
7.6 6.6 5.6 4.6 3.6
1.717 6.2 + 0.3 5.0 ± 0.0 1.7 ± 0.6 2.5 ± 0.5 1.7 ± 0.8
1.037 5.2 ± 0.3 3.3 ± 0.8 1.3 ± 0.3 2.2 ± 0.3 1.5 ± 0.0
0.410 3.7 ± 0.7 3.2 ± 0.3 1.3 ± 0.3 1.5 ± 0.0 1.5 ± 0.0
0.061 3.2 ± 0.3 3.0 ± 0.0 0.7 ± 0.3 1.2 ± 0.3 1.0 ± 0.5
0.016 1.7 ± 0.8 2.2 ± 0.3 0.7 ± 0.3 1.2 + 0.3 1.0 ± 0.5
Mean HSA binding (5 ml, 40 mg/ml) of 100 mg Rivanol columns over 3 cycles. NB. abberation 
about the 5.6 and 4.6 points which lie about the p[ o f 4.9.
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TABLE XXV. THE EFFECT OF pH ON hIgG BINDING TO Riv-PS
Substitutiopn
(Riv/PS-HO)
hIgG (mg/g, mean ± SD) binding of Rivanol solid phases at pH:
7.6 6.6 5.6 4.6 3.6
1.717 4.0 ± 0.2 3.4 ± 0.1 2 .8  ± 0 .0 2.4 ± 0.1 1 .6  ± 0.1
1.037 3.2 ± 0.2 2 .6  ± 0 .2 2 .0  ± 0.1 2 .2  ± 0.1 1.7 ± 0.3
0.410 2 .8  ± 0 .2 2 .2  ± 0 .2 1.9 ± 0.2 2.2 ± 0.5 1.5 ± 0.1
0.061 2.6 ± 0.3 2.1  ± 0 .2 1.6  ± 0 .2 1.8 ± 0.1 1.4 ± 0.1
0.016 1.8 ± 0 .0 1.5 + 0.4 1.2 ± 0.3 1.5 ± 0.0 1.4 ± 0.1
Mean hIgG (5 ml, 17 mg/ml) binding of 100 mg Rivanol columns over 3 cycles.
Increasing ionic strength generally had the effect of lowering the protein binding of 
Riv-PS. Elevated NaCl levels in batch adsorption studies resulted in reduced Riv-PS protein 
capacity (Fig. 33b). The protein binding of Riv-PS was improved by increasing the Na^HPO^ 
of the adsorption solution from 0 to 2 0 0  mM (table XXVI). This observation was possibly due 
to an increase in the adsorption solution pH at higher phosphate levels. Furthermore, high salt 
concentrations have a chaotropic effect (reducing hydrophobic interactions); NaCl being much 
further up the Hofmeister series (Roe, 1989) than Na2HPO^, so that it has a far greater 
desorbing effect.
Titrational analysis of a Riv-PS solid phase indicated little variation in the net surface 
charge (charged groups of equivalent charge) with pH. The pH of molar KCl changed from 
very alkaline (pH >  10) to very acidic (pH <  2) by the addition of 1 meq of HCl per gram 
of solid phase (Fig. 34). Protein separations on Riv-PS carried out in an HIC manner had 
limited success: proteins eluted as a single broad peak over 5 col vols. HIC would suggest a 
hydrophobic component to the adsorption mechanism (Fig. 35).
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TABLE XXVI. THE EFFECT OF IONIC STRENGTH ON HSA BINDING TO
RIV-PS
Substitution
(Riv/PS-HO)
Salt concentration (Na2HP0 4 , mM)
0 20 2 0 0
1.717 2.7 ± 0.8 5.3 ± 2.1 4.0 ± 0.0
1.037 2.2 ± 0.3 2 .0  ± 0 .0 3.2 ± 0.6
0.410 1.5 ± 0.0 1.7 ± 0.3 2.3 ± 0.3
0.061 1.0  + 0 .0 1.7 ± 0.3 1.8 ± 0.3
0.016 0.5 + 0.0 1.0  + 0 .0 1.7 ± 0.3
Mean HSA capacities of 100 mg Rivanol columns over 3 cycles.
pH
■^HCI -Q-NaOH
1 ^  (*x)K)i(X)ioi()ioioii9tæieK:
20 250 5 10 15 30 35 40 45
meq
Figure 34. Determination of the effect of buffer pH on the surface charge 
of Riv-PS.
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Figure 35. Assessment of hydrophobic interactions on Riv-PS (Roe, 1989).
Riv-PS (1 ml) was loaded with MAb (5 vols) in buffer A  
(NaH2P0 4 ; 100 mM, (NHJzSO^; 1.5 M); and gradient eluted in 
buffer B (NaHzPO^; 100 mM).
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Figure 36. Determination of the protein binding capacity of Riv-PS by 
batch isothermal analysis (Harris and Angal, 1989).
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Figure 37. Kinetic analysis of Riv-PS protein binding.
Riv-PS had a higher capacity for hIgG than HSA when assessed by adsorption 
isothermal analysis (Fig. 36). Batch equilibrium analysis of HSA and hIgG binding on Riv-PS 
gave capacities {q^ or Q) of 91 and 140 mg/g respectively, with dissociation constants (A j of 
5.8 X 10'^  and 2.7 x 10'^  M /L respectively (Fig. 37). When expressed in terms of an equilibrium 
isotherm, this further demonstrated the greater efficiency of HSA binding with respect to that 
of hIgG (Fig. 38).
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Figure 38. Equilibrum isothermal analysis of Riv-PS protein binding.
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On injecting sheep serum to an HPLAC system containing a Riv-PS column (1 ml), 
most of the proteins present were adsorbed. Proteins eventually emerged as a single broad peak 
on applying a gradient of salt (NaCl, to IM, Fig. 39a). When the quantity of protein applied 
was below Q, the separation profile of breakthrough and elution peaks remained unchanged 
with respect to size/area ratio and distance irrespective of the sample size, column, or gradient 
length. By adding lactic acid (0.1 M) to the salt eluting buffer, the single elution peak was 
further resolved into a number of peaks which appeared at the same points in the development 
of the salt/pH gradient, regardless of flow rate or the rate of gradient development (Figure 
39b). Attempts to further resolve the protein peaks by adjusting the HPLAC separation 
procedure (using; pH, salt, amino acids, PEG, flow rate, sample loop size) proved unsuccessful. 
However, the fact that this elution profile could by produced and manipulated repeatedly 
would suggest it was more than just an abberation due to the equipment used.
The most appropriate operating conditions for the Riv-PS HPLAC system were to use 
a 0.1 M Na2HPO^ adsorption and washing buffer, with a salt (2 M), lactic acid (0.1 M) gradient 
elution. Operating under these condituions, proteins with a high pi did not bind to Riv-PS, 
when injected into the HPLAC system. An example of this was the binding of hIgG, when at 
pHs below 8 , it did not bind to Riv-PS but did so (in equilibrium studies) when at its mean 
pi (approximately pH 7.3; Appendix 1), when at its most insoluble, and prone to hydrophobic 
interactions. A standard solution of proteins of various pi’s (Pharmacia GOLD lEF standard) 
when injected into the Riv-PS HPLAC system emerged as a diffuse peak (Fig. 40).
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Figure 39. HPLAC of sheep serum on Riv-PS: a) buffer A was N aH 2PO^ 
(100 mM), and B was NaCl (1 M); b) buffer B was substituted 
for NaCl (1 M), lactic acid (0.1 M).
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Figure 40. HPLAC of pi standards solution on Riv-PS: buffer A  was 
NaH 2P0 4  (100 mM), and B was NaCl (1 M), lactic acid (0.1 M).
Human serum emerged from the Riv-PS HPLAC system as a series of discrete peaks 
(Fig. 41a). When the Riv-PS isolated human serum peaks were examined by lEF 
electrophoresis, consecutive peaks had the suggestion of a sequential increase in pi cut off at 
which point proteins were released or bound. Proteins with a pi above 7 made up the majority 
of the breakthrough. During the process of eluting serum proteins from RIV-PS by applying 
salt/lactic acid gradient, the protein fraction for those proteins with a lower pi increased with 
each peak (Fig. 41b).
Maximal Riv-PS protein binding was achieved in solutions of neutral to alkaline pH, 
with little evidence of binding occurring at acidic pH ’s (below 3). On applying a cell culture 
supernatant (mlgG^, containing 5 % NBCS) adjusted to pH 4.9 (cit/phos) to a Riv-PS column
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(1 ml), the fraction eluted with salt (NaCl, 2M) appeared to consist exclusively of albumin on 
electrophoretic analysis. On increasing the adsorption pH to 6.7, IgG and albumin were 
detected on silver staining electrophoretic gels, but notCoomassie staining. This would indicate 
IgG to be present at a concentration between 0.3 - 0.5 )Ltg/ml< IgG <  2 0  - 30 jug/ml (for 1 
fA band vols). On increasing the adsorption pH still further to 7.8 (slightly above the mean pi 
of IgG), only the IgG heavy chain protein band was visible on silver staining, the light chain 
component being too low in mass to be visibly stained, suggesting an IgG presence of 
somewhere between 0.9-1.5 <  IgG <  60-90 /^g/ml (Figure 42).
On frontal analysis of a MAb containing trace SpA-T^  ^ (230 ng/mg of m lgG j on a Riv- 
PS column, the mlgG^ had little or no binding to the solid phase. The progress of SpA through 
the column was retarded (Figure 43). Consequently, the SpA contamination of a MAb could 
be reduced by more than 10 fold by applying the contaminated MAb to a Riv-PS column and 
collecting the breakthrough until the C /C o ratio for SpA reached 0 .8 .
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Figure 41. HPLAC of human serum on Riv-PS: buffer A  was N aH 2PO^ 
(100 mM), and B was NaCl (1 M), lactic acid (0,1  M); a) elution 
profile, and b) lEF electrophoretic analysis of peaks (S = Std.; F 
= feed).
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Figure 42. The effect of adsorption pH on the purity of MAbs eluted from 
a Riv-PS column.
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Figure 43. Frontal analysis of SpA-F^  ^contaminated MAb on a Riv- 
PS column.
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6.5 DISCUSSION
Rivanol was covalently attached to the aldehyde groups of chemically modified 
organisilane coated silica. The degree of ligand immobilisation may be varied by adjusting the 
amount of free ligand available, the pH, or reaction time. Maximum immobilisation of Rivanol 
on PS-CHO was achieved at acidic pHs, as excess H^ ions promote the formation of Schiffs 
bases. Increasing the concentration of Rivanol immobilized on solid phases lead to a higher 
plasma protein binding. However, it has previously been reported that dye-ligand solid phases 
with a higher immobilized dye density are sometimes less "efficient" at protein binding than 
those with a lower level (Clonis, 1988).
In addition to dye density, the immobilized dye-protein interactions are also influenced 
by buffer pH and ionic strength, due to the ionic/hydrophobic nature of the Rivanol molecule. 
Generally there appeared to be a sigmoidal relationship between pH and the plasma protein 
capacity of Riv-PS, consistent with its reported precipitation results (Neurath and Brunner., 
1969). Riv-PS protein binding was highest in alkaline conditions where albumins represent 
polyvalent anions, and the immobilized Rivanol represents a monovalent cation.
Titrational analysis of a Rivanol solid phase suggested little variation in the number of 
immobilized charge groups with pH. Hence the binding of plasma proteins to Riv-PS columns 
may be considered to have been a result of the proteins net surface charge at a given pH, which 
in turn was pi dependent. Ionic attraction may the would appear the most likely primary force 
in Riv-PS protein binding. When proteins are in close proximity to the immobilized dye, 
secondary adhesive dye-protein and lateral cohesive protein-protein hydrophobic interactions 
may further stabilise the binding.
Elution of adsorbed proteins from Riv-PS was achieved by increasing the salt content 
of the irrigating buffers, by lowering their pH, or by reducing hydrophobic interactions. High 
salt concentrations and organic solvents may lower hydrophobic interactions, though their 
presence may irreversibly damage the tertiary structure of proteins (destroying bioactivity). The 
elution peak achieved on HIC evaluation of proteins on a Rivanol solid phase would suggest 
a hydrophobic component to the adsorption mechanism. However, this elution peak appeared
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too broad to be considered the result of eliminating the sole protein binding mechanism, as 
might be considered if the peak emerged within 3 col vols.
The hIgG and HSA capacities of Riv-PS were differentially affected by variations in salt 
and pH. When at neutral pH the affinity of Riv-PS binding to HSA was greater than that for 
hIgG; this difference was improved further by more acidic conditions. This property may be 
exploited in the resolution of albumin and IgG from solutions containing both, though due to 
the time dependence of Riv-PS binding, a stirred-tank mode of operation may prove the most 
appropriate for large sample volumes.
At pHs below 4, no binding was found on applying a MAb under gravity flow to a 
rivanol column, and less than a third of the solid phase’s optimal albumin capacity found as 
a result of equilibrium studies at this pH. Rivanol chromatography has proven a quick and easy 
method of extracting albumins from a MAbs in cell culture supernatant (mlgGj. The use of 
Riv-PS to extract albumin fromMAbs may also be expected to be applicable to all the IgG 
I  iso types as none are precipitated by free Rivanol (Franek, 1986).
From the results of protein binding experiments in this study, it may be suggested that 
the mode of protein Riv-PS adsorption is predominantly via electrostatic attraction. On 
applying a gradient of salt and decreasing pH, elution of proteins occurs as the net result of a 
number of forces. On moving from adsorption to desorption conditions proteins start off 
electrostatically bound. On approaching their pi, the predominant force becomes their weak 
hydrophobic binding. As the buffer salt increases and the pH moves further to the acidic side 
of their pi the predominant electrostatic force shifts from one of attraction to one of repulsion. 
Consequently, proteins are eluted from a Riv-PS column in broad peaks about their pi.
The use of silica-immobilized dyes for use as an HPLAC solid phase has previously 
been reported for the resolution and purification of a number of proteins (Lowe et aL, 1981). 
Porous microparticulate silica-immobilized Rivanol is a general purpose protein binding 
adsorbent. By virtue of its inherent robustness, this solid phase shows great promise as a 
versatile HPLAC adsorbent. The low cost, solvent resistance, mechanical stability, reusability, 
and ability tobe autodavedif necessary, are of particular value. Possibly of greatest value may be 
its selective use in the stirred tank processing of biologicals for the semipreparative clean up
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of isolated proteins. This method is of particular use in the process scale production of proteins 
for therapeutic applications as neither the ligand or the immobilisation chemistry are toxic.
The main drawback of the use of Riv-PS solid phases found in this study was was the 
lack of purity of isolated proteins. This problem was further exacerbated by the apparent lack 
of consistency of purifications from one purification cycle to another. Therefore really efficient 
Riv-PS resolution of proteins requires the constituents to have very different protein 
electrostatic properties.
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CHAPTER 7
AN AUTOMATED lAC-EUSA SYSTEM FOR DETECTING THE ANABOLIC 
AGENT CLENBUTEROL IN BOVINE BILE SAMPLES
7.1 SUMMARY
A rapid automated method for the isolation and determination of the fS-agonist 
Clenbuterol (Cb), present in the gall bladder bile of cattle at slaughter has been developed. Cb 
was first extracted from untreated bile by immunoaffinity chromatography (lAC) on CPG 
immobilised antibodies. This one step bioselective isolation was followed by quantitative 
assessment of Cb by chemiluminescent ELISA. The assay had a working range between 0 .1  and 
10 ng/m l (CV <  5%) with a lower limit of detection of 0.04 ng/m l (CV <  2%; Bq - 2 SD). The 
automated lAC-ELISA analytical strategy resulted in an overall "System" sensitivity of 0.033 
ppb, for Cb in bile, consistent with the UK MRL for Cb in biological samples of 0.5 ppb (or 
0.5 ng/m l of bile). The inter-assay variation (CV, %) of a high QC, and control, bile samples 
in the System were 21.2% and 12.2% respectively. Comparison of EC "ring test" lyophilised 
bovine urine samples in this system gave a correlation coefficient of 0.999 (estimated = EC x 
1.152 + 0.227). When the system ELISA was compared with a commercially available RIA-Kit 
for Cb estimations of lAC processed "spiked" buffer and bovine bile samples, these gave 
correlation coefficients of 0.952 (ELISA = RIA x 0.638 + 0.155) and 0.970 (ELISA = RIA x 
1.469 - 0.009) respectively. The total running time for the pilot semi-automated analysis of a 
24 sample batch was 2  hours (5 minutes per sample). The intended field system should increase 
the sample throughput still further, by repeatedly running process batches of 4 X  40 samples 
in consecutive cycles. The pilot automated analytical system was evaluated for the mass 
screening of bile samples, at sample throughputs applicable to the commercial scale production 
of cattle carcases for meat. The automated System was used to estimate the Cb content of 
randomly collected "suspect" and "clean" bile samples. The mean Cb content of these samples 
was found to be 0.253 + 0.413 (n = 282) and 0.0417 ± 0.211 (n = 237) ng/m l respectively. 
Statistical analysis of the means of these two groups suggested a significant difference in their 
incidence of Cb contamination (Student’s t-test; T = 7.1125, p <  0.001). For the suspect group 
125 (44 %) were found positive, and 16 (6.8  %) were found positive of the clean bile samples.
The procedure has been operated for more than 2 0 0  cycles, and evaluated by 
representatives of the Scientific Veterinary Committee of the Commission of European
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Communities, with a view to its incorporation in the overall production and screening of meat 
for human consumption within the EEC.
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7.2 INTRODUCTION
Cb is a drug, illegally used in the meat industry, as a means of improving the lean to 
fat ratio of livestock, and hence their market value at slaughter. Cb (4-amino-3,5-dichloro-a- 
[[(l,l-dimethylethyl)amino]methyl]benzenemethanol; C12H 18CI2N 2O), found commonly as the 
hydrochloride (Cb.HCl, C12H 19CI3N 2O), is a white microcrystalline powder with a molecular 
weight of 313.7 (Sigma). Cb is a tocolytic agent, and was originally developed as an alternative 
to salbutamol in the treatment of bronchial disease. Cb has been classified in the therapeutic 
category &2 agonist; that is it causes relaxation of involuntary (smooth) muscles (jR), and is 
specific for bronchial and uterine muscle receptors (subgroup 2) (Lands et al.y 1967).
Though the effect of these &2 substances is different to that of the traditional anabolic 
compounds, eg, 17fiOHTb, stilbenes and Zl, they are commonly classified together as growth 
promoting agents. These f^-agonist compounds demonstrate sympathomimetic activity in 
livestock, altering the "partitioning" of nutrients away from adipose tissue deposition and 
towards muscle building, resulting in leaner meat (Baker et a l,  1984; Dalrymple et a l,  1984; 
and Ricks et a l, 1984).
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In order to achieve the desired anabolic effect Cb needs to be given to cattle in 
quantities 5 to 10 times higher than the required therapeutic dose (Miller et al., 1988). The 
withdrawal of fi-agonists from treated animals results in a rapid compensatory deposition of 
fat. In cimaterol treated sheep, the carcass improvement persisted for three weeks, but the 
reduction in carcass fat was abolished within 28 days. Hence, in order to gain the greatest 
profit illegally treated animals are given a withdrawal period of no greater than 10 days (Peters, 
1989).
In the rat, the level of Cb detectable in the liver over 72 hours accounts for 0.5 % of 
that applied, and in the faeces 24.6 %, post oral administration. It has further been suggested 
that post intra-duodenal injection, 7 % of the administered Cb is secreted to the lower gut in 
the gall bladder bile via the enterohepatic circulation (Kopitar and Zimmer., 1976). This would 
suggest that the pancreatic bile fluid as possibly a good sample for Cb residue analysis.
Recent studies would suggest the eye may prove an appropriate source of tissue for Cb 
estimations. Postmortem analysis of eye fluid may provide a good estimation of the 
antemortem serum chemistry profiles. Levels of Cb found within the eye of slaughtered 
animals treated with Cb has been reported as being 50 to 100 times that found in the liver 
(Hanna et a l, 1990; and Sauer and Limer., 1993).
Due to the lucrative illegal trading and use of Cb as a growth promoter, a number of 
laboratories are currently believed to be synthesizing a few of the more well known beta- 
agonists, while introducing subtle chemical modifications to avoid detection. This hampers any 
attempt at routine regulatory control as the EC directives 87/410 and 89/610, and require 
direct comparison between "standard" analyte and the analyte present in the suspected sample 
for confirmation purposes. There is an almost infinite diversity of compounds within this class 
of growth promoting agents with more or less high pharmacological activities. This diversity 
has resulted in a number of analytical problems in that there is a need for low  limits of 
detection (LLD’s), determination and identification (Ginkel, et al., 1991).
Traditional, analytical forensic strategies for drug residue analysis have been based on 
a two step approach; first developing an optimized method for high sample throughput (a 
"screening test" with no false negative results); and secondly, the development of a reliable
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method for identifying the analyte in question (a "confirmatory test" without false positive 
results). Conventional residue screening technologies have tended to be time consuming, labour 
intensive, and costly. Consequently, routine evaluations within the EEC at present typically 
involve a small sample size, and slow throughput, usually a representative 30 bovine urine 
samples over a week (Kenny, 1991). As a result it is presently considered impossible to police 
the illicite use of Cb in all carcases passing through abattoirs.
At the time of conducting this study a number of analytical methods for detecting the 
presence of Cb in biological samples had previously been documented. Many of these protocols 
had been collated and published in the EC reference manual for drug residue analysis (Ed.; 
Heitzman, 1992). These methods tended to be time consuming, requiring solvent extractions 
and quite often involved each sample being applied to an analyser in turn.
This chapter outlines the development and application of an automated analytical 
strategy (a "System") for the rapid monitoring of Cb in bovine bile, consisting of 
immunoaffinity chromatography (lAC) followed by enzyme-linked immunosorbent assay 
(ELISA). This lAC-ELISA technique further exploited the fast flow characteristics of silica 
based affinity solid phases, offering a rapid screening protocol applicable to the throughput of 
livestock at an abattoir.
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7.3 MATERIALS AND METHODS
7.3.1 Immunogen/plate coat synthesis (diazo Cb protein coupling)
Lyophilized protein (BSA, porcine thyroglobulin, or rabbit IgG; 100 mg) was dissolved 
in 1.3 ml of carb/bicarb buffer and equilibrated, stirring, in an ice/salt bath. To 1.3 ml of Cb 
(2.2 mM) in H 2SO4 (0.5 N), equilibrated, stirring for 15 minutes in an ice/salt bath, 350 fA of 
sodium nitrite (0.3 M, equilibrated in the ice/salt bath) was added, and allowed to react for 5 
minutes. The diazo-Cb (yellow coloured Cb/acid/nitrite) solution was then transferred to the
protein solution, and the pH adjusted to neutral by adding N aO H  (2.5 N). The reaction
mixture was allowed to react for a further 4 hours (the temperature rising to ambient), and 
dialysed against 4 changes of PBSThio for 16 hours at 4°C.
7.3.2 Salbutamol protein (Thy or BSA) conjugate synthesis
i Two stage bis-oxirane coupling of Sal to Proteins: protein (200  mg) was
dissolved in 1.4-butane diol diglycidoxy ether (bis-oxirane 10 % v /v , 5 ml) and 
stirred for 3 hours at room temperature. The epoxy activated protein was then 
dialysed against water (3 X 1000  vols). Salbutamol (1 mg/ml) was then added to 
fractions (100, 50 and 50 mg) of the protein to give hapten to protein
molecular ratios of 10 , 5, and 15 to 1 respectively. This solution was roller
mixed for an hour at room temperature and dialysed for a further 16 hours 
against 3 changes of PBSThio (1000 vols) at 4°C.
ii One stage bis-oxirane coupling of Sal to proteins: protein (100  mg) and
salbutamol (to give molar hapten:protein ratios of 5, 10, an 15 to 1) were 
dissolved in water (5 ml) and bis-oxirane added (100  /xl). These solutions were 
then vortexed for 1 minute and roller-mixed for 3 hours at room temperature. 
This reaction was performed a number of times in order to establish the best, 
Salbutamol to protein ratio, reaction time, and concentration of bis-oxirane.
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7.3.3 Enzyme labelled Cb synthesis
i Coupling via a diazo bridge: this was carried out as above for plate coat 
synthesis.
ii Coupling via a hydrazinyl bridge: to diazo-Cb (1 mg of activated Cb, 500 fA ;  
formed as above) zinc chloride was added ( 1 0 0 fA ;  O.IM in 2N  HCl) and the 
solution incubated for 1 hour in an ice salt bath. To HRP (1 ml, 4 mg/ml) 
sodium periodate (0.5 ml, 0.1 M) was added and the solution roller-mixed for 
30 minutes at room temperature. This solution was then dialysed for 16 hours 
(overnight) at 4°C, against 1 litre of acetate buffer (10  mM, pH 5.6). To the 
HRP solution (2 ml, diluted to 2 mg/ml) the hydrazine activated Cb was added 
(92.2 f A ,  equivalent to a 10:1 hapten to protein ratio) and roller-mixed for 4 
hours at room temperature. Remaining active sites were then blocked by adding 
0.1  ml of NaBHjCN (0.16 M), and rollering for 5 minutes followed by the 
addition of 0.1 ml of ethanolamine, (1 M) containing glycine (0.2 M) pH  7.6, 
and roller mixed for a further 30 minutes. The conjugate was then dialysed for 
16 hours at 4°C against 3 changes of 2000 vols of PBSThim, and finally cleaned 
up by passing through a Sephadex G50 column (1 ml fractionsjall the fractions 
which 10 f A  of produced an O D  >  1 on addition to 2 0 0  f A  of TMB substrate 
buffer were pooled).
iii Coupling via an aminophenol bridge: diazo-Cb (500 f A ,  as produced in ii) and 
4- aminophenol (100  jul, 50 mM colour goes bright blue) were reacted for an 
hour in an ice/salt bath and 150 f A  of the resulting blue solution coupled to 
HRP as above for hydrazidyl-Cb. Aminophenol was used to increase the 
number of free phenolic groups available on the HRP molecule. HRP was 
periodate activated and challenged with aminophenol prior to coupling to diazo- 
Cb.
iv Cb protein coupling via a carboxymethyl-Cb (CbCM) bridge: copper sulphate 
(5 ml, 1.3M, pH 2; H 2SO4), and potassium cyanide (1.3 ml, 5M) were mixed,
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and the resulting light blue precipitate (cuprous cyanide, Vogel, 1967) washed 
three time with water (5 ml). KCN (100  mg) and cuprous cyanide (100  mg) 
were dissolved in 2  ml of water at 70°C. Diazo-Cb (10  mg of activated Cb, 500 
/d; formed as above), was added and the solution incubated for 1 hour 
("Sandmeyer Reaction"; a brown oil forms, ). The Cb-nitrile was 3 times 
extracted with an equal volume of ether, and the extract washed with equal 
volumes of NaO H  (2.5 M, removing Cb-OH), H 2SO4 (IN, removing Cb-NC 
isocyanate), and water (removing inorganics). The ether was blown down, and 
the residue refluxed for 2  hours in N aO H  (50 ml, 2.5 M). The pH  was then 
adjusted to 1 (HCl) and incubated for 16 hours at 4°C. The white CbCM 
crystals were extracted 3 times with ether, and the ether dried (anhydrous 
Na2S0 4 ) and blown down.
CbCM was dissolved in dry DMF (500 fA, 0.5 mM) and N- 
methylmorpholine (6.5 fA )  and incubated for 30 minutes at -15°C (ice/salt bath). 
HRP (350 f A ,  6  mg/ml) and DMF (375 f A )  were mixed and incubated at -15°C 
(hapten to enzyme ratio of 10:1). To the CbCM solution isobutyl-chloroformate 
(6.5 f A )  was added and the solution further incubated for 3 minutes. The 
enzyme solution was then added and the pH adjusted to (NaOH, IM). The 
reagents were allowed to react for one hour at -15°C and a further 2  hour at 
4°C. The conjugate was dialysed for 16 hours at 4°C against 5 changes of 5 
litres of PBSThio.
7.3.4 Antibody production
Four rabbits were immunized with Cb-BSA as described by Dixon (1980), and PAbs 
to Cb (Cbl, 2, 3, & 4) raised at the Institute for Animal Disease Research, Compton, 
Newbury, Berkshire, England. PAbs were also raised in four sheep following the standard 
operating procedures of the Experimental Biology Unit, University of Surrey, Guildford, 
Surrey, England. All serum samples were evaluated in-house.
The specificity of antibodies raised to Cb-BSA was determined by the method described
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by Thorneycroft et al. (1970), using the "System" ELISA for the assay Cb specific antibodies 
(Cb3 and Cb4), and a conjunction of ELISA and RIA methods for the lAC column antibodies 
(CAL/S/9, 10 , 11, & 12).
7.3.5 Bile sample collection(s)
i English ("clean") cattle samples: bile sample were collected at random by 
removing the gall bladder from the carcases of freshly slaughtered animals and 
decanting the contents via the bile duct into new clean 30 ml sterile plastic 
universals. The samples were coded with the date and run number, and then 
stored in boxes of 500 (n = >  2000) at -20°C prior to assay.
ii Irish ("control" and "suspect") cattle samples: two sets of bile samples were 
collected; those from guaranteed Cb free farmed animals (divided into the sub­
groups: steers, cows, and heifers; n = 105) and from normal slaughtered 
animals (n = >  1000). Bile samples were taken in 10 ml vacutainers from the 
gall bladder of freshly slaughtered cattle. This process was carried out during the 
routine abattoir inspection of meat carcases by a veterinary surgeon. Vacutainers 
were then transported in dry ice, and stored in batches of 24 and stored frozen 
prior to assaying.
7.3.6 Pre-treatment of bile samples prior to assay
To bile samples phosphotungstic acid (0.1  vols, 2 0 0  mM) and magnesium chloride (0.1  
vols, 3M) were added and the solutions vortexed (for 1 minute). Samples were then incubated 
for 10 minutes at room temperature and centrifuged at 2 0 0 0  g for 10 minutes. The reagents 
urea (IM), (NH 4)2S0 4  (1 M), PBS (0.75 M), lyophilised bile (20 %), and sodium cholate, 
PEG6000 proteins (BSA, casein, gelatin, and polypep) were also evaluated as agents to to limit 
the effects of inter-bile variations
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7.3.7 Immunoaffinity column synthesis
Cb specific antisera (raised in rabbits and sheep) were immobilised on silica and CPG 
in-house and commercially (Bioprocessing Ltd). The performance of these lAC columns (Cb 
capacity, NSB of bile pigments, and antibody leakage) was assessed for the effects of 
binding/blocking chemistries and antibody density, by radio-label, ELISA, RIA, and optical 
density evaluations.
The System CAL\SPE\Cb column solid phase was manufactured finally in accordance 
with GLP and GMP by Bioprocessing Ltd. Columns consisted of 200 mg of damp solid phase 
packed between two fritts, with a 3.5 ml reservoir; these were packed and packaged in batches 
of 5 by Jones Chromatography Ltd.
The stability of the System CAL\SPE\Cb pre-packed cartridges was assessed by 
measuring the level of ligand leakage (sheep IgG, sIgG) in Cb eluting buffer (30 mM HCl) of 
5 columns over 6 cycles by sIgG specific ELISA. Column stability was also assessed by 
performing 2 0  subsequent lAC System clean-up cycles of bovine bile on three consecutive days 
(n = 60) on 4 columns with control bile spiked at the UK MRL (0.5 ng/ml).
7.3.8 lAC processing of bovine bile samples
i Column preparation: the column(s) were primed with HCl (1ml, 30mM), 
ethanol (1 ml, 10 % v/v), HCl (1 ml, 30mM), and PBS (3 ml, 150 mM) 
consecutively, and allowed to drain through under gravity flow.
ii Sample processing: sample (3 ml) was applied to the column and allow to drain 
through; completion was vacuum assisted by applying a gentle vacuum. The 
column was then washed twice by applying ROW ( 2 X 2  ml), allowed to drain 
through, and vacuum applied to remove any remaining traces of water. The 
extracted sample was eluted with HCl (0.75 ml, 30 mM), under gravity flow  
vacuum assisting completion, and collected into LP4 tubes. The sample extract 
was the processed by ELISA.
iii Column regeneration: the column was washed with ethanol (1ml, 50%),
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followed by HCl (1 ml, 30 mM), and finally PBS (3 ml, 150 mM). These were 
allowed to drain through the column under gravity flow, with a gentle vacuum 
being periodically applied to assist column flow.
Prior to System Cb evaluations, bile samples observed to contain particulates were 
filtered through a plug of glass wool. Other biological samples assessed have included urine 
samples, which were diluted 1 in 5 with PBS and lAC processed or directly evaluated by 
ELISA, and fish (muscle tissue) samples, which were homogenized in PBS (200 mg/ml) and the 
supernatant applied to the System.
7.3.9 Preparation of standards
25 mg of Cb was weighed accurately into a clean new 5 ml glass vessel. 2  ml of HCl 
(0.1 M) was added and the Cb dissolved by repeated sipping and expelling from a Pasteur 
pipette. When dissolved the Cb solution was added to a 50 ml volumetric flask. The glass vessel 
was rinsed 5 times by further pipette slurrying HCl (2 ml, 30 mM) and applying the rinsings 
to the flask. The flask was then topped up with HCl (30 mM) to the 50 ml mark, and stored 
at 4°C wrapped in aluminium foil. 5 ml aliquots of this solution were periodically taken and 
used as a working stock. The concentration of Cb in solution was determined by RIA against 
a commercially prepared standard.
7.3.10 Assay validation
Optimal concentrations of plate coat conjugate (Cb-Thy, 10/91; 2 0 0  fû/well at 125 ng - 
4 jLtg/ml) and Cb antisera dilution (Cb4/iiib, 1:500 - 1:256,000) was assessed by two 
dimensional titration determinations, keeping the Cb level constant at 0 .1  ng/m l. The effects 
on the ELISA standard curve of control (clean) bovine bile was evaluated before and after lAC  
purification. The effect of assay pH (4.6 - 6 .6), and of incubation time ( 1 - 3  hours at 37°C) 
were also evaluated.
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7.3.11 ELISA protocol
Microtitration plate(s) were coated with conjugated Cb in coating buffer (Cb-Thy 10/91; 
2 0 0  f A ,  at 500 ng/m l in carb/bicarb pH 9.8), for 16 hours (overnight) at 4°C. Any remaining 
active sites were blocked by washing four times with PBST (400 fxi, Denley Wellwash) and 
finally incubating for 30 minutes with PBSGT (400 f A ,  Denley Wellfill). Plates were then used 
in the ELISA, or incubated with lactose/Thimerosal (300 fA ;  5% and 0.05% respectively) for 
, 30 minutes at room temperature, desiccated, and stored at 4°C. Sample(s) (neutralised by adding 
0.33 vols of 10 X  PBS) and standards were then added (150 fA )  and primary antibody added 
(Cb4/iiib at 1:80,000 in PBST, 100  f A ) .  The plate was then incubated on an Enfer 1000  shaking 
incubator for 40 minutes at room temperature (18 - 25°C). The plate was then washed (4 X  
400 f A  of PBST), and enzyme labelled second antibody added (Do'R-HRP(Ic); 1:6 ,0 0 0  in PBST) 
and again incubated in the shaking incubator for 30 minutes at room temperature. The plates 
were again washed (4 X 400 f A  of PBST), substrate solution added (Amerlite, 150 fA )  and 
incubated for 3 minutes in the shaking incubator. The light signal was then assessed in an Enfer 
1 000  luminescent plate reader.
7.3.12 Automated liquid handling validation
The following instruments were selected for evaluation:
i Denley Wellprep II (Denley Instruments, UK).
ii Quatro 200 (Quatro Biosystems, UK).
iii RSP 5051 ID (Tecan UK Ltd.).
and iv RSP 5032 (Tecan UK Ltd.).
The performance of these machines was tested by comparing the results of System lAC, 
and ELISA stages when performed by-hand against those performed by the machines. All 
instrument were initially installed, and programmed by representatives of their respective 
companies prior to their evaluation. Further optimization of the automated operations was 
performed in house.
The final automated System (lAC-ELISA) analytical strategy developed is summarised 
in figure 45.
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Figure 45. An automated lAC-ELISA analytical strategy for detecting the 
anabolic agent clenbuterol, present in bovine bile samples. 1) 
automated lAC (I conditioning column, II load sample. III wash 
column, IV elute extract, V & VI eluate netralization) and 2) 
automated ELISA (I plate coating, II free Cb conpetitive l°A b  
binding. III 2°Ab-HPR detection, IV chemiluminescent signal 
detection.
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7.3.13 Automated system validation
7.3.13.1 Standard calibration curves
7 assay curves with 4 replicates at each calibration point were obtained on three 
consecutive days. The resulting curves were plotted as B/Bq against Cb concentration (ng/ml), 
and subjected to statistical assessment of homogeneity. The possible matrix effects of extracted 
control bile samples on the system calibration curves was compared in "parallelism" studies 
(Heitzman, 1984).
7.1.13.2 Assay sensitivity
The lower limit of detection (LLD) of the System was determined by analysis of 24 
system buffer samples (in duplicate), in a single assay. The System sensitivity was determined 
as the mean buffer signals of the Bq - 3 standard deviations (S). The mean System buffer Bq 
values and those achieved on assaying lAC processed system buffer samples (n = 4) were 
compared statistically (Student’s t-test) to ensure their normal distribution below the allocated 
LLD.
7.1.13.3 Intra-assay variation
The within assay variability was determined by calculating the coefficient of variation 
(n = 6 ; CV % = S/mean x 100) of signals achieved for the standards in an assay and expressing 
them as a CV profile along with the standard curve. The CV profile of an immunoassay 
standard curve was usually boat shaped, the CV’s being highest at the calibration curves 
extremities. The "working range" of the assay standard curve was determined to be within the 
zone of the CV profile with values below 10 %. The "sensitive region" of assay standard curves 
was determined to lie in the region of the CV profile with values below 5 %.
7.1.13.4 Inter-assay variation
A "high" QC and a control (untreated) bile samples were run, along with test samples, 
in 5 consecutive lAC-ELISA system Cb evaluations. The inter-assay variation was then
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determined as being the CV values of these Q C ’s.
7.1.13.5 Lower limit of detection (LLD)
Bq sample valucs for 105 control bile samples, obtained from untreated animals, were 
analyzed in five assays. The value ascribed as the LLD was determined as the mean Cb content 
(from Bq sample value) plus 2 SD. Control bile samples were obtained randomly from groups of 
"clean" steers (n = 57), cows (n = 20), and heifers (n = 28). These samples were assessed 
statistically as a normal population against system buffer blanks (Student’s t-test), and also as 
individual groups for homogeneity of variances (Bartlett’s test).
7.1.13.6 Limit of determination (LD)
The LD was defined as being the minimum quantity of Cb (ng/ml) required to spike 
bile samples to achieve a statistically significant difference in the System Cb evaluations from 
those of the LLD "normal" group.
7.1.13.7 Bile volume determination
Clean bile was spiked with Cb (1 ng/ml) and volumes from 63 fil to 6 ml evaluated by 
the System (n = 3). The apparent Cb concentrations of the eluted fractions were compared for 
linearity with the volume of bile extracted.
7.1.13.7 Quality Control samples
The accuracy of the system Cb evaluations was tested by processing incurred veal urine 
samples (samples from animals to which Cb was administered orally; a blank, two positives, 
and a high) from an EC co-operative study on 3 consecutive System runs. The system precision 
was also assessed by comparing the level of Cb detected in "clean" bile samples, and those 
spiked at above and below the UK MRL (low bile <  0.5 ng/m l <  high bile). Samples were 
System lAC processed followed by assaying for Cb by the System ELISA or by a commercial 
RIA.
The precision of the lAC-ELISA system was assessed by comparing a number of within
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system Cb estimations for pools of "spiked" and field bovine bile samples. These estimations 
were statistically processed and used to determine the inter- and intra-system variations 
(expressed as CV %). In addition, these estimations were also conducted by fellow researchers 
at the MAFF Central Veterinary Laboratory, Weybridge, UK, and the result compared 
statistically (linear regression correlation, and t-test).
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7.4 RESULTS
7.4.1 Cb-protein conjugates
Cb coupling to HRP via a hydrazinyl bridge was achieved with relative ease, all the 
diazo-Cb becaming hydrazide-Cb, as revealed by testing with aminophenol (no colour change). 
However, this immobilization process resulted in labels with very poor enzyme activity. The 
production of Cb-enzymes via aminophenol bridging appeared to be a far gentler coupling 
procedure, resulting in little or no degradation of enzyme activity. These labels had low titres 
when evaluated by a "capture antibody" ELISA technique (cELISA; fig. 46), indicative of poor 
coupling efficiency. Introducing additional phenolic groups to the surface of HRP molecules 
prior to Cb coupling produced labels with a high Cb to protein ratio but without enzyme 
activity. Cb-HRP labels made by diazo coupling produced very good assay curves in a cELISA 
technique. However these labels resulted in assays with erratic intra- and inter-assay variation.
Cb
Cb
< Cb 
b
IV
< ,Cb
'Cb
Substrate
Product (Chemiluminescence)
Figure 46. The "capture antibody" ELISA technique (cELISA: I excess 2 °Ab 
plate coat, II & III free and labelled analyte compeat for l°A b  
binding, while the l°A b is bound by the 2°Ab, IV immobilized 
enzyme detection).
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The most suitable Cb-HRP labels appeared to be achieved by the rather involved 
process of CbCM synthesis followed by "mixed anhydride" coupling. The process employed 
in this study to synthesize CbCM bad a yield of 14.5 % (2.3 mg). Cb-HRP labels prepared 
using a carboxymetbyl (CM) bridge produced reproducibly good standard curves when used 
in a capture Ab ELISA for Cb (inter- and intra-assay, CV %, <  20 and <  10 respectively). The 
optimal hapten to enzyme ratio for these conjugates was 25:1 (Fig. 47), which gave labels with 
an in-assay titre of 1 in 200. Unfortunately, the cELISA’s gained using CM bridged hapten 
labels were very sensitive to the matrix effects of bile (Fig. 48).
OD (450 nm)
0.6 Cb:HRP
■ ^ 10:1
0.5
0.4
0.3
0.1
0.1 1 10 100
Cb (ng/ml)
Figure 47. The effect of enzyme label hapten to enzyme ratio on a 
"capture antibody" ELISA technique for detecting clenbuterol.
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Figure 48. The effect of bovine bile on a "capture antibody" ELISA 
technique for detecting clenbuterol.
Due to the labile nature of Cb-HRP labels and the fickle nature of the cELISA 
techniques attempted, the development of Cb-HRP labels was considered inappropriate for the 
development of a robust rapid ELISA. Therefore, effort was applied to the production of an 
appropriate Cb-protein plate coating conjugate.
All plate coating and immunogen Cb-protein conjugates were successfully synthesized 
by diazo binding. Cb-Alb synthesized with a hapten to protein ratio of 100  to 1 was used to 
immunize all the animals used for antisera production. When used as a plate coat for the 
ELISA, Cb-Alb though effective was not appropriate, as its use resulted in very high NSB’s due 
to the PAbs recognizing BSA. NSB’s were reduced by the addition of BSA (0.1 %) to the assay 
buffer (PBST) but this was at the cost of further increasing the intra-assay variability.
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Rabbit IgG (rIgG) Cb conjugate (Cb-rIgG) was a very good plate coat when used in the 
ELISA with pooled CAL/S/10 and CAL/S/9 (PAb: sheep anti-Cb). However, the Cb specific 
antibody of choice for the final System assay protocol was a rabbit antiserum Cb4 (bleeds iiib, 
and iva; the terminal bleed), detected with a peroxidase labelled second antibody, disqualifying 
the use of a Cb-rIgG plate coat.
A Cb conjugated to thyroglobulin plate coat (Cb-Thy) appeared to give the best assay 
results. In particular, the use of a porcine thyroglobulin conjugate proved most applicable to 
the assay system, as those made using bovine thyroglobulin resulted in assays with 
comparatively higher NSB’s. A diazotised Cb to porcine Thy molar ration of 10 to 1 gave the 
greatest assay signal achievable without loss of assay sensitivity due to excess bound Cb. 
Furthermore Cb-Thy coated plates when lactose/Thimerosal preserved have been stored dry 
at 4°C for more than 4 months with no appreciable loss of antibody binding.
Salbutamol protein conjugates (Sal-Thy, and Sal-BSA) were best prepared by a 1 stage 
procedure. Having all the reactants together in one vessel, this procedure proved very sensitive 
to variations in pH, temperature, reaction time, and volume. The best results were achieved 
synthesizing Sal-Protein conjugates with Sal/Bis-oxirane/protein ratios of 15:100:1. When Sal- 
Thy was used as the plate coat in the Cb System ELISA the cross-reactivity for Sal was 
improved from 12.5 % to 35 %. However, as previously noted the inter-batch variation of Sal- 
Thy conjugates was such as to make its use inappropriate for routine analysis. Consequently, 
Sal-Protein conjugates (Sal-BSA) were used only as immunogens to boost the Sal cross-reactivity 
of sheep antibodies from the two worst anti-Cb PAb producing sheep (CAL/S/11 & 12).
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TABLE XXVII. SUMMARY OF ELISA PROTOCOLS FOR Cb EVALUATED
ELISA System Sensitivity 
(ng/ml)
System Precision 
(CV%)
Comments
LLD LD Intra- Inter-
Da:R:Cb4iiib, Std & 
CbAP-HRP
- - - 1 label binding 
in ELISA
DaR:Cb4iiib, Std & 
CbH-HRP
- - - 1 1 Enz activity
DaR:Cb4iiib, Std & 
Cb-APHRP
- - - i l l  Enz
activity
Do:R:Cb4iiib, Std & 
CbDA-HRP
0.5 10 > 40 1 reprod., T bile 
variation.
Do:R:Cb4iiib, Std & 
CbCM-HRP
0.5 < 15 > 25 1 label titre 
(1:200)
CbDA-BSA: Cb4iiib, 
& Std:Do:RHRP
1.0 < 10 < 25 t NSB in 
ELISA
CbDA-rIgG: Cb4iiib, 
& StdrDaRHRP
2 > 10 > 50 1 bile tolerance, 
t ELISA time.
CbDA-rIgG: Std & 
Cb4iiib-HRP
0.5 < 8 < 20 I bile tolerance, 
i  label titre
CbDA-Thy:Std & 
Cb4iiib:DaRHRP
0.04 < 0.1 < 5 < 20 Best properties.
Cb-APHRP, clenbuterol aminopropyl horseradish peroxidase; Cb4iiib,!rabitt anti clenbuterol; Cb4iiib-HRP, rabitt anti clenbuterol peroxidase conjugate;
CbAP-HRP, clenbuterol- aminopropyl peroxidase conjugate; CbCM-HRP, clenbuterol-carboxymathyl peroxidase conjugate; CbDA-BSA, clenbuterol-diazo
albumin conjugate; CbDA-HRP, clenbuterol-diazo peroxidase conjugate; CbDA-rIgG, clenbuterol-diazo rabbit immunoglobulin conjugate; CbDA-Thy,
clenbuterol-diazo thyroglobulinconjugate;CbH-HRP,clenbuterol-hydra:pdeperoxidaseconjugate;Do!R, donkey anti-rabbitIgG;DaRHRP, donkey anti-rabbit
peroxidase conjugate; Std, clenbuterol standard. |
7.4.2 Antibodies.
The antibodies utilised in the lAC and ELISA stages of the automated Cb detection 
System were raise in sheep and rabbits respectively, the immunogen was a Cb-BSA 
(hapten/Protein; 100:1) conjugate. The cross-reactivity (Chapter 2; N o. ) of the System 
antibodies are summarized in figure 49 and table XXVIII.
Two of the Cb-BSA immunised sheep (CAL/S/11 & 12) produced a poor PAb 
response, these were therefore immunized with Sal-BSA in an effort to improve their cross 
reactivity. This resulted in an improvement in the PAb Sal cross-reactivities of CAL/S/11 & 
12 from 3.7 and 5 % respectively (for the BIIc bleeds) to 12,000 and 100 % (for the Sal, Pa 
bleeds, nomenclature explained in section 2.1.7) respectively.
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Figure 49. General structure of frequently used fi2"^gonists.
TABLE XXVIII. THE CROSS-REACTION OF THE lAC-ELISA SYSTEM 
ANTIBODIES WITH B^-ACONISTS
NAME FUNCTIONAL CROUPS mol wt % CROSS 
REACTION
RI R2 R3 R4 IAC(Q) ELISA
Cimaterol N  =  C NHz H H 219.3 58.3(70) 1.4
Cimbuterol N  =  C N H 2 H CH3 233.3 - 6.7
Clenbuterol Cl N H 2 Cl CH3 277.2 1 0 0 (100) 100
Mabuterol CF3 N H 2 Cl CH3 310.8 - 100
Mapenterol CF3 N H 2 Cl CH2CH3 324.8 - 55
Salbutamol H OH CH2OH CH3 239.0 10.5(70) 12.5
Terbutaline OH H OH CH3 225.0 14.1(12) 8.3
Q, Jf-agonist capacity {ng/ml col vol).
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7.4.3 Sample processing.
Chemical pre-treatments of crude bile samples prior to assaying were unable to reduce 
the matrix effects of bile in the system ELISA. Of the treatments attempted the most 
appropriate appeared to be either saturation with lyophilised bovine bile (10  % w /v), or 
tungstic acid precipitation. The addition of lyophilised bile to assay standards and samples 
produced inconsistent results due to the heterogeneous nature of bovine gall bladder bile. 
Tungstic acid pre-treatment was quick and extremely effective, resulting in clear colourless 
supernatants. Unfortunately, on assessing tungstic acid extracts of spiked bile samples, these 
appeared devoid of Cb, though the acid itself had no effect on the system ELISA’s standard 
curve.
The use of sodium borohydride (1%) to stabilise Schiffs’ bases and remove remaining 
aldehyde groups in the production of Cb lAC solid phases resulted in very poor Cb capacity. 
An ethanolamine/glycine blocking solution proved the more appropriate (Chapter 5). The 
Systems CAL\SPE\Cb cartridges were found to have an average Cb capacity of 50 ng (57 ng, 
C /C o = 0.5; 42 ng, eluted). The effect of Cb sample purification buffer on the ligand leakage 
from the CAL\SPE\Cb columns has been summarized in figure 50. The effect of reusing these 
columns for 2 0  cycles over 3 days is summarized in figure 51. These columns have been stored 
dry (7 days), and damp (>  3 months) at 4°C, with no apparent loss of Cb capacity.
7.4.4 Sample evaluation.
The optimal plate coat and primary antibody concentrations as determined by a two 
dimensional titration assay, and the appropriate labelled second antibody titre was summarised 
earlier in the ELISA protocol (7.3.11). The quality of the in-house Cb standard solution when 
assessed by commercial RIA was equal to that supplied in the RIA-Kit (100%, cross-reaction).
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Figure 50. The effect of Cb purification buffer on the ligand leakage from 
packed Cb I AC columns (CAL\SPE\Cb), A and B are storage 
overnight at 4°C (PBSTbim).
sIgG (ng/ml) CV (%)
100200 mean ~  CV (%)
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Figure 51. The effect of column reuse on the performance of packed Cb 
lAC columns (CAL\SPE\Cb).
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7.4.5 Validation of automated liquid handling
A problem continually encountered using the Quatro automated liquid handler was one 
of carry-over due to non-specific binding of bile components and Cb to the probe. This was 
eventually resolved by increasing the volume of the probe washing stages and the addition of 
methanol (20  %) to the water wash.
The Denley Wellprep instrument produced extremely good standard curves for the 
machine’s first few runs, though the precision profiles of assays deteriorated over a weeks use. 
This was attributed to degradation of the instrument’s disposable polypropylene syringes, 
curves being unreliable after a week’s continual use. In addition, design of the linear-tracking 
carousel sample rack was such that when in use tubes or other equipment could be trapped. 
This instrument was therefore considered unsuitable for the proposed System use ( 4 X 4  
microtitration plates, 5 days a week).
The Tecan robotic sample processors were by far the most expensive of the automated 
liquid handling systems evaluated, and the least user friendly on attempting to manipulate 
programmed protocols (user training course required). However, when their use was optimized, 
these instruments consistently produced reproducible assays with limited inter- and intra-assay 
variations.
7.4.6 System validation
Standard calibration curves and sample evaluations were carried out on the Tecan 5031 
instrument. Figure 52 represents an amalgamation of the data obtained from 7 standard curves 
with 4 replicates at each calibration point; it was plotted as B/B q against Cb concentration 
(ng/ml) created on three consecutive days, with the appropriate reproducibility of the assay 
precision profile). The effect of bovine bile (control, untreated animals) on the System 
calibration curve in parallelism studies was minimal, there being little or no effect on the 
calibration curve when compared to extracted buffer (Fig. 53).
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Figure 52. The inter-assay varriation of automated clenbuterol ELISA’s 
performed on a Tecan 5031 robotic instrument (n = 7; 4 
replicates per assay standard).
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0
0.1
buffer +  bile
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Cb (ng/ml)
Figure 53. The effect of bovine bile on an automated clenbuterol ELISA, 
performed by an automated Tecan 5031 robotic instrument (n 
= 7; 4 replicates per assay standard).
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The System sensitivity determined as the mean of the Bq - 3 standard deviations (S, n 
= 24) was 0.04 ng/ml. Figure 54 shows the results of comparing unprocessed buffer samples 
(neutralised acid; HCl, 22.5 mM and PBS 375 mM), with those sent through the whole System 
(lAC followed by ELISA). The extracted buffer signal and the standard calibration curve zero 
results were 3030 ± 65 (n = 24) and 2928 + 58 (n = 4) respectively; on application of a t-test 
to these results the means were not significantly different (p = 0.066).
Signal
3,500 norm  "®' I AC
3,000
2,500
2,000
1,500
1,000
500
100.10.010.001
Cb (ng/ml)
Figure 54. The effect of the automated lAC processing of buffer and bovine 
bile samples on an automated clenbuterol ELISA.
Assessment of the System intra-assay variation typically resulted in CV profiles with 
values below 6  %, when standard curves were run in neat buffer or System lA C  extracted 
control bile. Hence for a robust System precision the working range of the assay was assigned 
the values 0.1 to 10 ng/m l (CV <  5 %), equivalent to a sample Cb content of 0.033 to 3.3 
ng/ml. A "high" QC bile sample and a control (untreated) bile at the extremes of the 
calibration curve, when evaluated by the Cb System (n = 5) gave estimates of inter-assay 
variation of 12 .2  % and 2 1 .2  % respectively.
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The System LLD for bovine control bile was 0.052ng/ml (mean value ± S: 0.027 ± 
0.012ng/ml; n = 105), as determined by the mean Bq sample value + 2  S. A  breakdown of the 
data according to animal type was as presented in table XXIX.
TABLE XXIX. AUTOM ATED lAC-ELISA SYSTEM ASSESSMENT O F THE  
PRESENCE OF Cb (ng/m l) IN  "CONTROL" CLEAN BOVINE BILE SAMPLES.
Animal Group Cb (ng/ml) detected
mean S CV(%) n
Steers 0.027 0 .0 1 2 44.4 57
Cows 0.033 0.015 45.5 20
Heifers 0.026 0 .0 1 0 38.5 28
The difference in mean bile Cb levels estimated for the animal sub-groups steers, cows, 
and heifers was found not to be statistically significant when assessed by a Bartlett’s test for 
homogeneity of variances. This method of statistical analysis gave a "found" value for M  of 
5.627; less than 5.99 for a with 2 d.f. p = 0.05.
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TABLE XXX. DETERMINATION OF THE LD OF A lAC-ELISA Cb 
DETECTION SYSTEM BY STATISTICAL COMPARISON OF CLEAN AND 
SPIKED (0.05 AND 0.1 ng/ml) BILE SAMPLES
Cb Spiked 0 0.05 0.1
0 - -
-
0.05 T = 1.7079
p = 0.180
- -
0.1 T = 9.1437
p <  0.001
T = 1.8993
p = 0 .1 2
The System LD was assessed by estimating the presence of Cb in control clean bile 
samples spiked at 0.05 (n =11)  and 0.1 ng/m l (n = 11), and comparing these values with those 
found for a control bile sample (n = 105). Control bile samples spiked 0 , 0.05, and 0.1 ng/m l 
with Cb, were assessed to contain Cb levels of 0.052 ± 0 .0 1 2  (n = 105), 0.036 + 0.92 (n = 11), 
and 0.89 ± 0.019 (n = 11) ng/ml respectively. These values were compared statistically by 
Student’s t-test for differences in their means (table XXX). When these values were assessed by 
a Bartlett’s test for homogeneity of variances these produced a "found" value for of 8.18. M 
was therefore greater than 5.99 for a with 2 d.f. P = 5%, indicative that the variances of 
these three means are significantly different. Estimations from a number of manipulations 
coupled to the result of statistically evaluating spiked bile data would suggest that the System 
LD to lies in the range 0.05 <  LD < 0 . 1  ng/ml.
The volume of bovine bile processed by the System appeared to have little effect on 
estimations of sample Cb content. When the level of Cb was compared to the bile volume 
extracted, the linearity of the regression of the resulting plot gave a correlation of 0.994, 
indicative of good recovery precision (Fig. 55; n = 3).
*(mean ± SD)
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Figure 55. The effect of volume on an automated lAC-ELISA processing 
and determination clenbuterol in bovine bile samples.
The accuracy of the System Cb estimations was assessed by comparison of EC "ring 
test". Lyophilised bovine urine samples gave a correlation coefficient of 0.999 (Fig. 56; 
estimated = EC x 1.152 (± 0.023) + 0.227 (± 0.105)). Statistical comparison of the System 
estimated Cb content of the bile samples and the average values found in the ring-test would 
suggest a significant difference in our estimated values (table XXXI).
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lAC-ELISA System means
25
20
5 10 15 20 25
CEO " r in g - te s t"  m eans (ng /m l)
Figure 56. Comparison of System Cb evaluation of lyophiliised bovine 
urine samples with the mean of evaluation carried out by an 
CEC "ring-test".
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When the System’s ELISA was compared with a commercially available RIA-Kit for 
estimating the Cb content of lAC processed "spiked" buffer and bovine bile samples, these gave 
correlation coefficients of 0.952 (ELISA = RIA x 0.638 4- 0.155) and 0.970 (ELISA = RIA x 
1.469 - 0.009) respectively (Fig. 57). Comparison of the System estimation of the Cb content 
of biles with those found by workers at CVL gave values of System Cb (ng/ml) = CVL Cb 
(ng/ml) X  3 (Sauer, 1992).
ELISA (ng /m l)
fH3
3 4
RI A ( n g / m l )
E LI S A ( n g / m l )
b )
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1
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0
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Figure 57. A comparison of the System automated ELISA and a 
commercially available immunoassay for the anabolic agent Cb 
present in the automated System lAC process buffer (a) and 
bovine bile samples bovine bile samples.
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7.4.7 lAC-ELISA System evaluation of randomly collected "field" samples
The automated System was used to estimate the Cb content of 282 "suspect" (Irish), and 
237 "clean" (UK) randomly collected bile samples. The mean estimated Cb content of these 
samples was 0.253 ± 0.413 and 0.042 + 0 .211  ng/ml respectively. Statistical analysis of the 
means of these two groups suggest a significant difference in their means (Student’s t-test; T = 
7.1125, p <  0.001). Taking a value of 0.1 ng/ml (>  the LLD) as the cut-off, of the randomly 
collected "suspect" group of biles 125 (44 %) were found to be positive, and of the "clean" 
group of samples 16 (6.8  %) were found positive.
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7.5 DISCUSSION
A number of the reagents synthesized for use in the earlier attempts at developing an 
ELISA for Cb were dismissed as inappropriate on the grounds that they were unable to tolerate 
the presence of bile. As the System developed to incorporate an lAC sample clean-up, many 
of the earlier reagents may be worthy of re-evaluation.
The use of a Cb-Thy conjugate as the plate coat in the ELISA developed allowed the 
production of this reagent with stable characterized off-the-shelf items. Following the procedure 
outlined for its production, batch preparations of this reagent have been made more than ten 
times with no apparent variation in the ELISA. In addition, both the Cb-Thy reagent (stored 
at -20°C) and coated plates (stored at 4°C desiccated) have been stored for more than 6  months 
without showing any signs of degradation. It was therefore suggested that pre-coated preserved 
plates should become an integral part of the System. The ELISA was developed with a view  
to its being sensitive and specific for Cb, but fortunately cross-reacted with a number of the 
"new" E-agonists (including cimbuterol and mapenterol). It was believed that the lower cross 
reactivities of these compounds in our System ELISA should not present a problem as these 
values largely reflect their efficacy as partitioning agents (Ginkle, 1992). Hence at their growth 
promoting doses, all these compounds should be detected.
The lAC system was developed with a view to its general use for E-agonist purification. 
In order to improve the Sal cross-reactivity of the PAbs used for lAC column synthesis, two 
approaches available may be to blend CAL/S PAbs, or alternatively to immunise sheep 
producing PAbs to Cb with Sal-BSA. An immunization approach to improving the cross­
reactivity of PAbs was exemplified by the greater than 3,000 fold increase in the Sal cross­
reaction of PAbs from sheep CAL/S/11 (previously primed and boosted with Cb-BSA) on 
boosting with a Sal-BSA conjugate. By using 4 sheep in which to raise PAbs to Cb for lAC  
column synthesis, it was intended to gain a large supply of antiserum to ensure sufficient 
material for the production of large numbers of columns.
The Cb lAC columns (CAL/SPE/Cb) created in this study had a Cb capacity far 
greater than the expected contamination of a bile sample. This was so as to favour the rapid 
capture of Cb from the 3 ml bile samples, and prevent analyte desorption during the System’s
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suction assisted washing stages. Having an excessive System lAC column Cb capacity was also 
at the risk of increased non-specific adsorptions (NSA), and hence contaminating co-purificants 
in the System lAC processed samples. Fortunately, excessive N SA ’s proved not to be a 
problem, taken care of largely by the use of an N aO H  (10 mM) washing stage prior to sample 
elution, with an ethanol (10  % v/v) clean-up washing stage between each sample application. 
Consequently, sample volume (62.5 /xl to 6 ml) had no effect on the system Cb determination 
of bile samples.
Attempts to immortalize the production of sheep anti-Cb Ab by MAb creation using 
interspecies fusion (Groves, et al 1987) have, to date, proved unsuccessful. The enzyme labelled 
antibody used for the detection of the "bound" antibody was raised in a donkey against rabbit 
IgG. This IgG was affinity-selected by stepped elution from a rIgG-CPG column prior to to 
being conjugating to horseradish peroxidase. Currently, supplies of antibodies will allow for 
the assay of approximately 2 0  million tests (columns and immunoassay).
As found when dealing with immobilized SpA-CPG solid phases, the ligand leakage 
from the System lAC columns was invariably greatest when they were first removed from 
storage. In addition, ligand leakage required the presence of the sample matrix (biological 
sample preferably containing ligate) before appreciable levels of leakage occurred. Furthermore, 
on removal from storage after repeated use, the level of ligand leakage was found to have 
returned to its initially higher level. Consequently, a primary pre-sample lA C  System 
conditioning cycle was performed, by applying control "clean" bile to the System prior to 
runing subseqent clean-up cycles of "suspect" samples.
The automation of the lAC-ELISA Cb detection process (the "System") was developed 
in order to make bile screening a rapid process, requiring as little operator assistance as 
possible. The most difficult aspect to optimise of the automated liquid handling proved to be 
the handling of crude bile samples on the Tecan RSP 5051 instrument. This required the 
manufacture of a purpose-built controllable vacuum unit, which required required a long 
assessment of the times and duration of the application of vacuum pulses in order to lAC  
process biological samples (mostly bile) on affinity columns. In addition, the use of automated 
liquid handlers in a unidirectional system flow path limited the likelihood of errors due to
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accidental reagent addition or inter-operator variations.
All incubations were performed on the Enfer 1000 shaker-incubator at ambient. This 
was so as to avoid any microtiter plate inter-well variations due to evaporation of liquid from 
the wells. Shaking the chemiluminescent plates during incubations reduced by more than a half 
the time taken to achieve comparable binding at 37°C. By comparison to colorimetric ELISA’s 
performed earlier in the development of the System ELISA, the sensitivity of the System 
chemiluminescent end point ELISA showed little improvement. However, the increased signals 
achieved using a chemiluminescent end point has resulted in the System ELISA having lower 
assay variations. A chemiluminescent end point also had the advantage of lowering the 
substrate incubation period from 30 minutes (at 37°C) to 3 minutes (shaking at ambient).
The standard calibration curves performed by the Tecan 5031 instrument were 
comparable to those performed by hand in terms of speed and precision (CV’s <  5 %). The 
lAC-ELISA System for Cb assessment had a LLD of 0.052 ng/ml, a LD of the order of 0.07 
ng/m l, and working range (with respect to bile Cb content) between 0.033 and 3.3 ng/ml. 
With this System the level of Cb detected in positive samples (above 0.1 ng/ml) were typically 
in the region 1 to >  5 ng/ml, well above the UK MRL of 0.5 ng/ml.
The LD of 0.1  ng/m l assigned to the System so as to have a value with a highly 
significant difference in mean Cb content to that of control clean biles. In doing so it was 
hoped to further ensure that the system would not produce false positive results when used to 
screen biles, yet was still less than a tenth of the UK MRL so could detect trace levels.
By selecting a high and control (clean) bile samples to assess the inter-System run 
variation, the levels of precision found (CV %, 12.2 and 2 1 .2  respectively) may be considered 
the worst case results as these samples lie at the very edges of the calibration curve.
The "ring test" urine samples used to test the accuracy of the Cb detection System were 
used throughout the EC as part of a co-operative study. 24 establishments in all evaluated these 
samples for Cb content using a variety of techniques including: gas chromatography, mass 
spectrometry, immunoassay, liquid chromatography, ultra violet detection, and thin layer 
chromatography. Comparing the results of System evaluating these samples with those found 
in the ring-test suggests the System Cb est imations show a good correlation with those of other
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analytical procedures conducted throughout the EEC (correlation of 0.999). Furthermore, these 
results would also suggest the System offers accurate estimated values of Cb in biological 
samples, as the System Cb content determinations did not significantly differ statistically from 
those produced throughout the EC.
Suspect bovine bile samples were collected from slaughtered animals in Eire, as at the 
time of this study the widespread illegal use of Cb in the Irish beef industry was widely 
publicized (Shannon, 1991; and Murdock, 1992). Bile was taken as the assay sample, largely 
because of its ease of collection, and limited pre-treatment required prior to apply to lAC  
columns.
The component in the rapid lAC-ELISA System developed is the performance of the 
silica based lAC solid phase. As a consequence of its mechanical stability and specific high 
affinity for Cb samples, biological samples could be processed in a rapid automated manner. 
Essential to the performance of the lAC-ELISA system was the longevity of the CAL\SPE\Cb  
columns and reproducibility of sample clean-up processes performed on them. The average 
ligand leakage from CAL\SPE\Cb columns on repeated Cb purification cycles was 0.8 ng/m l 
(sIgG). This level of ligand leakage would be consistent with an apparent reduction in Cb 
content of eluates of 3 pg/m l or 1 pg/ml bile sample; based on the assumption that all eluted 
antibodies are biologically active and bivalent. Furthermore, the level of ligand leakage from 
CAL\SPE\Cb columns over repeated continual use (60 cycles) remained consistent (Inter­
column, variation CV % <  20).
In the summary the System was described as semi-automated. This was because a degree 
of operator involvement (and occasionally, intervention) may have been required. Periodically, 
viscous bile samples require manual assistance to begin or complete their passage through the 
SPE lAC columns. However, by assigning a sample identity at the outset (bar coded 
Vacutainers) and maintaining that identity to the point of computerised data reduction, 
operator dependent variables were kept to a minimum. Furthermore, the level of operator 
expertise required may be minimal also. This technique further exploited the fast flow  
characteristics of silica based affinity solid phases, offering a rapid screening protocol applicable 
to the throughput of livestock at an abattoir. In doing so, an attempt was made to develop a
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technique requiring minimal sample preparation in order to maximize sample throughput.
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CHAPTER EIGHT 
CONCLUDING DISCUSSION AND FURTHER STUDIES
8.1 OVERVIEW OF STUDY AREA
The unique properties and formidable processing problems associated with the isolation 
and purification of components of, or from, biologically derived materials have become a major 
challenge to those working in the areas of analytical chemistry, chemical and biochemical 
engineering. During the past 30 years much effort has been spent by workers in the 
development of methods for the production of therapeutic or analytical grade isolates from 
biomaterials, reflecting the increasing interest in the safety of intensively farmed edible products 
and the growth in use of products of mammalian cell culture. The extraordinarily high 
standards demanded of biomaterial for human use (food stuffs and therapeutics) by the 
regulatory authorities further increases the demand for isolation techniques applicable to the 
resolution of components of biomaterials to a high grade of purity.
Largely due to their high selectivity, affinity chromatographic techniques have found 
their way into a multitude of preparative processes for separating biological molecules. The use 
of bio-specific interactions to separate components of complex mixtures may result in very high 
resolutions in a single step. The study presented here documents the findings of experiments 
within which it was intended to utilise the chromatographic selectivity of immobilized 
bioselective ligands, while taking full advantage of the mechanical properties of rigid silica-based 
matrices (porous silica, PS and controlled pore glass, CFG).
This study set out to examine the practicalities of producing PS and CPG based solid 
phases for the process scale purification of proteins and the rapid affinity clean-up of analytical 
samples prior to quantitative assessment. This has required the development of techniques for 
activating silica-based matrices, immobilizing ligands to activated matrices and evaluating the 
performance of the resulting solid phases. The utility of PS and CPG based solid phase 
preparations was also determined by comparing their performance against those more 
commonly used. Furthermore, PS and CPG based matrices were exploited in conditions of 
high pressures and flow rates where more conventional matrices employed for the production 
of affinity solid phases may prove inappropriate.
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8.2 THE USE OF SILICA-BASED MATRICES FOR BIOSEPARATIONS
Silica-based matrices are rigid and mechanically stable, and also have a high particle 
density in comparison to most AC matrix materials allowing rapid settled bed formation. Also, 
packed beds of silica-based matrices do not change their volume with differences in ionic 
strength or pH, as is common for organic matrices such as Sepharose, or Sephadex. 
Furthermore, these silica-based materials may be manufactured in the form of uniform spheres 
of defined particle and pore sizes.
Initial investigations into the production of silica-based solid phases conducted in this 
study were performed using the PS matrix material Matrex™. The disadvantage of using this 
material for process scale or high flow rate applications was its tendency to produce fines as 
a consequence of the nature of its manufacture. PS matrix particles are usually produced by 
sintering smaller solid particles of silica to form a large block, which is then crushed and the 
resulting porous particles sieved into size fractions. This results in matrix preparations in which 
the particles have irregular shapes with pore sizes dependent on the variation in sizes of the 
initial smaller solid silica particles used. Consequently, when used as an AC matrix material, 
the solid phases produced have a tendency to produce fines, as small silica particles are chipped 
off the edges of the matrix particles. This matrix also has the disadvantage of adjacent particles 
within a packed bed forming narrow channels ending in minute blockages, resulting in band 
spreading and poor solute resolution. However, PS matrices have the advantage of being 
exceptionally cheap, costing about one tenth of the price of CPG.
CPG matrix particles are produced as a result of acid etching solid spherical particles 
of borosilicate glass. Therefore, these matrices consist of rigid granules of quartz glass 
permeated by an interconnecting network of pores with very narrow size distributions. As a 
result, these matrices produce solid phases with excellent mechanical stability and may 
therefore be used in fluidized-bed processes; they produce good resolution of solutes and allow 
rapid solvent flow rates (greater than 100  col vols per hour).
A drawback to the use of PS or CPG matrices is that, unlike matrices more commonly 
used in the production of affinity solid phases, these materials may non-specifically adsorb
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(NSA) proteins by the formation of Lewis acid sites if left untreated. The NSA of proteins to 
silica-based matrices has been suggested as one of the reasons for their lack of popularity in 
producing affinity solid phases. However, the results of experiments conducted in this study 
would suggest the NSA of proteins to PS and CPG matrices to be completely eliminated 
(below the LLD of experiments) by the process of silanization.
The main reported objection offered for not using silica-based matrices in the 
production of affinity solid phases has been their apparent lack of stability in alkali conditions. 
This problem has been further exacerbated by the fact that molar N aO H  has largely become 
the method of choice for sanitizing and depyrogenation of affinity solid phases between 
purification cycles (Hodgson, 1990).
Sanitizing SpA-PS preparations by slurrying with molar N aO H  between eight MAb 
purifications cycles in this study would suggest N aO H  had no apparent effect on either the 
MAb capacity or degree of ligand leakage. However, these solid phases were found to have low  
MAb capacities (Q = 2-3 mg/ml) when compared to a commercially prepared SpA-CPG 
preparation Prosep A HC (Q = 15 mg/ml). Prosep A HC columns, when sanitized with molar 
N aO H  between MAb purification cycles, showed a ten fold decrease in MAb yield and a 5 fold 
increase in the SpA content of purified MAb’s when compared to a control (adsorption buffer 
sanitized).
Zn^ "^  ions when present at levels of 10 mM or more were found to reduce the level of 
background ligand leakage from a Prosep A HC-/^^ by more than 100 fold when present in 
a low salt adsorption buffer (glycine, IM; NaCl, 0.15M, ZnCl2, lOmM; pH 8 .6). Furthermore, 
the reduction in MAb capacity of Prosep A HC on NaO H  sanitizing was lowered to 3 fold 
by the addition of 10 mM ZnCl2 to the sanitizing solution, with an increase in SpA 
contamination to 10 fold. Under these conditions dissolution of the solid phases surface was 
prevented by the formation of aluminosilicate groups on the solid phase surface providing a 
protective layer.
Unfortunately, direct incorporation of aluminium ions onto the surface coating of PS 
based SpA-PS solid phases during silanization resulted in an increased level of ligand 
contamination of purified MAb’s eluted from the resulting solid phases. However, increasing
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the concentration of Al-ethoxide present in PS silanizing solutions from 0 to 1 % resulted also 
in SpA-PS solid phases with increasingly higher capacities for MAb’s.
Alternative sanitizing conditions to using molar N aOH, which have been used to clean 
up SpA-(PS or CPG) solid phases in this study without any ill effects have included GuHCl 
(6 M), Urea (6 M), chloroform/methanol/water (5:4:1), acetic acid (10%), formic acid (10%), 
chloroform, methanol and acetone. By pre-treatment with 5 col vols of acetone, it was possible 
to restore performance to old Prosep A columns (to near their original MAb capacity and flow  
rate) when removed from storage, or after repeated use. Additionally, silica-based matrices may 
be subjected to heat sterilization processes, be treated with concentrated acids, and/or organic 
solvent. Hence, silica based matrices may be rigorously cleaned allowing the aseptic purification 
of biological isolated for therapeutic applications.
If it were possible to overcome the resistance of operators to a change from N aO H  AC 
solid phase sanitizing treatments then silica-based matrices may be cleaned by a variety of 
alternative techniques limited only by the stability of the particular ligand in question. Perhaps 
the most important point to note about affinity solid phase clean-up is that the harsher the 
conditions used, the greater the possibility of damage occurring to the immobilized ligand, 
which in turn may result in reduced sample resolution efficiency due to increased non-specific 
binding.
Another criticism offered as a drawback to the use of silica based matrices in the past 
has been their cost in comparison to other commercially available matrices. This would appear 
to have been a problem historically where the supply of matrices such as CPG was limited. 
Currently, the cost of litre quantities of CNBr activated Sepharose 4B is £2,000 (Sigma), of 
CPG-NHz is £2,200 (Schott) and of Matrex Si is £220.
The production of functionalized PS and CPG matrices in this study proved a time 
consuming process, syntheses taking as long as three days in many cases. However, once 
produced, functionalized silica-based matrices were found to remain stable (on the bench) for 
more than two years. Experiments conducted involving the binding of BSA to activated PS 
preparations would suggest aldehydes as the appropriate functional group to introduce onto the 
surface of a matrix for protein binding. These were produced by either forming AP-PS by
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silanizing PS with APTS followed by glutaraldehyde activation, or by silanizing with GPTS 
followed by acid hydrolysis to diols and periodate oxidation to aldehyde groups. These 
activation procedures resulted in matrices with BSA capacities of 63 and 76 m g/g respectively, 
with the protein binding reaching the matrix capacities in under 2 hours (section 5.4.1). 
Proteins bound to aldehyde activated matrices via their surface primary amine groups by the 
formation of imine or Schiff’s base bonds. These groups were found to be unstable in aqueous 
conditions and would slowly hydrolyse allowing BSA to leach from solid phases.
Protein leakage from Schiffs base bonded stationary phases was reduced by around a 
thousand fold by stabilizing the Schiff’s base bonds with a reducing agent such as sodium 
borohydride (table XV). Sodium borohydride also reduced any remaining aldehyde groups on 
the surface of activated silica-based preparations preventing any further binding of proteins. 
However, on borohydride reduction^immobilized antibodies tended to lose a great deal of their 
antigen binding ability suggesting disruption of their tertiary structure. Sodium 
cyanoborohydride when used to reduce ligand immobilizing Schiff’s base bonds proved to be 
a more selective reducing agent, appearing to affect Schiff’s base bonds alone, whilst leaving an 
activated matrix’s aldehyde groups and the ligand intact. Sodium borohydride was therefore 
used as an addition to all reaction processes where the promotion of Schiff’s base formation 
was of an advantage (protein-PS coupling, section 5.3.2.3; protein-protein coupling, section 
■2.3.8).
The binding of BSA to PS via epoxide groups introduced by silanization with GPTS 
required an incubation period of more than 7 hours to reach half the matrix BSA capacity. 
Also, removal of active epoxides post ligand coupling required incubating for an equal period 
with a concentrated solution of a nucleophilic compound such as molar glycine or for shorter 
periods in strong hydrolysing conditions such as with molar sulphuric acid. The findings of this 
study, like that of Chang et al (1976), would suggest epoxide bond immobilized proteins tend 
to be stable. These observations would suggest epoxide ligand binding to be most appropriate 
for non-labile ligands.
The degree to which a matrix is activated prior to immobilizing a ligand may require 
tailoring to the ligand or the ligate in question. The capacity and stability of BSA bonding to
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activated PS matrices was discovered to be greatest at higher levels of matrix activation. 
However, the performance of immobilized bio-ligands may depend upon their tertiary, or 
quaternary structure for effective biological activity. Excessive immobilizing bonds may exert 
deforming forces on immobilized biomolecules and as a result alter their specific functional 
configuration. Hence, a balance must be established between that level of ligand bonding which 
provides minimal leakage against that which produces minimal reduction of specific activity.
The production of activated PS or CPG matrices unlike that of a number of organic 
matrices may be conducted using reagents with relatively low associated health risks. By using 
aldehyde activated matrices the use of CNBr and triazine reagents which are highly toxic is 
avoided, removing any threat of these agents leaching from the solid phases together with 
affinity purified products (Dertzbaugh et al., 1985). The low toxicity of the ligand binding 
reagents may be considered of particular concern where the solid phase in question is intended 
for use in the production of therapeutic isolates. Moreover, the findings of this study would 
appear to concur with the findings of studies conducted by Peng et al (1986) and Füglistaller 
(1989), indicating that ligand contamination of affinity purified products was lowest when 
ligands were immobilized via Schiff’s base bonds.
Ideally, ligands for affinity purifying biologicals should be the fully characterized 
products of industrial scale processes. Such ligands may be examples of dyes, genetically 
engineered proteins (produced in continuous culture), or computer designed bio-mimetic 
molecules. These compounds may be reproducibly synthesized in large quantities, to a 
characterized quality and high grade of purity. Hence, the outcome of producing solid phases 
from these ligands may be fully characterized for a given process.
Generally, synthetic ligands have the advantage of being mechanically stable and 
resistant to chemical and biological attack. The drawback of using synthetic ligands, as 
demonstrated by the use of immobilized Rivanol in this study, is the non-specific nature of 
protein adsorptions. Dye-ligand purified proteins therefore have a tendency to contain a 
number of co-purified contaminants. Solid phases made using immobilized dyes also have a 
tendency towards high levels of ligand leakage. Samples of BSA eluted in high salt 
concentrations from Cibacron Blue F3G-A solid phases often emerge blue in colour.
229
Biological ligands have the advantage of being very ligate specific, binding occurring in 
a bioselective manner. In this study, the use of bio-ligands such as second antibodies to purify 
primary antibodies or SpA to purify antibodies typically produced isolates with a degree of 
purity of greater than 98 % in a single step. The disadvantage of many bio-ligands (such as 
MAh’s and enzymes) is that they are often mechanically unstable and prone to microbial or 
biological attack. Consequently, solid phases made from bio-ligands tend to be relatively short 
lived as their performance falls off rapidly on reuse or prolonged storage.
In this study, the bio-ligand SpA was widely used as a general purpose ligand for 
evaluating the performance of affinity solid phases. N o difference was discovered between using 
bio-ligands from genetically manipulated biological sources and those from their native source. 
Recombinant protein A (rPro A; Repligen Ltd.) appeared to have both the same 
immunoactivity and ligate binding as the native protein (SpA, Fermentech). Generally speaking 
though, solid phases made by immobilizing whole antiserum had higher shelf-lives than those 
made using either purified Igs or Mabs. This was perhaps as a result of the other proteins in 
antisera preparations providing mechanical and/or physicochemical support to immobilized 
antibodies.
The capacity (Q) and efficiency (percentage of applied ligate bound) of ligate adsorption 
of an affinity solid phase will largely be reflected in the degree of ligand immobilization. The 
performance of immobilized SpA-PS solid phases (MAh, Q; low SpA leakage) was found to be 
best for those solid phases with lower levels of ligand substitution. Increasing the level of SpA 
immobilized on SpA-PS solid phases increased both their MAh capacity and level of ligand 
leakage. However, the level of ligand contamination of MAbs’ affinity purified on SpA-PS solid 
phases was greatest for those with either very high or very low levels of ligand substitution and 
lowest for average (around half the total matrix ligand capacity) levels of substitution.
SpA-PS matrices made with a lower level of ligand loading (<  0.2 X  max binding) may 
have the ligand stabilized by numerous bonds, though have a low specific activity (moles of 
MAh purified per mole of immobilized SpA) due to distortion of their tertiary structure. At 
higher matrix loadings SpA-PS matrices reached a threshold of MAh capacity and it was found 
that increasing the ligand loading further did not increase the capacity due to steric hindrance
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of binding. It appears that a balance must be struck between that level of ligand substitution 
which provides levels of ligate binding appropriated for the purification application in question, 
and just sufficient ligand substitution to ensure limited leaching from a solid phase (ideally none 
at all).
Matrices with too high a capacity for their proposed ligate loading also have the 
disadvantage of providing sites for non-specific adsorption, resulting in less efficient sample 
clean-up. While it is essential to limit the level of bio-ligand leakage from solid phases intended 
for use in the production of therapeutics, the problem of leakage is further exacerbated by the 
need also to assess the actual ligand content of the purified products. Contaminating ligands 
present in affinity purified products occupy an environment in which their complementary 
ligate is at a huge stoichiometric excess. Therefore, in order to sequester and detect a 
contaminating ligand in a purified product such that a quantitative assessment of its presence 
can be made, the forces of ligand-ligate affinity and ligate concentration promoted ligand-ligate 
binding must be overcome.
Over four purification cycles, the level of SpA contamination of MAbs purified on 
Prosep A  H C fell from an initial level of more than 35 ng/mg to less than 7 ng/m g (section 
4.5). Similarly, the level of ligand (sIgG) detected in the elution fractions from CAL\SPE\Cb 
lAC columns fell from around 11 ng/m l to less than 1 ng/m l over four bile extraction cycles 
(section 7.4.3). This observed fall in the level of ligand contamination of affinity purified 
products over subsequent purification cycles was found in this study not to be an occurrence 
unique to the use of silica-based matrices. Francis and his co-researchers (1990) also reported 
a similar observation on re-using Sepharose based SpA solid phases. Furthermore, ligand leakage 
from affinity solid phases seldom occurred to any appreciable degree until the columns were 
first challenged with the ligate in the biological material for extractions. It may therefore be 
suggested that an essential stage in an analytical affinity purification run may be to first 
condition affinity columns by having a blank initial bio-material run prior to applying the first 
sample.
On frontal analysis, ligand leakage (SpA from Prosep A HC) appeared to fall to less 
than 10 % of its initial level, slowly recovering as the solid phase loading reached its capacity.
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It appeared that during the MAh adsorption process SpA which would otherwise leave a 
column by leaching from the stationary phase was prevented from doing so by either steric 
hindrance or by the relatively higher concentration of ligate binding sites available attached to 
the solid phase. Thus, the level of ligand leaving the column fell but showed signs of recovery 
on approaching the solid phase ligate capacity (C/Co >  0.8). Consequently, columns developed, 
in this study were such that their expected loading would never exceed 80 % of their maximum 
capacity.
Similarly, it may be suggested that process-scale purifications should be monitored for 
input and output ligate concentrations (C  ^ and C respectively) and the application of ligate 
ceased on attaining a C/C^ ratio of 0.8. In doing so the availability of free ligand sites able to 
NSA biologicals is kept to a minimum, the loss of ligate to the breakthrough is kept to a 
minimum and a return to higher levels of ligand leakage is avoided. The problem of leached 
ligand being retained by adsorbed ligate may be overcome by the use of specific monovalent 
ligands for purifying monovalent ligates as the most appropriate strategy for the development 
of affinity solid phases.
Investigations into the adsorption stage of the process of affinity purifying MAbs on 
immobilized SpA solid phases based on a number of matrices (section 4.4) would suggest that 
on purifying biologicals on immobilized bio-ligands the ligand leakage from affinity solid phases 
is lowest when using a buffer consisting of molar glycine containing sodium chloride (0.15 M) 
pH 8 .6 . Under these conditions, the level of non-specifically bound plasma protein emerging 
in the eluate from a Prosep A "high capacity" column on applying the neat protein was highest 
for transferrin (300 ng/ml). Background levels of ligand leakage in this buffer showed a poor 
correlation with the MAh capacity of SpA solid phases, indicative of the greater influence of 
immobilization chemistry and not merely the degree of immobilization.
The non-specific binding of proteins to silanized matrices by nucleophilic interactions 
was not observed to be a problem in this study. The major problem found while using silica 
based solid phases appeared to be one of non-specific hydrophobic interactions between 
components of biological samples and the immobilized ligand or spacer molecules of the 
stationary phase. Consequently, packed beds could become blocked by the accumulation of
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fatty deposits. This was proven not to be a problem for SpA-Silica solid phases as these could 
be cleaned with hydrophobic solvents such as ethanol (10 %) or acetone without any ill effects. 
In the case of immobilized Abs rapid flushing with 5 to 10 col vols of 10 mM N aO H  or 10 
% acetone were used for defouling, resulting in visibly cleaner columns with recovered ligate 
capacities.
An observed phenomenon peculiar to the use of immobilized bio-ligands (SpA and Abs) 
was one of solid phase performance recovery. On repeated use of solid phases their capacity 
was found to drop-off, accompanied also by a lowering of their level of ligand leakage. On 
storage (usually overnight at 4°C), the capacity of the solid phases was again restored to levels 
close to that initially observed. The level of ligand leakage from solid phases however returned 
to about two thirds of that initially observed.
Elution occurs as a result of slight shifts in the tertiary conformation of ligand’s. 
Depending on the nature of the elution conditions used, bio activity may be lost on repeated 
solid phase use due to loss of intramolecular covalent cross-linkages, hydrophobic, ionic and 
hydrogen interactions. Renaturation of a ligand occurs as a consequence of the time dependent 
re-establishment of these forces. It may therefore be suggested that the most appropriate 
approach to cleaning immobilized bio-ligand solid phases would be to apply denaturing 
conditions in a rapid process in order to limit protein damage and then to store solid phases 
for a long period before reuse to allow for the recovery of bioactivity.
Affinity purifications performed in packed beds of silica based solid phases on a 
laboratory scale presented were easily performed. Scale up of packed-bed systems to an 
industrial scale invariably involves increasing the diameter of a packed bed whilst keeping the 
bed height constant. The findings of ligand leakage studies conducted using packed beds of 
Prosep A "high capacity" in this study, would suggest the linear velocity of solvent flow during 
affinity separations on CPG matrices to be more important than the volumetric flow rate. 
Silica-based matrices may then be used in fast flow HPLAC or FPLC modes for resolving 
protein mixtures in a rapid manner.
Models offered to describe the performance of AC systems tend to work on the premise 
that interactions will occur in a thermodynamically ideal manner. Furthermore, the modelling
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of an affinity purification system is performed assuming that equilibrium is established and does 
not include an assessment of how quickly equilibrium is approached. It is usually accepted that 
the mass transfer resistance of an affinity chromatographic process will present the rate limiting 
factor. However, it is difficult to model the composite mass transfer adsorption effect if the 
adsorption isotherm is non-linear (Hubble, 1987).
It was observed in this study that unlike the predictable elution profile of solutes from 
stationary phases employing physicochemical processes, the elution of solutes from bio-selective 
matrices was rarely quite as predictable. This was exemplified by the relative sizes and positions 
of eluted solute peaks in HPLAC experiments conducted remaining fairly consistent; however, 
retention times could vary widely. It is presently widely accepted that modelling an affinity 
process is but one of many tools which operators may use in order to select guidelines in the 
development of a process scale separation process.
In this study, predictions of the expected performance of affinity solid phases in affinity 
separation processes were offered as a result of a pragmatic course of repeated experimentation. 
By adopting an empirical approach to evaluating the performance of affinity columns is was 
hoped to present in this study "rule of thumb" guidelines to the development and use of new  
affinity solid phases. Ideally, to conform to a mathematical model,immobilized ligands should 
be homogeneous and pure, which would suggest that all protein ligands should be made from 
recombinant proteins or from immortalized cell lines. Furthermore, immobilization should not 
result in any loss of ligand specific activity due to steric hindrance or denaturing.
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8.3 LIMITS TO ANALYTICAL TECHNIQUES OF STUDY
While every effort was made to avoid experimental errors, the variety of silica-based 
solid phases prepared and diversity of tests conducted on them in this study may have provided 
scope for inadvertently introducing errors in the assessment or interpretation of experimental 
results. Limitations of reagent costs, the performance of equipment and time constraints have 
precluded exhaustive repetitive investigation and analysis into all areas covered within this 
study. Where possible, an attempt was made to limit experimental errors by including large 
sample sizes, or conducting operations in duplicate (or by using more replicates).
SpA was used as a general ligand for assessing the performance of affinity solid phases. 
When employed for the preparation of solid phases this reagent was always used sparingly, as 
it currently costs in the order of £10/mg. A question which arose on evaluating the accuracy 
of the automated Cb detection System was one of analyte purity. Unless otherwise stated in 
a suppliers specifications notes, all reagents were assumed pure, which may or may not have 
always been the case. Similarly, radio-labelled compounds were always assumed to be pure and 
to have specific activities high enough to add nothing to the analyte content of a biological 
samples, if added in addition to the cold analyte as a "spike".
Optical density at 280 nm (ODjgonm) was used throughout this study as a general means 
of qualitatively assessing the presence of proteins in solution. By comparing samples solutions 
with standard solutions of analytical grade proteins or by comparison with the documented 
absorbance of proteins, ODjgonm was also used as a quantitative determination of the presence 
of specific proteins in homogeneous solutions. Quantitative OD2gonm measurements were used 
only in order to compare solutions where the proteins were prepared fresh from stocks or 
purified and known only to contain minute trace quantities (the order of parts per million) of 
impurities. For more sensitive protein estimations Coomassie dye binding was used. This was 
a very good technique, particularly for detecting the presence of albumin in solution. 
Unfortunately, Coomassie dye binding proved of little use in detecting Ig’s or SpA in solution, 
as the degree of dye binding per unit mass of these proteins was particularly low. However 
Istocks of Coomassie solution have been stored on a cold tray for more than a year without
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signs of degradation in the dye-binding assay curves.
Electrophoresis using the Pharmacia PhastSystem™ was a valuable technique for 
assessing the homogeneity of isolated protein purified by affinity chromatography. However, 
differences in levels of buffering salts of samples and standards could result in misleading 
protein mobilities. The best electrophoretic results were achieved by dialysing all samples and 
standard solutions against a low salt buffer (such as 10 mM Na2HPO^, HCl to pH  7) prior to 
separation. Another problem commonly found on running PhastGel’s was one of secondary 
band (contaminant) distortion on sample titration. When samples were applied to 
electrophoretic gels at concentrations high enough to reveal contaminants, the main protein 
component had a swamping effect. This resulted in the main band "tailing", producing distorted 
position(s) for the contaminant band(s), making concentration and identification determinations 
difficult. Hence, SpA affinity purified MAh’s which may have total contaminating protein 
levels of much less than one part per thousand, tended to appear pure when examined by 
electrophoresis.
On lEF evaluation of affinity purified MAbs, they appeared to produce a characteristic 
five band pattern (a central dark band with two bands on either side of decreasing density). 
This pattern was also noted by Anderson and co-researchers (1979) and was believed to occur 
as a result of differences in the surface charge of MAbs with differing levels of glycosylation.
A drawback to the use of antibodies either for the production of lAC affinity columns 
or for use in immunochemical assays was that the supply of antibodies may be limited by the 
lifetime of the immunized animal in question. In addition, the nature of antiserum samples 
taken from an animal is most likely to change over the lifetime of an animal. Furthermore, the 
use of PAb’s may result in unwanted cross reactivities when the isolation process required 
should be ligate specific. It is therefore difficult to standardize the production of affinity solid 
phases or immunochemical techniques unless a large pool of antiserum is available. Hence, the 
use of MAbs from stabilized mammalian cell lines may be the best approach to the production 
of antibodies.
The production of antibodies to SpA by immunizing laying hens and isolating anti-SpA 
IgY antibodies from their egg yolks proved a very successful technique. Animals in the trial
236
required minimal attention and their eggs could be collected on a daily basis. In a 
social/political climate where animal experimentation is presently under close scrutiny, this 
non-invasive technique for isolation of antibodies from the yolks of laying hens may prove a 
good alternative to the more conventional technique of routine blood sampling by 
venipuncture.
Another alternative to the use of large animals for the production of large amounts of 
antibodies used in this study was the hollow fibre bioreactor. The main drawback of this piece 
of apparatus was its high demand for operator attention and technical expertise. Sampling of 
media for environmental monitoring (lactate, glucose, glutamine,and ammonia) had to be 
performed three times a week, at aseptically isolated leurlock junctions. In addition, 60 litre 
media (RPMI) and waste containers of the IC circuit (appendix II) and supplement (HLl) and 
harvest vessels of the EC circuit required aseptically changing at regular intervals. All these 
manipulations were performed at the risk of contaminating the cell line. Nevertheless, this 
study harvest volumes were always in excess of 10 litres and contained MAh at an average 
concentration of around 1 mg/ml.
In developing the SpA ELISA technique presented in this study for detecting trace levels 
of SpA in affinity purified MAbs, the forces of SpA:Fc binding affinity and excess MAb 
promoted SpA binding were overcome by the use of specific antibodies and low pH. By using 
an ELISA plate coat of high (affinity-selected) specific antibodies and low pH  SpAzFc 
dissociation was promoted while not inhibiting the assays specific Ab:Ag interactions. Another 
approach might be to incubate purified MAbs in non-denaturing dissociating conditions (such 
as in eluting buffer) and to resolve the ligand and ligate on the basis of differences in their 
physicochemical properties using techniques such as ion exchange (using a strong exchanger) 
and gel filtration. Finally, a means of confirming the isolated contaminant as being ligand must 
be used. This analytical technique may prove a very time consuming process when compared 
to the immunoassay technique presented here and would suggest immunoassays an appropriate 
course of action.
The ELISA techniques developed for determining the presence of Cb in biological 
samples when optimized for chemiluminescent or colorimetric end points produced tests with
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very similar precision and limits of detection. The advantages of a chemiluminescent above a 
colorimetric end point in ELISA techniques only became apparent on optimizing these 
approaches for the rapid throughput of samples. By using a shaker-incubator, the 
chemiluminescent assays’ incubation times could be shortened from 2  hours at 37°C to 30-40 
minutes at ambient. Furthermore, the Amerlite chemiluminescent reagent was able to produce 
far greater differences in signal per unit increase in immobilized peroxidase (steeper B/Bo curve) 
than was possible with a TMB colorimetric substrate. Consequently, assays achieved using a 
chemiluminescent end point proved to be particularly robust, having good precision, being 
resistant to matrix effects and were quicker to perform (no substrate colour development 
required).
On assessing the ligate capacity of bio-ligand solid phases in this study both the dynamic 
(C/Co) and working (elute on saturation) capacities were quoted. This was because, even when 
unbound, biologicals tended to have their passage through bio-ligand affinity columns retarded 
by non-specific interactions. Consequently, solutes would emerge within three col vols preceded 
in 0.5-1 col vols by the solvent front. Similarly, the void volume (Vo) of bio-ligand solid phases 
was determined by monitoring the volume within which the cationic dye Rivanol emerged 
from the columns when applied in acidic conditions. This technique was used in addition to 
comparing wet and dry solid phase weights, as weight techniques alone take no account of the 
greater volume occupied by hydrated than dehydrated bio-ligands.
Small physiologically active molecules such as the veterinary drugs assessed for lAC  
isolation from biological samples in this study tended to be hydrophobic in nature. 
Consequently, the majority of existing analytical strategies for their detection in biological 
samples almost invariably begin with removal of the residue from an extract by reverse phase 
HIC using a column such as a C l8 Sepak. The tendency of residues to form hydrophobic 
bonds presents additional problems when attempting to isolate residues from biological matrices 
by affinity chromatography. Quite often the presence of hydrogen binding disruptive agents 
(such as CuHCl and methanol) are required in the eluting buffers in order to recover adsorbed 
residues such as steroids.
Column fouling was found to be the main problem limiting the longevity of lA C SPE
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cartridges developed for purifying drug residues from biologically derived materials. This was 
of particular concern when developing the automated SPE of Cb from bile samples. Due to the 
heterogeneous nature of bile samples, some samples flowed freely through columns while 
others required the application of gentle suction. In order to overcome this problem, failsafe 
subroutines were built into the computerized system to summon an operator’s attention on 
column blocking.
On affinity purifying residues from biological samples (bile, urine and liver) a problem 
which occurred with tritium labelled analyte studies was one of quenching. Residual levels of 
co-purificants tended to give eluates a straw coloration, quenching tritium detection on 
scintillation counting. Where necessary this problem was overcome by spiking blank purified 
samples with tracer. Quenching was never found to be a problem in studies employing the use 
of iodine-125 labels, though these had the disadvantage of having relatively shorter shelf lives.
Experimental data produced in this study were subjected to statistical analysis in order 
to further support the assertions of likeness or unlikeness of analytical results. Where possible, 
data analyses were conducted using computer software in order to limit the possibility if 
operator sources of experimental error.
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8.4 APPLICATIONS INVESTIGATED IN STUDY
Initial experiments would suggest that the development of silica-based ion exchange solid 
phases is quite possible. The protein capacities of the ion exchange solid phases prepared in this 
study appeared somewhat lower than those of commercially available non-synthetic matrices. 
However, when subjected to electrophoretic evaluation, plasma protein samples appeared to 
be more homogeneous when purified on silica-based solid phases developed in-house, compared 
to those Sepharose-based commercially available.
By connecting high pressure columns packed with Prosep A H C to an HPLC, it was 
possible to achieve a rapid resolution of antibodies from biological samples by HPLAC. Under 
the experimental conditions presented in this study (section 5.4.4), the process rate limiting step 
appeared to be the adsorption stage. The washing and elution stages of MAb clean-up by 
HPLAC on Prosep A HC have been performed at flow rates of greater than 200 col vols an 
hour with no apparent loss of purification efficiency. Furthermore, by altering the dimensions 
of columns while maintaining the linear velocity of solvent flow it appeared that the conditions 
employed for rapid purifications optimized using an HPLAC technique may be scaled up to 
process-scale applications.
Rivanol-PS proved to be a general purpose protein binding dye-ligand affinity solid 
phase, binding more or less all plasma proteins to some degree. Unfortunately, immobilized 
Rivanol proved to be of limited use as proteins were adsorbed as a result of the culmination 
of a number of forces. Hence, the elution peaks of proteins appeared to be broad, as no distinct 
adsorption desorption cut-off conditions were discovered.
The most appropriate AC ligand for residue binding appeared to be an Ab, raised to 
be extremely ligate specific. However, target residue along with a number of other molecules 
present in biological samples may bind non-specifically by hydrophobic interactions to 
immobilized Abs. Similarly, by using immobilized PAb’s; there is the problem of cross­
reactivities to overcome if an AC sample clean up is to be residue specific. Furthermore, 
residues specifically bound by antibodies tend often to be difficult to recover, due to the 
formation of hydrophobic bonds at the Ab active site excluding water.
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As a result, mere changes in pH alone were not sufficient to elute adsorbed Z1 or Tb 
residues from lAC columns. Elution was promoted by the use of chaotropic agents or the 
inclusion of hydrophobic reagents in the eluting buffer. Under these conditions, antibodies may 
be denatured thereby lowering the lifetime (reusability) of lAC columns. This would suggest 
MAbs are most appropriate for the large scale production of lAC solid phases. lAC columns 
could then be used a limited number of times (or once) and disposed of so that the quality of 
antibodies will not be limited by either the size of a bleed, or lifetime of an animal.
lAC on silica-based solid phases was a very efficient and selective clean-up procedure. 
Typically, the purification of an antibody from crude serum by using an immobilized second 
antibody coupled to PS could be processed at the rate of 1 ml every 5 minutes (in column 
mode). By immobilizing antibodies raised to smaller molecules, it was possible to extract 
residues from biological samples such that a qualitative assessment of their presence could be 
made. Furthermore, using such an lAC solid-phase it was possible to effect a chiral separation 
of the alpha and beta isomers of the anabolic agent trenbolone (section 5.4.2).
The lAC-ELISA developed in this study for Cb in bile demonstrated the rapid clean-up 
of analytical samples from biological sources on silica based matrices. The lAC SPE cartridges, 
developed for the preparatory processing of biological samples prior to quantitative assessment, 
had flow characteristics applicable to automated analytical systems. Consequently, it was 
envisaged that the solid phase could be packed into high pressure columns such that they may 
be connected to MS, or HPLC instruments.
The CAL\SPE\Cb solid phases material developed in-house in this study was then mass 
produced commercially in litre batches by Bioprocessing to a CMP grade of production 
control. The reproducibility of CAL\SPE\Cb column separations of Cb from bovine bile was 
consistent over 60 consecutive cycles applicable with the batch processing of beef carcases for 
residue analysis at an abattoir. However, in order to gain an absolute determination of the 
presence of an analyte in a sample, some mean of confirmatory analysis may be required. This 
is of particular concern where the analyte in question is a prohibited substance which may or 
may not be present in a suspect sample. lAC-ELISA techniques such as developed in this study 
may therefore serve best as a technique for screening samples prior to confirmatory evaluation
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and, where necessary, legal action.
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8.4 FURTHER WORK
A course of investigations has begun to assess the feasibility of producing a MAb with 
"on-line" affinity purification using Prosep A HC. This work is being carried out presently at 
the University of Sheffield in conjunction with Drs Kami Beyzavi (Bioprocessing Ltd.) and 
Simon Smith (University of Sheffield). It is envisaged that a pre-packed half filled column of 
Prosep A  "high capacity" could be made sterile by irradiation. This column could then be 
connected aseptically to a sterile culture media reservoir and the packed bed fluidized. The 
column could then be incorporated into the external circuit of a hollow fibre bioreactor 
(Appendix II). In doing so, solid phase particles should allow the passage of whole cells. 
Presently, initial investigations have been limited to assessing the performance of Prosep A HC  
in fluidized bed of solvents of different viscosities and the purification of cell culture 
supernatant.
Initial experiments would suggest it possible to process biological samples for the 
detection of more than one analyte by using an lAC-ELISA System. The anabolic agents 
zeranol (Zl) and clenbuterol (Cb) have been detected in a single ELISA technique by coating 
microtiter plates with a mixture of Zl and Cb thyroglobulin conjugates. Bound and free 
analyte in samples were then made to compete for binding to a mixture of sheep anti-Zl and 
rabbit anti-Cb antibodies. Binding was then detected by using a either a donkey anti-rabbit or 
anti-sheep peroxidase labelled second antibody. This dual analyte system had no interanalyte 
cross reactivity. Similarly, when the combined primary antisera were immobilized on a CPC 
matrix, Zl could be eluted by the addition of 20 mM N aO H  and Cb by the addition of 30 mM 
HCl, both adsorbing in PBS.
In addition to Cb, work is presently being carried out in-house to develop lAC-ELISA 
detection systems for an additional three other illegal anabolic agents (19 nortestosterone, 
trenbolone and zeranol). It is intended to develop and make generally available lA C  columns 
for routine analysis of these substances using fully characterized MAbs from immortalized in- 
house cell lines.
Work is also in progress in conjunction with colleagues at the MAFF Food Research
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Institute (Norwich, UK) to incorporate the CPG immobilized anti-Cb antibody columns in 
the clean-up of samples, as an alternative to GC prior to determination by mass spectrometry. 
The proposed fully automated lAC-MS system should consist of samples being loaded onto an 
lAC column. The aqueous eluate may then be loaded onto a reverse-phase stacking column, 
followed by evaluation by MS.
It appears evident from the findings of this study that solid phases incorporating metal 
ions may prove valuable matrices. Preliminary experiments carried out using porous alumina 
preparations would suggest alumina as an alternative to CPG for preparing solid phases because 
it is not as prone to alkali attack. It is intended that other matrices of this nature will be 
investigated further.
8.5 CONCLUSIONS
Silica based matrices have proven and continue to prove themselves valuable materials 
for the development of robust affinity solid phases. The chromatographic performance of solid 
phases produced using PS and CPG matrices in this study have performed in a manner 
comparable to many commercially available solid phases. Furthermore, silica based matrices 
have allowed the development of rapid AC processes without loss of purification efficiency. 
In the light of the findings presented within this study, many of the more common objections 
aimed at the use of silica based matrices for AC applications would appear largely unfounded.
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APPENDIX
Appendix 1
1
The Tecan robotic automated sample processors (a), model RSP 5051 ID; b), 
model RSP 5032) used in the development of the automated Cb analytical 
System. Legend: 1, arm shield; 2, robotic arm; 3, diluter; 4, control computer; 
5, vacuum pump; 6, waste reservoir; 7, SPE vacuum box; 8, linear rack; 9, bar 
code reader; 10, sample probe; 11, bar code wand; 12, ELISA plate platform; 
and 13, sample rack.
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The schematic diagram of the ACUSYST-Jr hollow fibre bio reactor.
Appendix III
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Isoelectric focusing (lEF) electrophoretic calibration of proteins standard curve 
using the Pharmacia PhastSystem™ (Gold lEF calibration kit, N o. 17-0471-01; 
PhastGel, 3-9).
Appendix IV
SDSPAGE
Gradient 10-15 (Pharmacia Ltd. UK)
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
calibration of proteins standard curve using the Pharmacia PhastSystem™ (Red 
mol wt. calibration kit, No. 17-0446-01; PhastGel, 10-15).
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